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ABSTRACT OF DISSERTATION 
 
 
MITOCHONDRIAL AND NEUROPROTECTIVE EFFECTS OF PHENELZINE 
RELATED TO SCAVENGING OF  
NEUROTOXIC LIPID PEROXIDATION PRODUCTS 
 
Lipid peroxidation is a key contributor to the pathophysiology of traumatic brain injury 
(TBI).  Traditional antioxidant therapies are intended to scavenge the free radicals responsible for 
either the initiation or propagation of lipid peroxidation (LP). However, targeting free radicals after 
TBI is difficult as they rapidly react with other cellular macromolecules, and thus has a limited 
post-injury time window in which they may be intercepted by a radical scavenging agent.  In 
contrast, our laboratory has begun testing an antioxidant approach that scavenges the final stages 
of LP i.e. formation of carbonyl-containing breakdown products. By scavenging breakdown 
products such as the highly reactive and neurotoxic aldehydes (often referred to as “carbonyls”) 4-
hydroxynonenal (4-HNE) and acrolein (ACR), we are able to prevent the covalent modification of 
cellular proteins that are largely responsible for posttraumatic neurodegeneration. Without 
intervention, carbonyl additions render cellular proteins non-functional which initiates the loss of 
ionic homeostasis, mitochondrial failure, and subsequent neuronal death. Phenelzine (PZ) is an 
FDA-approved monoamine oxidase (MAO) inhibitor traditionally used for the treatment of 
depression. Phenelzine also possesses a hydrazine functional group capable of covalently binding 
neurotoxic carbonyls. The hypothesis of this dissertation is that carbonyl scavenging with PZ will 
exert an antioxidant neuroprotective effect in the traumatically injured rat brain mechanistically 
related to PZ’s hydrazine moiety reacting with the lipid peroxidation (LP)-derived reactive 
aldehydes 4-hydroxynonenal (4-HNE) and acrolein (ACR).  Data from our ex vivo experiments 
demonstrate that the exogenous application of 4-HNE or ACR significantly reduced respiratory 
function and increased markers of oxidative damage in isolated non-injured rat cortical 
mitochondria, whereas PZ pre-treatment significantly prevented mitochondrial dysfunction and 
oxidative modification of mitochondrial proteins in a concentration-related manner. Additionally, 
PZ’s neuroprotective scavenging mechanism was confirmed to require the presence of a hydrazine 
moiety based on experiments with a structurally similar MAO inhibitor, pargyline, which lacks the 
hydrazine group and did not protect the isolated mitochondria from 4-HNE and ACR. Our in vivo 
work demonstrates that subcutaneous injections of PZ following TBI in the rat are able to 
significantly protect brain mitochondrial respiratory function, decrease markers of oxidative 
damage, protect mitochondrial calcium buffering capacity, and increase cortical tissue sparing 
without decreasing neuronal cytoskeletal spectrin degradation.  These results confirm that PZ is 
capable of protecting mitochondrial function and providing neuroprotection after experimental TBI 
related to scavenging of neurotoxic LP degradation products. 
 
KEYWORDS:  phenelzine, lipid peroxidation, 4-hydroxynonenal, acrolein, brain 
mitochondria 
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Chapter 1 
Introduction and Background 
 
 (Portions submitted for publication in Free Radical Biology and Medicine) 
 
1.1 Introduction 
Traumatic Brain Injury (TBI) is a condition that presents serious challenges to the 
health and welfare of civilians, soldiers, and veterans. In the United States alone, 1.7 
million persons are diagnosed with TBI each year [1].  5.3 million persons in the United 
States are living with permanent or temporary posttraumatic disability [2].  Additionally, 
the military subset population is realizing an unprecedented shift in TBI occurrence since 
the onset of the wars in Iraq and Afghanistan.  Military TBI diagnoses have almost tripled 
in 8 years with 30,000 diagnosed soldiers in 2012, from approximately 10,000 soldiers in 
2004 [3]. The Center for Disease Control (CDC) has previously advocated TBI as a “major 
public health epidemic,” calculating an overwhelming economic burden of over $16 billion 
a year and $56 billion overall [4]. 
 
1.2 Classifications and Models of Traumatic Brain Injury 
 There exist two broad classifications of traumatic brain injury (TBI.)  The 
classifications are sequential and describe two sources of damage: primary and secondary 
damage.  Primary damage is characterized by mechanical forces acting externally on the 
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brain either by rapid changes in acceleration, blunt force trauma, penetrating trauma, or 
from primary blast waves [5].  This type of damage directly disrupts membranes and their 
permeability [6].   
Unfortunately, primary damage cannot be prevented by surgical or 
pharmacological intervention and prevention is generally the only true means available to 
treat primary sources of injury.  Secondary damage is, however, a source of injury that is 
often the target of surgical or pharmacological treatment.   Secondary sources of TBI 
develop within hours to weeks after the primary insult and often exacerbate with time [6, 
7].  In fact, 40% of patients admitted to hospitals for TBI continue to deteriorate weeks 
after the primary mechanical insult [8, 9].   
The pathophysiology of the secondary injury cascade is complex and the current 
clinical classification to describe the severity of injury is the 15-point Glasgow Coma Score 
(GCS) [10].  However, the GSC is not applicable to rodent models of TBI nor does it 
communicate much regarding the pathology of TBI [11] which can vary substantially. 
Experimental models of TBI are designed to decrease this variability by mimicking 
a particular type of brain injury (diffuse, focal, mixed diffuse/focal complex) in a controlled 
and repeatable manner.   
The controlled cortical impact (CCI) model of TBI is just one means to 
experimentally induce a brain injury.  The CCI model uses a pneumatically controlled 
piston to physically contact the brain through a craniotomy in the skull and deform/displace 
the tissue to pre-specified distance with a controlled velocity and dwell time.  The model 
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was first employed in ferrets [12] but was adapted and validated in mice [13, 14] and rats 
[15]. 
It is important to recognize that the CCI-TBI model is considered a focal model of 
TBI; however, reports demonstrate that the contusion is not entirely focal.  These 
experiments were able to show diffuse neuronal damage in the cortex, hippocampus, and 
corpus callosum of the ipsilateral (insulted) and contralateral (non-insulted) hemisphere.  
Furthermore, it was concluded to be mediated primarily by retrograde and anterograde e.g. 
Wallerian degeneration [13].  Therefore, special consideration should be made when 
designing experiments to account for this observation as to not unintentionally obfuscate 
the interpretation of data as in the instance when ipsilateral treatment groups are compared 
internally to their “control” contralateral counterparts. 
Our lab uses the CCI-TBI model to induce a severe brain injury in rats.  
Accordingly, this model is intended to represent the respective severe-TBI population in 
humans.  It is our intention to measure the efficacy of pharmacological treatments 
following severe TBI first, then to assess the treatment potential of a “less severe” TBI. 
 
1.3 Initiation of the Secondary Injury Cascade 
Following the primary mechanical insult, neuronal membrane integrity is 
compromised and excessive excitatory neurotransmitters such as glutamate are released 
from the presynaptic neuron. Glutamate under normal physiological conditions will bind 
to NMDA (N-methyl-D-aspartate) and AMPA (α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid) receptors to facilitate the influx of sodium (Na+) and calcium 
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(Ca2+). Perpetual activation of NMDA and AMPA receptors by excitatory 
neurotransmitters facilitates excessive influx of sodium and calcium ions and efflux of 
potassium (K+) ions. [16-18].  The influx of Ca2+ can have dire consequences that effect a 
multitude of cellular and physiologic processes which will be considered individually later 
in this chapter. 
Though described broadly, this excitotoxic environment exacerbates the disruption 
of ionic homeostasis, increases formation of reactive oxygen species (ROS), decreases 
mitochondrial function, increases peroxidation of membrane and organellar lipids, and 
increases the formation of deleterious reactive aldehydes otherwise known as cytotoxic 
carbonyls. 
Evidence for glutamate as a facilitator of excitotoxicity was gained from 
experimental animal TBI models in which a dose-dependent relationship was found to exist 
between glutamate levels and severity of brain injury [19].  
 
1.4 Calcium Homeostasis & Pathology 
 The physiologic role of calcium is widespread and is involved in multiple processes 
regarding membrane excitability, synaptic plasticity, modulation of cytoskeletal structure, 
enzymatic activation and subsequent signal transduction, as well as calcium-regulated gene 
expression. 
Many of these cellular processes are manipulated by controlling the concentration, 
movement, or localization of Ca2+ within the neuron. Typical intracellular calcium (Ca2+i) 
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concentration is approximately 100 nM, whereas the extracellular calcium (Ca2+e) 
concentration is on the order of 1-2 mM.  This concentration gradient facilitates the natural 
influx of Ca2+ through voltage-operated channels (VOCs). Ca2+-ATPase pumps on the 
plasma membrane (PM) and the endoplasmic reticulum (ER) and the Ca2+/Na+ exchanger 
also contribute to Ca2+i regulation. 
Ionotropic channels on the PM such as NMDA and AMPA receptors respond to 
glutamate and mediate the influx of Ca2+. Whereas, metabotropic receptors generally 
localized to the (ER) facilitate the efflux of Ca2+ into the cytosol.  The cell is additionally 
equipped with the ability to buffer Ca2+ through Ca2+-binding proteins and more powerfully 
through the sequestration by the mitochondria.  Despite the expansive array of Ca2+ 
modulating mechanisms traumatic brain injury can overwhelm these systems.   
 Following mechanical trauma neurons sustain non-specific leaks that facilitate Ca2+ 
influx and depolarization.  Excitatory neurotransmitters such as glutamate become elevated 
in the synaptic cleft following TBI [20].  Excessive stimulation by glutamate prolongs 
depolarization and activates NMDA and AMPA Ca2+-permeable channels [21].  Support 
for glutamate mediated increase of Ca2+i concentration was demonstrated in vitro, wherein 
high concentrations of exogenously applied glutamate elevated Ca2+ influx in neuronal 
cultures [22].  And, the Ca2+ influx was determined to be mediated by activation of the 
NMDA receptor [17].  Other investigators support these observations by concluding that 
Ca2+i can increase transiently from injury as demonstrated in in vitro fluid shear stress 
injury models [23]. 
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 The consequence of intracellular Ca2+ accumulation has pathological implications.  
Two notable pathologies involve the generation of free radicals and mitochondrial 
dysfunction, both of which will be discussed in later sections.  Aside from contributing to 
free radical formation and mitochondrial dysfunction, intracellular Ca2+ can activate 
phospholipases, kinases, and endonucleases which contribute to aberrant cellular processes 
and contribute to the depletion of adenosine triphosphate (ATP) energy reserves along with 
excessive Ca2+-ATPase pump activity.   Additional pathological consequences involve that 
of Ca2+ activated proteases such as calpains [24]. 
 Calpains are cytoplasmic cysteine proteases that are activated by Ca2+.  Two types 
of calpains are µ-calpains and m-calpains [25].  The former µ-calpains are activated by µM 
concentrations of Ca2+ (while m-calpains are activated by mM concentrations of Ca2+)  and 
are located in the cytosol near the plasma membrane.  Excitotoxic concentrations of Ca2+ 
(5-10 µM) [26] and reactive aldehydes discussed in later sections activate calpains which 
mediate cytoskeletal breakdown [27].  Calpains target a wide variety of substrates and 
cleave their targets not based on primary amino acid sequence, rather, on secondary and 
tertiary structure [25, 28]. 
Among the variety of calpain targets is spectrin, a scaffolding protein involved in 
the maintenance of the PM.  Calpains are activated to cleave αII-spectrin to influence 
synaptic remodeling and plasticity [29].  In vitro models have demonstrated a link between 
injury, Ca2+, and calpain activation when various Ca2+ chelators prevented the cleavage of 
fluorescent calpain substrates following stretch injury [30].  Extensive work has 
demonstrated clapain activation in multiple instances of traumatic axonal injury [31, 32] 
and in in vivo TBI models [33, 34].  
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While it is apparent that intracellular Ca2+ increases after injury, and subsequently 
calpains are pathological activated, the success of pharmacological intervention by virtue 
of calpain inhibition has been modest.  Compounds such as Calpain Inhibitor 2 and SNJ 
1945 reduce spectrin degradation [35, 36].  Other compounds such as AK295 have 
attenuated motor and cognitive deficits in the rat following TBI [37].   
It is important to note that while calpain inhibition is a potential therapeutic 
strategy, the work of this dissertation aims to pursue a new means of pharmacological 
intervention, but maintain the spectrin degradation assay as a relevant and capable 
biomarker for the assessment of drug efficacy in the treatment of TBI. 
 
1.5 Reactive Oxygen Species 
 Free radicals are essentially molecular fragments that can exist in mono or poly 
atomic form and contain at least one unpaired electron [38].  Because the outer most atomic 
or molecular orbital lacks a paired electron then the species is capable of either oxidation 
or reduction.  Gaining the “missing” electron means the species reduces its oxidation state.  
If the species “loses” its unpaired electron the species is said to oxidize.  While the 
designation “free radical” has an inherently negative connotation, a free radical can 
function beneficially in a biological system as an anti-oxidant e.g. donates its free electron 
which stabilizes both compounds in the reaction.  Alternatively free radicals can be used 
to destroy bacterial invasions in many eukaryotic cells.  Free radicals have been extensively 
documented as being either harmful or beneficial [39], and some free radicals discussed in 
this chapter are relatively stable and do not damage biological tissues.  
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 Free radicals and reactive oxygen species (ROS) are closely related but one species 
facilitates the other.  ROS produce free radicals and some ROS species are examples of 
free radicals; examples are given below.  The exception to the nomenclature involves 
peroxynitrite which is regarded as a reactive nitrogen species (RNS).  ROS-generated free 
radicals mediate oxidative damage and can be categorized into superoxide (O2
•-) and those 
derived from such.  The use of the “•” which precedes or follow an atomic symbol indicates 
the presence of an unpaired electron on that particular species. 
 
Examples of reactive oxygen species: 
 Hydrogen peroxide (H2O2) 
 Peroxynitrite anion (ONOO-) 
 Peroxynitrous acid (ONOOH) 
 Nitrosoperoxocarbonate (ONOOCO2) 
 
Examples of free radicals: 
 Superoxide (O2•-) 
 Superoxide-derived: 
 Hydroxyl radical (•OH) 
 Nitrogen dioxide (•NO2) 
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 Carbonate radical (CO3-) 
 Peroxyl radical (LOO•) 
 Alkoxyl radical (LO•) 
 Iron-oxygen complexes 
 
1.6 Superoxide Radical 
 The superoxide radical (O2
•-) is an aberration of diatomic oxygen (O2).  O2 is unique 
in that it is a diradical, wherein the each oxygen is contains one unpaired electron, as 
opposed to the molecule containing a pair of electrons in its outer orbitals.  Therefore 
diatomic oxygen (O2) can serve as an oxidizing agent, meaning it can accept electrons.  
Normal cellular processes can cause the partial reduction (gain of an electron) of O2. 
Subsequently, the species becomes a free radical: superoxide radical (O2
•-).  The generation 
of superoxide radical is physiologically sequestered by innate cellular antioxidant 
mechanisms.  It is only when free radical production surpasses the ability of endogenous 
control mechanism that free radicals contribute to a pathological state of “oxidative stress.” 
Oxidative stress or nitrosative stress (for nitrogen passed radicals) is defined as the 
state wherein the production of free radicals has the potential to elicit damage[40].  The 
term oxidative damage is the state wherein free radicals have irreversibly impaired 
function. 
The largest contributor of oxidative stress and greatest source of oxidative damage 
is the mitochondria [41].  Specifically Complex I, a major protein complex of the electron 
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transport system (ETS), is the largest contributor to electron leak and subsequent 
generation of superoxide radical [42]. However, due to the complex nature of the 
mitochondria in a pathological state, this and other concepts will be discussed in further 
detail later. 
NADPH Oxidase: 
Another major contributor, though indeed apart of mitochondrial complexes, 
nicotinamide adenine dinucleotide phosphate-oxidase (NADPH oxidase) is utilized in 
neutrophil phagosomes to reduce O2 into O2
•- [43, 44].  NADPH oxidase is also utilized by 
microglia and is a considerable contributor of superoxide radical formation, especially 
during the later time points following traumatic brain injury (TBI)[45, 46].  In vivo support 
for the role of NADPH oxidase was recently and interestingly demonstrated in Gp91phox 
(NOX2) knockout mice that sustained a TBI.  In these experiments, mice lacking a 
functional domain of NADPH encoded by the gene NOX2 demonstrated reduced markers 
of apoptosis, superoxide radical formation, and peroxynitrite formation following a 
controlled cortical impact (CCI) TBI [47]. 
Xanthine Oxidase: 
Aside from immune-based contributors, other means of superoxide radical 
generation can be accounted by normal cellular purine metabolism.  Xanthine reductase is 
among such compounds that reside within endothelial cells that facilitates the oxidative 
metabolism of heterocyclic, aromatic compounds [48].  However, in a pathologic state i.e. 
abundance of free radicals, xanthine reductase can be oxidized to xanthine oxidase.  
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Xanthine oxidase will still metabolize substrates; however, the final transfer of electrons 
will be received by oxygen and hydrogen peroxide creating superoxide radicals. 
Heme Proteins: 
 The iron centers of heme contained within hemoglobin and myoglobin exist in a 
ferrous state (Fe2+) which facilitates the functionality of the red blood cell to transfer 
oxygen.  Due to the aromatic ring structure electrons are capable of delocalizing which 
creates a ferric (Fe3+) state that is incapable of binding O2.  Oxygen is reduced and the 
molecule released is a superoxide radical.  In a pathological state this process further 
catalyzes free radical formation, discussed later, by the Fenton and Haber-Weiss reactions. 
Many sources of superoxide radicals exist that are not elaborated upon in this text; 
however, typical processes under normal physiologic conditions will create superoxide 
radicals.  And, those process are often exacerbated by central nervous system (CNS) injury.  
Experiments in vivo utilizing the fluid percussion model were able to demonstrate an 
immediate increase in superoxide radical within brain microvasculature concurrent with 
auto-regulatory dysfunction that could be ameliorated with superoxide radical scavengers 
[49].   
 
1.7 Reactions with Superoxide Radical 
Typically following the primary injury, a mechanical depolarization of neurons 
leads to the loss of Ca2+ homeostasis and subsequent elevation of intracellular Ca2+.[50]  
As a result,   superoxide (O2
•-) production elevates due to a single electron (e-) reduction of 
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molecular oxygen (O2).  O2
•- is capable of stealing an electron (an oxidizing agent) or 
donating an electron (a reducing agent), this dual nature is the source of O2
•- modest 
reactivity. However, O2
•- can undergo several fates leading to generation of more prolific 
and excessively volatile radicals. Should O2
•- undergo either enzyme-mediated (superoxide 
dismutase, SOD) or spontaneous dismutation to create hydrogen peroxide (H2O2), iron 
from brain tissue hemorrhage can cause iron-catalyzed Fenton reactions which generate 
excessive hydroxyl radicals (•OH) [51].  The other fate of O2
•- is to react with nitric oxide 
radical (NO•).  NO• is readily produced in mitochondria upon activation of mitochondrial 
nitric oxide synthase (mtNOS) [52, 53]. Should O2
•- react with NO•, a temporary 
peroxynitrite anion (ONOO -) is formed, which in the context of TBI pathology leans 
towards protonation or reaction with CO2.  In the later circumstance, CO2 exposure will 
generate unstable nitrosoperoxocarbonate (ONOOCO2) whose degradation products 
generate carbonate radical (CO3
•-) and nitrogen dioxide radical (•NO2). In the former 
circumstance of protonation, peroxynitrous acid is formed and degraded into •OH and 
•NO2.  The chemistry of peroxynitrite formation and its generation of highly reactive 
radicals is shown in Figure 1.1. 
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Figure 1.1 Multiple sources contribute to superoxide (O2
•-) production.  
Superoxide can undergo enzymatic or spontaneous dismutation to form 
hydrogen peroxide (H2O2).  Subsequent iron catalyzed reactions contribute 
to the formation of hydroxyl radicals (•OH).  Superoxide in combination 
with nitric oxide radical (•NO) produces peroxynitrite anion (ONOO -).  
Peroxynitrite reacts with CO2 to produce intermediaries that degrade into 
the carbonate radical (CO3
•-), nitrogen dioxide radical (•NO2), and hydroxyl 
radical (•OH).  The generation of free radicals initiates lipid peroxidation 
cascades, protein oxidation and nitration.  Image modified from Hall, 2010. 
[54] 
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In vivo experimental evidence for hydroxyl radical (•OH) formation following TBI 
was demonstrated in the focal TBI rat model wherein the salicylate trapping method 
implicated that within the first few minutes following TBI,  •OH radicals significantly 
increased [55, 56] which was temporally concurrent with other neuronal injury models 
demonstrating lipid peroxidation, disruption of the blood-brain barrier [57] and glutamate 
release [58]. 
Equally useful experimental evidence of •NO2 radical formation has been generated 
through the indirect measurement of 3-nitrotyrosine (3-NT).  3-NT is the nitration of 
tyrosine residues on proteins which is primarily generated by the nitrogen dioxide radical 
(•NO2) [59, 60].  Accordingly, 3-NT is frequently used as a marker for •NO2 [61, 62].  3-
NT levels increased within the mouse brain simultaneously with lipid peroxidation within 
the first hour after injury in the weight drop model [63] and in the CCI model with an 
increase of oxidative damage and calpain-mediated cytoskeletal degradation [64].  
Experiments using a lateral fluid percussion TBI model also demonstrated that after injury 
endothelial nitric oxide synthase (eNOS) is increased concurrent with blood-brain barrier 
disruption 24 hours after injury.  eNOS generates •NO which as previously mentioned, 
reacts with superoxide radical to create peroxynitrite degradation products that form •NO2. 
Additional in vivo support for the increase of deleterious nitrogen radicals was 
developed from rat TBI models utilizing nitric oxide scavenger tempol.  Experimenters 
administered tempol to catalytically scavenge peroxynitrite derived radicals such as CO3
•-
, •OH, and •NO2 and demonstrated a dose dependent decrease in 3-NT following CCI in 
the mouse [65]. 
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1.8 Lipid peroxidation 
Free radicals e.g. •OH, •NO2, and CO3•- induce the lipid peroxidation (LP) of 
polyunsaturated fatty acids (PUFA) including arachidonic, linoleic, docosahexaenoic and 
eicosapentaenoic acids within cell and organellar membranes.  The LP begins with the 
abstraction of an electron from an allylic carbon by a free radical i.e. “initiation.”  
Subsequent reactions during “propagation” contribute to the overall demise of the fatty 
acid into a degraded aldehydic product such as 4-hydroxynonenal (4-HNE) or 2-propenal 
(acrolein; ACR).  The following describes the reactions of this process in further detail 
with the fatty acid arachidonic acid (AA) as an example. 
 
Initiation: 
A highly electrophilic radical (•OH, •NO2, or CO3
•-) steals an electron from 
hydrogen, bound to an allylic carbon (carbon surrounded by adjacent double bonds) of a 
PUFA e.g. AA.  The carbon-bound hydrogen has an unequal distribution of electrons which 
facilitates relatively “easy” abstraction [66].  The attack of a free radical (R•) converts the 
AA into a lipid or alkyl radical (AA•).  Subsequently the attacking radical is quenched by 
the electron-containing hydrogen. 
AA + R• → AA• + RH 
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Propagation: 
The alkyl radical (AA•) continues to react with a molecule of oxygen, which creates 
a lipid peroxy radical (AA-OO•). 
AA• + O2 → AA-OO• 
The peroxyl radical (AA-OO·) continues to react within the membrane stealing an 
electron forming a lipid hydroperoxide (AA-OOH) and a second alkyl radical (AA•). 
AA-OO• + AA → AA-OOH + AA• 
Iron-Catalyzed Propagation:  
The lipid hydroperoxide AAOOH can be further decomposed by two forms of ionic 
iron.  Ferrous (Fe2+) iron in the presence of hydroperoxide (AA-OOH) will react to form a 
lipid alkoxyl radical (AA-O•). 
AA-OOH + Fe2+ → AA-O• + OH- + Fe3+ 
Or, in the presence of ferric (Fe3+) iron, the hydroperoxide (AA-OOH) is converted 
back into a lipid peroxyl radical (AA-OO•). 
AA-OOH + Fe3+ → AA-OO• + Fe2+ 
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Chain Branching Reactions: 
Either alkoxyl (AA-O•) or peroxyl (AA-OO•) radicals arising from iron-catalyzed 
reactions will contribute to degradation of the nearby “chains.” 
AA-O• + AA →AA-OH + AA• 
AA-OO• + AA→AA-OOH + AA• 
 
Scission and Fragmentation: 
Among the products generated from the peroxidation of PUFAs are neurotoxic 
aldehydes such as 4-hydroxynonenal (4-HNE) and 2-propenal (acrolein; ACR) [67].  The 
following diagram demonstrates the creation of 4-HNE from AA.  
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Figure 1.2   Chemical initiation, propagation, and termination of 
arachidonic acid to 4-hydroxynonenal (4-HNE).  Adapted from Hall et al, 
2010 [68].  
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Reactive aldehydes such as 4-HNE and ACR will be discussed in further detail in 
this chapter, however, these LP-derived breakdown products are highly toxic and bind to 
various amino acids or can create protein aggregates.  Either consequence impedes or 
completely inhibits protein function thereby promiscuously disrupting normal cellular 
processes ranging from glutamate transport to mitochondrial function [69].  Other notable 
ramifications of LP are due to changes in membrane dynamics.  Lipid peroxidized 
membranes exhibit decreased membrane fluidity, increased permeability to substrates and 
molecules that were otherwise impassable, and inactivation of membrane or lipid-bound 
enzymes [66].  In vivo experiments have determine that following hydroxyl radical 
formation within the first 5 minutes after CCI in the rat, LP progressively increases with 
the breakdown of the blood-brain barrier [57].   
 
1.8.1 Treatment of Lipid Peroxidation  
 Multiple compounds have attempted to protect against LP and some have 
demonstrated neuroprotection (See Hall et al., 2010 for further review).  However, one 
compound tirilazad mesylate (U74006F), uses a scavenging mechanism which parallels 
that of a compound of this current work, save that the target of the scavenger is different.  
Tirilazad scavenges the lipid peroxyl radical (e.g. R-OO•) which limits LP by sequestering 
the ability of lipids to undergo chain branching.  The mechanistic concept of tirilazad was 
verified in both mice [70] and rats [71] and demonstrated neuroprotective efficacy.  
Tirilazad underwent testing in phase II and phase III trials but due to complications in the 
randomization of patients the results were never released in North America.  However, 
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European trials failed to demonstrate a beneficial improvement of Glasgow Coma Scale 
(GCS) score.  Though post-hoc analysis revealed a significant reduction of mortality in 
patients suffering a severe TBI with subarachnoid hemorrhage (tSAH) [71], the compound 
lost sponsorship for further development and clinical testing. 
 Pharmacological scavenging of lipid peroxyl radicals has the potential, in theory 
and in practice, to be a feasible clinically relevant intervention for the treatment of TBI in 
humans.  However, much criticism was received for tirilazad due to the limiting therapeutic 
window.  Lipid peroxyl radicals, much like many free radicals have relatively short-lived 
half-lives which requires early intervention if clinical efficacy is desired.  As previously 
discussed in the section regarding Ca2+ regulation, it is our prerogative to investigate a 
scavenging compound.  The work with tirilazad strongly supports the notion that 
scavenging is feasible as a neuroprotective mechanism especially if the scavenged 
substrates exhibit a longer half-life.  Of the available scavenging targets, reactive aldehydes 
possess several characteristics that are ideal for scavenging and in the following sections 
the role of reactive aldehydes will be further discussed. 
 
1.9 Reactive Aldehydes 
Lipid peroxidation compromises membrane integrity and interrupts phospholipid 
dependent proteins (e.g. ion channels and electrogenic ion pumps), however, the aldehydic 
breakdown products are additional, well-characterized toxic mediators of cellular damage 
as demonstrated in various experimental models of TBI [72-74]. 
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Specifically, 4-HNE and ACR possess carbonyl functional groups (Figure 1.3) 
capable of covalently binding lysine, histidine, and cysteine amino acids of cellular and 
mitochondrial proteins via Schiff base and/or Michael adducts [75, 76].  (See Figure 1.4)  
These alterations induce conformational changes in protein structure compromising their 
function, which contributes to overall cellular demise.  Both 4-HNE and ACR are highly 
electrophilic; the exception is the LP-derived 3 carbon containing molecule: 
malondialdehyde (MDA) [77].  MDA is a degradation product of LP and can be used in 
the assessment of LP, but it is non-toxic and often referred to as a “tombstone” marker.  
Free radical-induced LP is one of the most deleterious contributors of acute post-TBI 
pathophysiology [65, 78-82]. 
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Figure 1.3. Structure of 4-hydroxynonenal (4-HNE) and Acrolein (ACR), 
each possessing a nucleophilic aldehyde i.e. reactive carbonyl.  4-HNE and 
ACR are the aldehydic breakdown products of free radical-induced lipid 
peroxidation.  Carbonyls refer to compounds that contain double bonded 
oxygen (CHO) functional group, to include reactive aldehydes: 4-HNE and 
ACR. 
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Figure 1.4:  Example of 4-HNE and Schiff base and Michael additions to 
protein residues. Adapted from Hall et al, 2010 [68]. 
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1.9.1 Reactive Aldehydes in Traumatic Brain Injury 
 In various articles the LP-derived breakdown products such as 4-HNE and acrolein 
have been referred to as reactive aldehydes, carbonyls, or lipid aldehydes.  The term 
carbonyl simply refers to the COH bond in the parent compound.  The aldehydic reference 
applies to the placement of the double bonded oxygen (O) in the compound; a terminal 
position indicates an aldehyde.  For the remainder of this manuscript the terms reactive 
aldehydes and carbonyls will be used interchangeably in regards to specifically 4-HNE and 
ACR. 
 Reactive aldehydes or carbonyls, as previously mentioned, are capable of 
interrupting a wide variety of enzymatic processes [38]. And, carbonyls produced after 
traumatic brain injury are capable of disrupting vital cellular mechanisms such as those 
involved with signaling and mitochondrial function [83].  Not only are the processes 
interrupted but the structural integrity of the adducted protein is compromised [84].  
Adduction is a term coined to identify proteins that have been modified by such carbonyls 
[85].  It is important to note that protein adduction is a stronger mediator of cytotoxicity 
than the depletion of cellular reducing agents such as glutathione [75], which implies the 
expressed concern relative to treatment in TBI. 
  Experimental models of mouse TBI in vivo have helped to appreciate the spatial 
and temporal magnitude of aldehydic production after injury.  For instance, 4-HNE and 3-
NT were found to increase in mouse cortical tissue as early as 30 minutes after injury as 
demonstrated by immunohistochemical (IHC) staining [64] and can last for at least a week 
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after injury [63]. (3-NT is considered a marker of oxidation as well, but does not possess 
the same species of reactivity as 4-HNE).   
Although Scheff et al., published nearly identical experiments, results concerning 
the modification of proteins in the cortex versus the hippocampus were published in 
separate journals of the same year.  Nevertheless, these experimental CCI-TBI rat models 
provided support for the acute increase and persistent modification of synaptic proteins by 
4-HNE, acrolein, protein carbonyl, and 3-NT in the hippocampus [78] and cortex [86] 
concurrent with a depletion of antioxidant systems. 
Lipid-derived breakdown products like 4-HNE and ACR are both neurotoxic and 
broadly disrupt cellular function in an acute and persistent fashion, but ACR reportedly 
demonstrates additional toxicity and reactivity.  For instance, exogenously applied ACR 
was shown to exhibit a tenfold potency in the ability to reduce respiratory function 
compared to 4-HNE in naïve rat isolated mitochondria [50].  Acrolein has been shown to 
initiate membrane instability and initiate LP [87], but only recently was ACR reported to 
be involved in the destruction of myelin. In these experiments acrolein was reported to 
initiate and facilitate demyelination of neurons by interfering with glutamate uptake, which 
facilitates excitotoxicity.  When ACR scavengers were applied to the system demyelination 
was prevented [88]. 
Reasons for the increased potency of ACR are primarily implicated by its reactivity.  
Acrolein, of all unsaturated aldehydes, is the most reactive and reacts 110-150 times faster 
with other biomolecules such as proteins compared to 4-HNE [87, 89-91].  Other aldehydes 
that contain electron-releasing substituents exhibit a reduced charge of the carbon cation 
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intermediary.  Therefore, the lesser the partial positive charge of the 3-carbon the double 
bond will exhibit decreased electrophilicity and therefore reduced reactivity [89].  
Experiments on ACR 1:1 adduct formation demonstrate that ACR possesses the highest 
second order reaction rate constant 121M-1s-1 [89], meaning that the rate of the reaction is 
directly proportional to the square of ACR concentration. And, while the rate constant (k) 
is experimentally determined and does not change as a constant, the medium in which the 
reactants are permitted to interact can sterically interfere with the ability of the reagents to 
meet.  Additional consideration should also be made for environmental conditions such as 
pH that can affect conformation of a targeted protein for which acrolein is attempting to 
adduct.  In other words, in the case of TBI, wherein the cell exists in a state of distress, the 
rate of reactions is not solely determined by an experimentally determined rate constants.  
Rather, other influences such as pH, hydrophobicity, half-life, and proximity of reagents 
among other factors have appreciable weight in the reactivity of carbonyls to various 
targets.   
 
1.10 Mitochondria  
 Mitochondrial are colloquially regarded as the “powerhouse of the cell”.  The 
phrase is meant to convey the unequivocal contribution to cellular vitality.  However, as 
Mr. Benjamin Parker eloquently regards: “With great power, comes great responsibility.”  
So, while empirically it is true that the mitochondria are responsible for the oxidative 
phosphorylation which provides far more energy than glycolysis, much care is provided by 
the cell to regulate its homeostasis.  Else, dire ramifications usually yielding death are 
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likely should the cell be forced to reconciliate insults for which it cannot compensate.  
These details and more will be elaborated, but before the pathology it is important to first 
introduce form and prototypical functionality. 
 The mitochondrion can be described according to its major substituents: the outer 
mitochondrial membrane (OMM), the inner mitochondrial membrane (IMM), the inner 
mitochondrial space (IMS) and the matrix.  The OMM is a lipid bilayer that encompasses 
the other remaining elements.  The IMM is also comprised of lipid bilayer.  The torturous 
shape creates folds called cristae that increases the surface area for which the electron 
transport system (ETS) can transduce energy [92].  The IMS exists between the OMM and 
the IMM and serves as the space for which protons collect, driven against their gradient by 
the ETS.  The most internal aspect is the matrix. Wherein not complex computer programs 
exist, rather, enzymes necessary for the continued degradation of glucose in what is known 
as the tricarboxylic acid cycle (TCA), citric acid cycle, or Kreb’s cycle. 
 
1.10.1 Mitochondrial function 
 Adenosine triphosphate (ATP) is the molecule produced by mitochondria.  ATP 
serves as a type of “energy currency” for the cell.  And upon utilization, the chemical 
energy release from the removal of the phosphate groups can be used to drive other process 
or enzymes.  This production of ATP involves several complex components, and will be 
briefly detailed as dictated by their relevancy and pertinence.  
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Glycolysis:  
The generation of ATP begins outside the mitochondria in the cytosol during 
glycolysis.  One molecule of glucose is broken down into two molecules of pyruvate which 
allows two “turns” of the TCA cycle described below.  This process produces 4 molecules 
of ATP and 2 molecules of nicotinamide adenine dinucleotide (NADH), which is a 
conserved coenzyme required to drive complex I of the ETS.  It should be noted that the 
net production of ATP is limited to 2 molecules, not 4, as the reaction necessitates the 
difference in ATP to complete. 
Tricarboxylic Acid Cycle: 
Pyruvate enters the mitochondria with NADH and is catabolized into acetyl 
coenzyme A (acetyl CoA).  Acetyl CoA enters the TCA cycle wherein 8 specific reactions 
facilitate the reduction (gain of electrons) to specific electron carriers.  For instance during 
this process a single acetyl CoA molecule is oxidized e.g. loses its electrons to other 
compounds and in doing so the acetyl CoA is converted into 2 molecules of carbon dioxide 
(CO2).  The other compounds that were reduced (received electrons from acetyl Co A) 
were created at various stages in the cycle and in different quantities.  In this process the 
following molecules were reduced: 
 3 molecules of NAD+ were reduced to 3 molecules of NADH 
 1 molecule of FAD was reduced to FADH2 
 1 molecule of GTP was created. 
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Flavin adenine dinucleotide (FAD) molecule mentioned above has similar 
functionality to NADH in that it is has the capacity to oxidize and be reduced again.  
Guanosine triphosphate (GTP) is a purine nucleoside triphosphate and is regarded as a 
single ATP equivalent used frequently by G-protein based signal transduction. 
Electron Transport System & Oxidative Phosphorylation: 
 The reduction of NAD+ and FAD to create NADH and FADH2 as described in the 
previous section are major components of the electron transport system (ETS).  These 
molecules contribute their previously acquired electrons to various complexes associated 
with the IMM [93].  Complexes I-IV work in concert with other proteins to establish a 
proton gradient by oxidizing their respective substrates i.e. the complex receives high 
energy electrons from their substrates and the complex then contributes protons (H+) across 
the IMM.  The first two complexes describe below are both entry points for the ETS, and 
is the principle reason why data relative to mitochondrial respiration is expressed as 
Complex I and Complex II-driven respiration.  (See Figure 1.5)  
 Complex I:  Known otherwise as “NADH: ubiquinone oxidoreductase” or 
NADH dehydrogenase (ubiquinone).  Complex I accept electrons from 
reduced forms of NADH and contributes to 4 protons across the IMM. 
 Complex II: Succinate dehydrogenase, receives electrons from FADH2, but 
does not contribute protons across the IMM. 
 Ubiquinone:  Known otherwise as “Coenzyme Q10.”  Although, not 
designated as a “complex,” ubiquinone receives the high energy electrons 
from either Complex I or II and “shuttles” electrons to Complex III. 
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 Complex III:  Cytochrome bc1 receives electrons from Ubiquinone and 
translocates 4 protons across the IMM through a series of complicated, 
nearly theatrical, reactions described by what is called the “Q cycle.”  See 
Nicholls and Ferguson 2002, for further details. 
 Cytochrome C: Another electron carrying molecule that transports electrons 
from Complex III to Complex IV. 
 Complex IV:  Cytochrome C oxidase is the last step in the ETS and 
catalyzes the transfer of 4 electrons (4e-) from cytochrome C to O2 the final 
electron acceptor.  In addition to this reaction, Complex IV “pumps” 2 
protons across the IMM. 
 Complex V:  ATP synthase spans the IMM.  The proton gradient formed by 
the pervious complexes is used by Complex V to transduce protons back 
into the matrix down the electrochemical gradient.  In doing so, mechanical 
energy is created to join adenosine diphosphate (ADP) with inorganic 
phosphate to create ATP i.e. phosphorylate ADP. 
The process of oxidizing substrates to generate a proton gradient is coupled to the 
phosphorylation of ADP to create ATP, hence the term oxidative phosphorylation. 
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Figure 1.5 Illustration of the major components of mitochondrial electron 
transport system (ETS).  Vertical bars represent four different states of 
mitochondrial respiration.  Hashed lines can be followed from the protein 
complexes to the vertical bars; activated complexes are green bars while 
inactive complexes are red bars.  
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1.10.2 Mitochondrial States of Respiration 
The rate of mitochondrial respiration can describe the speed at which oxidation and 
phosphorylation take place.  However, this rate is a coupled mechanism involving multiple 
reactions that are tightly controlled and principally determined by the proton electrical 
potential (Δp) and the difference of redox potentials nearest to sites of proton translocation 
[93].  
Experimental models that utilized the Oxytherm or Seahorse Bioscience to 
determine mitochondrial rates of respiration are capable of only measuring the amount of 
oxygen that mitochondria respire.  This metric is representative of a single reaction (the 
rate at which O2 becomes the final electron acceptor).  In order to fully assess the 
components of respiration and better understand where and how dysfunction can be 
measured, various compounds can be introduced into the isolated mitochondrial solution.  
The addition of these compounds to experimentally investigate mitochondrial dysfunction 
is further described in the Material and Methods chapter. 
Briefly, the addition of various substrates or inhibitors induces various “states of 
respiration” originally described by Chance and Williams [94] and later adapted by 
Nicholls and Ferguson [93].  The following introduces the states of respiration by the 
sequential addition of various compounds. (See Figure 1.5) 
 State I: Mitochondria alone in the presence of inorganic phosphate (Pi) 
 State II: Complex I substrates added e.g. pyruvate and malate.   
 State III: Addition of Complex V substrate ADP.  
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o Describes the rate of coupled oxidative phosphorylation. 
 State IV: Addition of Complex V inhibitor e.g. oligomycin. 
o Describes integrity of the IMM.  
 State V: 
o State Va: Addition of protonophore e.g. FCCP 
 Describes maximal state of oxidative respiration for 
Complex I. 
o State Vb: Addition of Complex II substrates, and addition of 
Complex I inhibitor. 
 Describes maximal state of oxidative respiration for 
Complex II. 
The respiratory control ratio (RCR) is a metric that can provide insight on the state 
of mitochondria, specifically it is an index of how “coupled” oxidative and phosphorylative 
mechanisms are.  RCR is the ratio of State III respiration (in the presence of pyruvate, 
malate, and ADP) divided by State IV respiration (mitochondria in the presence of 
pyruvate, malate, ADP, oligomycin A-an inhibitor of ATP synthase).  
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1.10.3 Mitochondrial Superoxide Production 
 As promised, and likely to the reader’s dismay, mitochondrial dysfunction 
especially in the context of TBI will be further discussed.  The principle source of 
superoxide production occurs from “electron leak” during the ETS.  During the transfer of 
elections throughout the ETS, electrons can make a “quantum leap” from their intended 
destinations.  And, while a benevolent Ziggy does not provide assistance in where the 
electrons are transferred, leaping electrons will preferentially partially reduce O2.  As a 
result superoxide is produced (O2
•).  Recently reviewed, multiple sites within the ETS are 
capable of electron leak and subsequent superoxide formation [95].  Complex I and III are 
generally accepted as the principle producers of superoxide.  Complex I produces 
superoxide at its flavin prosthetic group within the NADH sub-component and at the 
ubiquinone sub-component. Complex II at the flavin site and Complex III produces 
superoxide at the ubiquinone binding site [95].  However, other sources of superoxide 
formation exist in the ETS.  For instance, in adjacent pathways to the ETS (not from 
pyruvate) rather the β-oxidation of fatty acids depend upon electron transferring proteins 
(ETF) [95].  Experiments in isolated mitochondria from naïve mice have contributed a 
wealth of knowledge regarding the idiosyncrasies of superoxide formation.  In particular 
Complex I and III are frequently attributed as the primary sources; Complex I contributing 
far more than complex III.  However, researchers have shown that the production of 
superoxide is complex (pun intended) and under conditions wherein Complex I is not able 
to function e.g. inhibited experimentally with rotenone, the enzymes within the matrix such 
as pyruvate dehydrogenase (PDH) and 2-oxoglutarate dehydrogenase (OGDH) produce 
more superoxide than Complex I in normal conditions [96].  This concept is important to 
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consider when trying to understand the wherein free radicals are produced following a TBI, 
especially considering that aldehydic breakdown products are capable of binding to a wide 
range of proteins to inhibit function.  
 
1.10.4 Mitochondrial Peroxynitrite Formation 
 As previously mentioned, the product of O2
•- and •NO, forms a temporary 
peroxynitrite anion (ONOO-) which degrades into further more toxic and reactive 
aldehydes.  The production of NO• is produced by nitric oxide synthase and is important 
for cellular signaling. Of the three forms, endothelial NOS (eNOS), neuronal NOS (nNOS), 
and inducible NOS (iNOS), mitochondrial NOS is activated by the influx of Ca2+.  Given 
the relevancy of Ca2+ homeostasis by mitochondria, discussed in the next section, 
dysfunctional mitochondria can contribute further to formation of free radicals.   
 After injury in the experimental mouse CCI-TBI model protein nitration, an index 
of peroxynitrite formation, increased in the cortex and hippocampus significantly 24 hours 
after injury and peaked at 72 hours.  The expression (mRNA) of eNOS did not increase, 
but protein levels of eNOS did significantly at 48 and 72 hours in the hippocampus and 
cortex.  These experiments also demonstrated at least a partial temporal relationship 
between NOS protein and marker of oxidative damage 3-NT [97]. 
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1.10.5 Role of Mitochondria in Calcium Homeostasis 
 Mitochondria play an important role in the regulation of Ca2+, especially after CNS 
injury [98]. Should the neuron reach an intercellular concentration of approximately 
500nM Ca2+i then mitochondria initiate means to accommodate the relatively high influx 
of Ca2+ [99].  Calcium regulation is driven by several Ca2+ channels.  A Ca2+ uniporter 
exists to move Ca2+ into the matrix; this channel is compelled by the mitochondrial 
membrane potential (ΔΨ).  The efflux of Ca
2+ on the other hand is driven by the Ca2+/nNa+ 
exchanger, whose functionality is partially dictated by the H+/Na+ exchanger [100].  The 
exact ratio of Ca2+ to Na+ is presently undetermined [93].  To a certain point the influx of 
Ca2+ can be buffered in the matrix by the creation of a calcium-phosphate gel [93].  
However, in the event of TBI mitochondria are often incapable of buffering the massive 
influx of Ca2+. 
 
1.10.6 Mitochondrial Dysfunction after TBI 
 In addition to the influx of Ca2+ from glutamate-mediated opening of NMDA 
channels, traumatic tearing, and failure of Na+/K+ ATPases in the cell membrane depolarize 
the cell.  Two major ramifications are subsequent to the Na+/K+ failure: (1) the 
depolarization causes voltage-gated Ca2+ channels to open and aberrant Ca2+ influx [101].  
(2) Loss of Na+/K+ ATPase functionality means the accumulation of intercellular Na+; the 
accumulation instigates the reversal of membrane Ca2+/Na+ exchangers to pump Ca2+ into 
the cell. 
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 Such a torrential influx of Ca2+ in the cell after TBI overwhelms the capacity of 
mitochondria to maintain homeostasis.  The excessive Ca2+ loading or cycling [102] as 
well as oxidative stress [103] will induce mitochondrial permeability transition (mPT).  The 
formation of the mPT allows the movement molecules up to ~150 kDa and the loss of the 
mitochondrial membrane potential (ΔΨ), exacerbates ROS formation, increases lipid 
peroxidation, and initiates apoptotic cellular death pathways[104, 105].  In an attempt to 
preserve and institute the proton gradient Complex V (ATP synthase) reverses [106] and 
contributes overall depletion of energy.  
 Strong evidence for mitochondrial dysfunction as a result of mPT following 
experimental CCI-TBI was demonstrated in experiments that investigated the treatment of 
cyclosporin A (CsA) in isolated rat mitochondria and synaptosomes.  In these experiments 
CsA treatment was able to reduce ROS formation and prevent mPT formation by excessive 
Ca2+ loading.  CsA was postulated to medicate the observed effects by either (1) preventing 
mPT formation by interacting with cyclophilin D, (2) reducing glutamate-mediated 
cycling/uptake of Ca2+, or (3) the CsA-cyclophilin complex could suppress calmodulin 
phosphatase which normally would activate NOS by phosphorylation [106].  CsA was later 
reported to spare 50% of otherwise lost cortical tissue following TBI in the same rat CCI-
TBI model. [107]. 
 As for the time course of mitochondria damage following TBI, experimental mouse 
CCI-TBI models were used to conclude that the onset of mitochondrial dysfunction is 
relatively early.  Mitochondria isolated from the cortex of mouse brains following a CCI-
TBI were reported to exhibit a significantly impaired ability to respire oxygen 30 minutes 
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after injury to the latest time point measured, which was less impaired but still significant 
at 72 hours following injury [73]. 
 Despite the acute onset of mitochondrial dysfunction, the possible therapeutic range 
for pharmacological intervention was reported to exist within 5 minutes to 24 hours after 
CCI-TBI in isolated cortical mouse mitochondria [108].  The investigators concluded this 
by administration of carbonyl cyanide 4-trifluoromethoxy phenylhydrazone (FCCP).  
FCCP is protonophore which acts to “uncouple” oxidation of substrates from the 
phosphorylation of ADP.  Though this treatment is considered an “insult” to the 
mitochondria, therapeutic worth is obtained in reducing Ca2+ influx, reportedly by reducing 
the membrane potential (ΔΨm) thereby reducing the chemiosmotic gradient and 
consequently reducing the influx of Ca2+ into the mitochondrial matrix.  The importance 
and relevance of this experiment to the current work will become apparent in the 
Discussion; however, it is important to note now that therapeutic intervention can be 
applied within 24 hours (as shown with FCCP) because the mitochondria are able to be 
uncoupled.  In other words, 24 hours post-injury mitochondria are still coupled regardless 
of how diminished.  
 Aside from Ca2+ dysregulation, mPT, and uncoupled state of mitochondria after 
injury, mitochondria are also seductive targets to potentiate another type, but related form 
of damage.  Given the rich in environment of polyunsaturated fatty acids in the lipid 
bilayers and the intrinsic ability to generate reactive oxygen species in both normal and 
pathological conditions, mitochondria are targets for not only LP but subsequent aldehydic 
attacks.   
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 Specifically, 4-HNE and ACR have been identified as reactive carbonyls capable 
of impairing mitochondrial respiration and contribute to the accumulation of oxidative 
damage markers [50, 73, 74, 109].  The impaired mitochondria become incapable of 
regulating ionic homeostasis, have severely reduced or completely inhibited ability to 
generate ATP through oxidative phosphorylation, and will initiate apoptotic cell death, 
thereby killing the neuron in which they reside [65, 73, 110-113].  It should be noted that 
while apoptotic cell death is the result of mitochondrial dysfunction, the death of ACR-
treated neurons in culture is by necrosis which does not directly involve cytochrome c 
release [27, 114]   
 
1.11 Carbonyl Scavenging 
 All of the previously described pathologic processes involve reactive aldehydes e.g. 
carbonyls.  In each instance 4-HNE and acrolein are capable of either initiating, prolonging, 
or exacerbating all of the aforementioned processes involving, but not limited to free 
radical generation, lipid peroxidation, Ca2+ dysregulation, and mitochondrial function.  
Additionally, the pharmacological prevention or amelioration of each of these pathological 
processes independently has been met with some success, but currently no Food and Drug 
Administration (FDA)-approved pharmacological intervention for the treatment of human 
TBI exists.  
 Increasingly, researchers have begun to investigate carbonyl scavenging.  Simply 
defined for the context of TBI: carbonyl scavenging is a means to prevent the binding of 
neurotoxic aldehydes to biological substrates, by offering an exogenous pharmacological 
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compound that will bind to the carbonyls instead. Carbonyl scavengers by definition 
exhibit a high reactivity to endogenous aldehydes [115], and the most effective scavengers 
contain a hydrazine pharmacophore [116].  The hydrazine moiety is a (-NH-HN2) 
functional group capable of binding to reactive aldehydes.  One of the more extensively 
studied hydrazine-containing compounds is the anti-hypertensive compound hydralazine 
(HZ). 
Hydralazine has shown potential for carbonyl scavenging in neurotrauma when first 
examined in spinal cord compression injuries.  In these experiments spinal cords extracted 
from guinea pigs sustained an ex vivo compression injury followed by immersion in 
500mM of hydralazine.  Hydralazine-treated spinal cords exhibited significantly less 
membrane permeability, reduced superoxide production,  and decreased acrolein 
accumulation by way of immunohistochemical statining (IHC) [117].   
 In other experiments also investigating the HZ compound, the utility of the 
hydrazine functional group was highlighted as an effective means to prevent adduct 
crosslinking [118].  Here, the authors were able to demonstrate that ACR rapidly causes 
cross-linking and oligomerization of acrolein adducted proteins and that HZ was able to 
prevent this even when added after the application of ACR.  This experiment is pertinent 
and therefore important for two reasons: 1) ACR even after bound is still reactive and can 
cross-link other proteins.  2) Hydrazine-containing compounds are able to prevent this.  
The authors concluded that the majority of toxicity is attributed to this mechanism and that 
the neuroprotective effects are primarily due to preventing cross-linking by adduct trapping 
and not only scavenging free aldehydes [118, 119].  Given the efficacy in this and other 
model paradigms, hydralazine possess significant potential for TBI.  However, HZ 
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possesses significant shortcomings. HZ is a potent vasodilator with a short half-life of 
approximately 30 minutes [120].  Early investigations with HZ advise that the therapeutic 
levels necessary for carbonyl scavenging are not tolerable in vivo considering the potency 
of the anti-hypertensive effects  [120]. 
 Another compound that retains the hydrazine moiety but does not possess 
hypotensive effects is the monoamine oxidase inhibitor (MAO-I) phenelzine (PZ).  (Figure 
1.6) 
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Figure 1.6. Phenelzine (PZ) is an FDA-approved drug for the treatment of 
depression and anxiety.  PZ is an inhibitor of monoamine oxidase A and B 
types which prevents the degradation of monoamines such as serotonin, 
norepinephrine, epinephrine and dopamine.   
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Phenelzine is an FDA-approved drug for the treatment of major depression by 
irreversibly inhibiting both A and B monoamine oxidase (MAO).  MAO is contained 
within the presynaptic neuron and within in the outer mitochondrial membrane.  The 
compound does contain a phenolic ring which is capable of acting as an anti-oxidant and a 
carbonyl scavenger, though predominantly by the latter means [116, 121].  Carbonyl 
scavenging (Figure 1.7). 
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Figure 1.7 Chemical scavenging reactions of phenelzine with reactive 
carbonyls: 4-hydroxynonenal and acrolein. 
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When smooth muscle cells in vitro were exposed to various oxidized lipoproteins, 
PZ treated cells were capable of reducing cytochrome c release, reduce hydrogen peroxide 
and superoxide production, reduced mPT formation, and reduce the presence of cytotoxic 
carbonyls such as 4-HNE and other compounds reactive to thiobarbituric acid [116].  
(Thiobarbituric acid reactive substances (TBARS) is an assay to detect malonodialdehyde 
which is not exclusively a by-product of lipid peroxidation.)  The authors made special 
effort to indicate that MAO-I s in these assays did not contribute to the formation of 
superoxide radicals because the medium did not contain MAO substrates. 
  The investigation of PZ in vivo as a treatment for neurotrauma is presently 
underwhelming, but what currently exists is promising.  In vivo experiments investigating 
the use of PZ in ischemia-reperfusion brain injury in the gerbil have demonstrated what the 
authors coined as “reduction of aldehyde load.”  Though, this phrase will not be used in 
this manuscript the experiments were useful in that PZ was able to reduce neurotoxic 
aldehydes in this injury paradigm with up to a 3 hour delay of administration [122].  
 Recently our laboratory has begun to investigate the efficacy of PZ as a treatment 
for TBI.  Initially the investigation of PZ took place in an ex vivo model, wherein cortical 
brain mitochondria were isolated from naïve mice and exposed to an exogenous application 
of 4-HNE.  Our mitochondrial respirations studies demonstrated that a 5 minute 
pretreatment of PZ was able to significantly protect the ability of mitochondria to respire 
oxygen for both Complex I and Complex II-driven respiration.  Similarly isolated, 
mitochondria exposed to a 5 minute pre-treatment of PZ significantly reduced 4-HNE, 
marker of oxidation via immunoblotting assay [50]. 
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 The investigation of PZ’s ability to protect mitochondrial function was further 
studied in vivo using the rat CCI-TBI model.  Rats were given a single 10 mg/kg 
subcutaneous injection of PZ 15 minutes after a severe CCI-TBI, and assessed 3 hours later 
for mitochondrial dysfunction.  PZ treatment groups exhibited significant protection of 
mitochondrial respiration for Complex I and II-driven rates and overall RCR. Additional 
experiments investigated the ability of PZ to preserve cortical tissue in the rat two weeks 
after a severe TBI.  PZ-treated rats using the same dosing paradigm as previously 
mentioned exhibited a significantly higher volume of spared tissue when compared to 
vehicle-treated (saline) animals [50].    
 
1.12 Dissertation Hypothesis 
 Given the involvement of reactive aldehydes in a wide range of secondary injury 
mechanisms following TBI, and the potential of PZ to effectively scavenge those reactive 
carbonyls-- we seek to further investigate the potential of PZ as a treatment for TBI by 
addressing the following hypothesis. 
 The Overall Hypothesis of this dissertation is that carbonyl scavenging with 
phenelzine (PZ) will exert an antioxidant neuroprotective effect in the traumatically injured 
rat brain mechanistically related to PZ’s hydrazine moiety reacting with the lipid 
peroxidation-derived reactive aldehydes 4-HNE and ACR. 
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Chapter 2 
Materials and Methods 
(Portions submitted for publication in Free Radical Biology and Medicine) 
 
2.1 Animals 
All experiments involving rats were performed with adult male Sprague-Dawley 
(SD) rats (Harlan, Indianapolis, IN) weighing 300-350g.  Rats were exposed to food and 
water ad libitum.  All protocols associated with this study are approved by the University 
of Kentucky Institutional Animal Care and Use Committee which abide by the National 
Institutes of Health Guidelines for the Care and Use of Animals. 
 
2.2 Drug & Substrate Preparation  
2.2.1 4-HNE and Acrolein 
 4-Hydroxynonenal (4-HNE) and 2-propenal (acrolein) were purchased from the 
manufacturer and prepared fresh before each experiment consistent with previously 
described methods and diluted in distilled water to the desired molarity [72].  Acrolein was 
purchased from Sigma-Aldrich (Supelco, Bellefonte, PA).  4-HNE was purchased from 
EMD Chemicals Inc. (Merck KGaA, Darmstadt, Germany).  Stock solutions were stored 
according to the manufacture’s suggestions at -20oC.   
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2.2.2 Pargyline 
Pargyline hydrochloride (Eutonyl - P8013) was purchased from Sigma-Aldrich. 
Pargyline was titrated in 0.9% saline to working solution of 5 mg/ml.  The final injected 
volume was calculated based on the weight of the rat to meet the desired dose concentration 
of 10 mg/kg.  Maintenance doses, when used, were diluted to final concentration of 5 
mg/kg. 
 
2.2.3 Phenelzine  
Phenelzine sulfate salt was purchased from MP Biochemicals (Solon, OH, USA) 
and titrated in 0.9% saline to working solution of 5 mg/ml.  The final injected volume was 
calculated based on the weight of the rat to meet the desired dose concentration of 10 
mg/kg.  Maintenance doses, when used, were diluted to final concentration of 5 mg/kg. 
 
2.2.4 Mitochondrial Substrates & Inhibitors 
Preparation of mitochondrial substrates and inhibitors for use with Clark-type 
oxygen electrode were based upon previously published concentrations [72, 108, 123].   
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Table 2.1.  Preparation of Mitochondrial Substrates and Inhibitors 
Compound Manufacturer Stock Preparation   
Pyruvate Sigma P-2256 500 mM 550 mg  to 200 μl of 1M HEPES in 10 ml 
diH20 * 
Malate Sigma M-7397 250 mM 335 mg  to 200 μl of 1M HEPES in 10 ml 
diH20 * 
ADP Sigma A-5285 30 mM 128.2 mg to 200 μl of 1M HEPES in 10 ml 
diH20 * 
Oligoycin-A Biomol CM-
111 
1 mg/ml 1 mg to 1 ml of methanol 
FCCP Biomol CM-
120 
1 mM 2.542 mg  to 10 ml of 100% ethanol 
Succinate Sigma S-7501 1 M 2.36 g to 400 μl of 1M HEPES in 20 ml 
diH20 * 
Rotenone Biomol CM-
117 
1 mM 3.94 g to 10 ml of 100% ethanol* 
* Adjust pH to 7.2 using KOH and HCl. 
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2.3 Controlled Cortical Impact Surgical Procedures 
 Young adult male Sprague-Dawley (SD) rats (Harlan Labs, Indianapolis, IN) 
weighing 300-350g were used in experiments wherein controlled cortical impact (CCI) 
procedures were used to induce a traumatic brain injury (TBI).  Rats were anesthetized 
with 5% isoflurane (SurgiVet, 100 series) and oxygen (SurgiVet, O2 flowmeter 0-4lpm).  
Heads were shaved and placed into a stereotaxic frame (Kopf Instruments, Tujunga, CA).  
Isoflurane was reduced to 2% for remainder of procedure.   
Lubrication was applied to the eyes to prevent drying and a rectal probe was used 
to maintain body temperature at 37o C via electronic heat pad under the animal.  A midline 
surgical incision was made to retract skin and expose the skull for a 6 mm unilateral 
craniotomy.  The craniotomy was performed with a Michelle trephine (Miltex, Bethpage, 
NY) centered between bregma and lamda sutures, lateral to the sagittal suture.  The cortex 
was exposed by removing the skull cap carefully without damaging the dura.  The exposed 
brain was injured with an electronically controlled impact device (TBI 0310; Precision 
Systems & Instrumentation, Fairfax Station, VA, USA) in accordance with previously 
described methods [50, 73, 106, 107, 124].  The dura was injured by a 5 mm beveled tip 
that compressed the exposed cortex 2.2 mm at a velocity of 3.5 m/sec, and a dwell time of 
500ms.  A thin veil of Surgicel (Johnson & Johnson, Arlington, TX) was placed over the 
injury.  A premade plastic cap with an 8 mm diameter was attached directly to the skull 
over the injury site with commercial cyanoacrylate. The cyanoacrylate was allowed to dry 
before the wound was closed with staples.  Rats were removed from stereotaxis and placed 
into an incubation cage, which provided heat via conduction by an electronic water pump.  
Rats were monitored until the righting reflex was regained.   
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 Sham groups are defined as rats which were exposed to only craniotomy, but not 
CCI.   
 Vehicle groups are defined as rats which are exposed to craniotomy, CCI, and 
received the vehicle solution (saline).   
 Treatment groups are rats which received the craniotomy, CCI, and the drug 
solution in its respective vehicle.  The drug administered in all in vivo experiments 
was phenelzine which required a saline vehicle.  Rats were randomly assigned to 
designated groups. 
 
2.4 Ficoll- Purified Mitochondrial Isolation and Protein Assay 
Isolation of rat brain mitochondria was performed on ice and is consistent with 
previously published methods [50, 73, 125]. Rats were exposed to CO2 for approximately 
1 minute until flaccid.  Brains were rapidly extracted after decapitated.  Ipsilateral cortical 
tissue was dissected from the rest of the brain and a 8mm diameter circular punch was used 
to extract tissue corresponding to the site of impact including the penumbra.  The cortical 
tissue was homogenized using Potter-Elvejhem manual homogenizer in 3mL of ice-chilled 
isolation buffer (215 mM mannitol, 75 mM sucrose, 0.1% bovine serum albumin, 20 mM 
HEPES, and 1 mM EGTA, pH adjusted to 7.2 with KOH).  Differential centrifugation at 
4oC was used to separate nuclei and cellular components from crude mitochondrial pellet. 
Tissue was exposed to two rounds of centrifugation (1300 x g for 3 min) at 4o C.  After 
each centrifugation the supernatant was decanted and diluted in isolation buffer with 
EGTA.  The supernatants were centrifuged at 13,000 x g for 10 minutes.  The pellet was 
resuspended carefully in 400µL of isolation buffer with EGTA which was place inside a 
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nitrogen bomb (Parr Instrument Company, Moline, IL) at 1,200 psi for 10 minutes to 
disrupt synaptosomes.  The samples were then added onto a discontinuous 7.5% and 10% 
Ficoll layered gradient.  The samples layered on the Ficoll column were centrifuged at 
100,000 x g for 30 minutes at 4o C within a Beckman SW 55ti rotor.  The resultant pellet 
was resuspended in 25 to 50 µL isolation buffer without EGTA to yield a concentration of 
~10 mg/mL.  Final protein concentration was determined using BCA protein assay kit 
measuring absorbance at 562 nm with a BioTek Synergy HT plate reader (Winooski, VT).  
For each experiment, fresh mitochondria and buffer solutions were prepared. 
 
2.5 Mitochondrial Bioenergetics Analysis  
2.5.1 Clark-type Electrode for in Vivo Use 
The Clark-type oxygen electrode (OXYT1/ED, Hansatech Instruments, Norfolk, 
UK) was used to assess the ability of mitochondria to respire oxygen i.e. a metric of 
mitochondrial function.  Approximately 180µg to 200µg can be isolated from injured and 
uninjured cortical punches.  However, 100 µg of isolated mitochondrial protein are used as 
previously described [126] to assess mitochondrial function.  Mitochondria were 
suspended in respiration buffer (215 mM mannitol, 75 mM sucrose, 0.1% BSA, 20 mM 
HEPES, 2 mM MgCl, 2.5 mM KH2PO4, pH adjusted to 7.2) in a volume of 250µL which 
was continuously stirred in a sealed chamber at a constant 37o C.   
 In accordance with previously published manuscripts respiratory function was 
measured as the amount of oxygen consumed over time (nmoles/min) [73].  Substrates 
were added to chamber in the order presented in Table 2.2. 
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 Table 2.2.  Inducers of Various States of Respiration (at Final 
Concentrations) 
 
 
 
 
 
 
 
 
 
 
 
 
 
State Substrates Amount  
I no substrates n/a Equilibrate for one minute. 
Contains only mitochondria and 
Respiration buffer 
II Pyruvate + 
Malate  
2.5 μL of 5 mM 
Pyruvate+ 2.5 mM 
Malate 
Complex I substrates allowed to 
mix with mitochondria and reach a 
steady rate 
III ADP 1.25 μL of 150 μM Allowed to achieve maximal 
respiration with a second bolus of 
ADP 
IV Oligomycin 0.25 μL of 1 μM Allowed to reach maximum effect 
in approximately 2 minutes 
Va FCCP 0.5 μL of 1 μM Allowed to reach maximum effect 
in approximately 2 minutes 
Vb Rotenone 0.2 μL of 1 mM Allowed to inhibit Complex I 
respiration 
 Succinate 5 μL of 10 mM Complex II substrates allowed to 
drive respiration. 
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2.5.2 Preparation of Seahorse Sensor Cartridge and Mitochondrial Substrates/ Inhibitors 
The Seahorse Extracellular Flux Analyzer, XFe24 (Seahorse Biosciences) can be 
used to quantify cell culture or isolated mitochondrial bioenergetics.[127-131]  In these 
experiments, XFe24 analyzer was used to quantify respiratory function and bioenergetics 
of mitochondria in intact and well-coupled (respiratory control ratio (RCR) >5).  
Mitochondria were isolated using Ficoll-gradient centrifugation as previously described 
[127].  The XFe24 analyzer offers a transient, 7 µL chamber within 24-well microplates 
that enables the real-time determination of oxygen and proton concentrations.[107, 131] 
Figure 2.1 A, depicts a representative mitochondrial oxymetric trace.  One day preceding 
experimentation 1.3mL of XF Calibrant solution (Seahorse Bioscience) was added to each 
well of the 24 well dual-anaylte sensor cartridge (Seahorse Biosciences).  The sensor 
cartridge was stacked on top of a Hydro Booster plate which was stacked on a Utility Plate 
(Seahorse Biosciences).  The stacked plates were incubated overnight in a 370 C incubator 
without CO2.  The sensor cartridge was removed from incubation and placed into the 
Seahorse XFe24 the day of experimentation, loaded with mitochondrial substrates and 
inhibitors at 10x concentrations.  For the initiation of state III respiration e.g. activation of 
complex I and IV, Port A of the sensor cartridge received  (50 mM) pyruvate / (25 mM) 
malate / (10 mM) ADP .   Port B contained 10 µM Oligomycin-A solution for the 
generation of state IV respiration.   Port C contained 40 µM solution of FCCP for 
uncoupled, ADP-driven [complex I] state IV respiration.  Port D contained 100 nM solution 
of Rotenone (Company)/ 100 mM of Succinate (Company) for assessment of uncoupled, 
Succinate-driven [complex II] state IV respiration.  During the automated sensor 
calibration, 7.5 µg of isolated mitochondria were suspended in 50µL in mitochondrial 
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isolation buffer and added to each well of Cell Culture plate (Seahorse Biosciences) 
excluding background wells which contained respiration buffer alone.  The plate was then 
centrifuged at 2000 rpm for 4 min at 40C to attach mitochondria to the 24-well cell culture 
plate.  After centrifugation 450 µL of warmed ( 370C) respiration buffer (215 mM 
Mannitol, 75 mM Sucrose, 0.1% BSA, 20 mM HEPES, 2 mM MgCl, 2.5 mM KH2PO4 
adjusted to pH of 7.2 with KOH) was added gently to the corner of each well for a total 
volume of 500 µL.  Figure 2.1 B illustrates the electron transport system, substrates, and 
status of activity for respective complexes. Experiments investigating the treatments of 
phenelzine, pargyline, 4-HNE, or acrolein followed once the mitochondria were fixed to 
culture plate and are described below.  The following Table 2.3 list the protocol for 
Seahorse mitochondrial respiration assay. 
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Table 2.3.  Standard Seahorse Mitochondrial Respiration Protocol 
 Standard Seahorse Mitochondrial Respiration Protocol 
1 Probe Calibration 
2 Mix 1 minute 
3 Time Delay: 1 minute and 30 seconds 
4 Mix 25 seconds 
5 Measure 2 minutes 
6 Mix 1 minute 
7 Injection Port A (pyruvate/ malate/ ADP) 
8 Mix 25 seconds 
9 Measure 2 minutes 
10 Mix 1 minute 
11 Inject Port B (oligomycin) 
12 Mix 25 seconds 
13 Measure 2 minutes 
14 Mix 1 minute 
15 Inject port C (FCCP) 
16 Mix 25 seconds 
17 Measure 2 minutes 
18 Mix 1 minute 
19 Inject port D (rotenone/ succinate) 
20 Mix 25 seconds 
21 Measure 2 minutes 
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4HNE and ACR Dose Response 
Experiments were performed to determine the optimal concentration of 4-HNE and 
ACR to inhibit approximately 50% (suboptimal dose) of mitochondrial function.  Isolated 
mitochondria affixed to culture plate (as described previously) were exposed to 4-HNE or 
ACR ranging from 10µM to 100 µM and 1µM to 10 µM, respectively.  Following 4-HNE 
or ACR treatment mitochondria were assessed by the XFe24 for oxygen consumption rate 
(OCR) (pmoles O2/min).  OCR were generated by Seahorse algorithms designed to 
calculate area under the curve.  Excel (Microsoft) software was used to isolate time specific 
points wherein the generated rate calculations reflected the OCR of Complex I and 
Complex II e.g. the specified time points following the auto-injection of pyruvate-malate 
and succinate, respectively.  Because mitochondria possess the capability to eventually 
utilize all of the ADP substrates and there exists a delay before oligomycin can inhibit 
respiration, the highest time points for ADP rates and lowest time points for oligomycin 
rates are used in place of software generated averages.  This is in accordance with 
previously published methods [127]. The current studies indicate optimal dose of 4-HNE 
and ACR was determined to be 30 µM and 3 µM, respectively. 
PZ Dose Response to 4-HNE or ACR 
Increasing concentrations of PZ (3 µM, 10 µM or, 30 µM) were exposed to isolated 
mitochondria (7.5 µg) in 24 well culture plates (Seahorse Biosciences) for 5 minutes.  
Immediately following PZ pretreatment mitochondria were exposed to reactive aldehydes 
such as 4-HNE and ACR (30 µM and 3 µM respectively) for 10 minutes.  Culture plates 
containing PZ pretreated mitochondria with subsequent reactive aldehyde exposure were 
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assessed for their ability to respire oxygen with XFe24, via measurement of OCR (pmoles 
O2/min). 
PZ or PG Treatment against 4-HNE or ACR 
Similar experiments were used to determine the efficacy of a PZ to prevent 4-HNE 
or ACR-induced respiratory inhibition.  In these experiments, isolated mitochondrial were 
exposed to a 5 minute pretreatment of PZ 30 µM, followed by a 10 minute exposure to 
reactive aldehyde 4-HNE or ACR.  Phenelzine pretreatment concentrations were chosen 
based on the PZ dose response to 4-HNE or ACR, and in accordance with previously 
published methods published in isolated cortical mouse brain mitochondria.[50, 72]  
Concentrations of pargyline (PG) were based on molar equivalency with the most effective 
dose of PZ. 
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Figure 2.1.  A) Typical oxymetric trace demonstrating mitochondrial 
bioenergetics as measured by oxygen consumption rate (y-axis).  The 
addition of substrates to mitochondria is indicated along the x-axis.  B)  
Illustration of the major components of mitochondrial electron transport 
chain (ETC).  The addition and the effect of exogenous substrates on the 
ETC is indicated by green hashed arrows (activation) or blunt red arrows 
(inactivation). C) Vertical bars represent four different states of 
mitochondrial respiration.  Hashed lines can be followed from the protein 
complexes to the vertical bars; activated complexes are green bars while 
inactive complexes are red bars.  There are depicted two State V respiration 
states V-1 and V-2 which represent Complex I and Complex II-driven 
states, respectively.  For example: at 14 minutes, oligomycin is added to the 
mitochondrial pool which inhibits (red blunt arrows) Complex V.  Hashed 
lines emerging from Complex V depict that the complex is activated during 
State III respiration (green bars), but is deactivated in all other measured 
states (red bars). 
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2.6 Mitochondrial Calcium-Buffering  
  In order to determine the extent to which mitochondria can buffer calcium, 
mitochondria were isolated from injured rat brains as described above and in accordance 
with previously published methods [73, 124, 132, 133].  A spectrofluorometer (Shimadzu 
RF-5301) was used to measure extra mitochondrial Ca2+.  Mitochondria (100 µg) within 
the spectrofluorometer, were incubated in a cuvette at 37oC in a 2 mL solution containing 
respiration buffer (125 mmol/L KCl, 2 mmol/L MgCl2, 2.5 mmol/L KH2PO4, 0.1% BSA, 
20 mmol/L HEPES at pH 7.2) and 100nM Ca2+-sensitive indicator Calcium Green 5 N 
(CaG5N) (Molecular Probes, Eugene, OR).  CaG5N possesses an excitation wavelength at 
506 nm and an emission wavelength at 532 nm, which is used to determine the point at 
which mitochondria can no longer sequester Ca2+.  The solution also contained 150 nM of 
tetramethyl rhodamine ethyl ester (TMRE) which is used to estimate the mitochondrial 
transmembrane potential (Δψm).  
Mitochondrial substrates were utilized to initiate respiration and were added in 
sequential order every minute starting with 5 mM pyruvate and 2.5 mM malate.   At minute 
two 150 µM of ADP was added.  At minute three 1µM of oligomycin was added.  At 
minute 5, a KD Scientific model 310 series infusion syringe pump (Holliston, MA) was 
used to infuse Ca2+ at a rate of 160nmol of Ca2+ per mg of mitochondrial protein per minute.  
Concentration of substrates and oligomycin inhibitor represent final concentrations.   
Values reported in Figure 5.9 were calculated based on the base-line CaG5N 
fluorescence readings before the infusion of calcium.  Signal above 150% was considered 
the point at which mitochondria were unable to buffer calcium.  This value was calculated 
by concentration of calcium infused (nmol/mg) prior to the point at which mitochondria 
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were 150 % above base-line.  The value in the trace of Figure 5.9 is the infusion rate of 
calcium per minute into the chamber divided by the amount of mitochondria in the chamber 
as measure previously by protein concentration assay: nmoles Ca2+/mg protein/min [132]. 
 
2.7 Western Blot Analysis 
2.7.1 Western Blot Analysis of Oxidative Damage Markers 
In order to measure markers of oxidative damage (4-HNE and ACR) the following western 
blot analysis was used, which is in accordance with previously published methods [36, 
134].  Mitochondrial samples assayed for 4-HNE adducts were separated on a precast gel 
(12% Bis-Tris w/v acrylamide; Criterion XT, Bio-Rad) with XT-MOPS buffer (Bio-Rad).  
Mitochondrial samples assayed for ACR adducts were separated on precast gel (4-12% 
gradient Tris-Acetate gels) using MOPS buffer (BioRad).  Proteins separated on gel were 
transferred to nitrocellulose membranes with Semi-dry electrotransfering unit (BioRad) at 
15 volts for 45 minutes at room temperature. Following transfer, membranes were blocked 
in 5.0% milk in TBS (Tris buffered solution; 20mM Tris HCl, 150 mM NaCl) for one hour 
at room temperature.  Membranes were then incubated at 40C overnight in primary 4-HNE 
or ACR antibody solution TBST (0.5mM Tween-20).  4-HNE rabbit polyclonal primary 
antibody (Alpha Diagnostics) was diluted 1:2,000.  ACR mouse monoclonal antibody 
(Abcam, United States) was diluted at 1:1,000.   
4-HNE and ACR primary antibodies were detected via 2 hour incubation at room 
temperature with goat rabbit immunoglobulin G (IgG) or anti-mouse IgG secondary 
antibody conjugated to infrared dye (1:5000, IRdye-800CW, Rockland) in TBST.  
Membranes were analyzed with LiCor Odyssey InfraRed Imaging System (Li-Cor 
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Biosciences, Lincoln, NE).  4-HNE and ACR protein smears were assessed from 150 kD 
to 50 kD and compared to single control group and expressed as percent of that group. 
No primary controls for 4-HNE and acrolein have been provided in Appendix B. 
 
2.7.2 Western Blot Analysis of Spectrin Degradation 
The analysis of α-spectrin proteolysis by western blot analysis discussed below is 
in accordance with previously published manuscripts [36, 64, 65].  Cortical punch samples 
from rats as previously described were rapidly dissected on a glass stage chilled with ice 
and submerged in Triton lysis buffer (1% Triton, 20 mM Tris HCL, 150 mM NaCl, 5 mM 
EGTA, 10 mM EDTA, and 10% glycerol) which contained protease inhibitors (Complete 
Mini Protease Inhibitor Cocktail; Roche Diagnostics Corp., Indianapolis, IN).  All samples 
were homogenized by sonication and centrifuged for 30 min (18,000 g at 4oC).  The 
resulting supernatant was decanted and transferred to a new centrifuge tube; the pellet was 
discarded.  Protein concentrations were determined using the BCA method described 
above.  All samples were diluted to an optimal target concentration of 10 mg/mL.  Samples 
where then separated on a 3-8% Tris-Acetate CriterionTM XT Precast gel (Bio-Rad, 
Hercules, CA).  Proteins were then transferred from the gel to a nitrocellulose membrane 
with a semi-dry electro-transfer unit (Bio-Rad, Hercules, CA).  Following transfer, 
membranes were blocked in 5.0% milk in TBS (Tris buffered solution; 20mM Tris HCl, 
150 mM NaCl) for one hour at room temperature. Membranes were then incubated at 40C 
overnight with primary mouse monoclonal anti-spectrin antibody (1:5000, Affiniti 
FG6090; Affiniti Biomol, Mamhead Castle, UK) in TBST (0.5mM Tween-20).  The next 
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day, the membranes were washed in TBS-T solution three times for 10 minutes each.  After 
wash, membranes were then probed for positive α-spectrin bands with a 1 hour incubation 
of secondary goat anti-mouse antibody (1:5000) conjugated to infrared dye 
(IRDye800CW, Rockland, Gilbertsville, PA).  β-tubulin primary antibody (1:10,000) was 
incubated overnight, and probed with a goat anti-rabbit IgG secondary antibody conjugated 
to an infrared dye (1:10,000, A-21109, Alex Fluor; Invitrogen) after spectrin antibody 
probing.  Membranes were quantified after scanning the membranes into the LI-COR 
Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, NE).  For every sample 
protein lane the 150 kDa and 145 kDa band was quantified by optical density in accordance 
with previously published methods [135], normalized β-tubulin, and expressed as percent 
of Untreated/ Sham control. 
It is important to note that an alternative methodology of quantification and 
normalization of spectrin degradation does exist.  This methodology quantifies by optical 
density, the proteolytic fragment bands of spectrin (145 kD or 150 kD) normalized to the 
intact actin band which is known as a poor calpain substrate.  The pretense for this 
methodology is based, in part, as a means to overcome possibility of β-tubulin 
fragmentation which has been previously reported by calpain I and II [136].  As a result of 
possible proteolytic cleavage of β-tubulin, epitopes on β-tubulin could be altered in a means 
to change affinity or avidity of probing antibodies.  Subsequent normalization of spectrin 
fragments with tubulin could potentially be skewed.   
However, a limitation of the LI-COR Odyssey Infrared Imaging System (LI-COR 
Biosciences, Lincoln, NE) is in the quantification of drastically over exposed bands.  If the 
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concentration of spectrin 280 kD band is beyond the detectable dynamic range of the 
imaging system, the band is inherently unquantifiable.  Therefore, as a means to control 
for some spectrin 280kD samples representing overexposed banding, we have quantified 
based on β-tubulin normalization.  β-tubulin normalization methodology is still consistent 
with recently published methodologies [64, 65, 135, 137].  Furthermore, for all western 
blots involving spectrin the optical density values of β-tubulin are exposed to the Grubbs’ 
test for outliers (extreme studentized deviate); no β-tubulin values qualified as an outlier.   
 
2.8 Mitochondrial Respiratory Control Ratio  
For all mitochondrial respiration experiments untreated/ control animals were 
assessed for respiratory control ratio (RCR) and were determined to be above 5.  The RCR 
can be used to determine how “coupled” mitochondria are e.g. coupled oxidative and 
phosphorylative mechanisms.  General laboratory practices regard an RCR >5 to mean that 
mitochondrial membranes are “intact” after isolation procedures to still properly respire 
oxygen. 
 
2.9 Tissue Processing and Histology 
 After 72 hours following TBI animals were anesthetized with an intraperitoneal 
overdose injection of pentobarbital (150 mg/kg) and transcardially perfused with 0.01 M 
phosphate buffer solution (PBS) followed by 4% paraformaldehyde (PFA) solution in 0.01 
M PBS at pH 7.4.  Brains were rapidly extracted and allowed to soak in 4% PFA.  Brains 
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were removed after 24 hours and allowed to soak in 20% sucrose + PFA solution for an 
additional 24 hours.  Tissue is rapidly frozen on the microtome platform at -20o for 10 
minutes.  A freezing microtome was use to cut coronal slices 40 µm thickness at a blade 
angle of 7.50 to the surface of the tissue. Sections were taken from the septal area (intra 
aural level 10.7) to the posterior hippocampus (intra aural level 0.3).  Every tenth section 
was taken for mounting; a total of approximately 12 sections represented one brain. 
Mounted sections were soaked in CHCL3 (100mL) + EtOH  ( 400mL of 95% EtOH) 
for 30 minutes. Then transferred to increasing concentrations of EtOH for dehydration 
(95%, 70%, 50%) for 3 minutes each then soaked in dH2O for 3 minutes.  Slides were then 
soaked in Nissl/ cresyl violet solution (5.64ml 1M acetic acid, 0.816g sodium acetate, 
500ml dH2O, and 0.2g cresyl violet powder [Sigma C1791]) for 5-10 minutes.  Then slides 
were dipped 8 times in dH2O, 50% EtOH, 70% EtOH, 95% EtOH + AcOH ( 500mL 95% 
EtOH +12 drops of acetic acid), then 3 minutes in 95% EtOH, 5 minutes in 100% EtOH, 5 
minutes in Citrisolv stock solution, then 5 minutes in a second batch of Citrisolv stock 
solution.  Tissue on slides were lightly covered with permount and coverslipped.   
Slides photographed under bright field microscope at x1.25.  Tissue sparing across 
groups was processed utilizing ImageJ (NIH Bethesda, MD) software.  Analysis of rat 
brains were blinded and employed the Cavalieri stereological protocol [138, 139]; the 
group for which each rat belonged (vehicle, PZ treatment type 1, or PZ treatment type 2) 
was unknown.   
Each section was separated by a known distance (d), where d = mean section 
thickness multiplied by the number of sections between the sampled sections.  The total 
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cortical area was measured by pixels and converted to mm2. The total cortical area is 
defined as the dorsal aspect of lamina I to the dorsal aspect of the corpus callosum, and 
was measured for each hemisphere.  Each area was multiplied by d to calculate a sub 
volume that when summed provided the respective total volume. 
The volume of the ipsilateral hemisphere was compared to the contralateral 
hemisphere and expressed as percent of spared tissue (ipsilateral volume/ contralateral 
volume * 100) [50].  Ipsilateral to contralateral comparison provided effective means of 
measuring spared tissue without having to compensate for variability in tissue fixation or 
processing across different brains, and eliminated the need to euthanize 8 sham animals.  
 
2.10 Statistical Analysis   
2.10.1 Mitochondrial Respiration  
In vitro results are calculated using Prism, GraphPad and expressed as means ± SD.  
All experiments investigating mitochondrial respiration and oxidative damage ex vivo were 
analyzed by one-way analysis of variance (ANOVA), followed by Dunnet’s post-hoc 
which allowed for multiple comparisons to a single control group.  The exception was for 
experiments wherein multiple comparisons between groups were made, not to a single 
control group.  Accordingly, it was necessary to analyze by one-way analysis of variance 
(ANOVA), followed by Student-Newman-Keuls multiple comparisons test (SNK).  
Additionally, SNK affords the advantage of testing multiple groups with more power 
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compared to Tukey’s range test, where power is defined as the means to correctly reject 
the null hypothesis [140].  
2.10.2 Calcium Buffering 
 Values of calcium buffering were computed as nmoles Ca2+/ mg mitochondrial 
protein / min for each measured sample.  Groups were compared by one-way analysis of 
variance (ANOVA), followed by Student-Newman-Keuls multiple comparisons test 
(SNK).  In all cases statistical significance was determined as p < 0.05. 
2.10.3 Spectrin Degradation 
 As previously described every sample protein lane the 150 kDa and 145 kDa band 
was quantified by optical density in accordance with previously published methods [135], 
normalized β-tubulin, and expressed as percent control.  Groups were compared by one-
way analysis of variance (ANOVA), followed by Student-Newman-Keuls multiple 
comparisons test (SNK).  In all cases statistical significance was determined as p < 0.05. 
2.10.4 Histology 
 Total volume of spared tissue was measured blinded then calculated as percent 
volume spared as described above.  Percentage of spared tissue for each rat within a single 
group was averaged and compared to other groups by one-way analysis of variance 
(ANOVA), followed by Student-Newman-Keuls multiple comparisons test (SNK).  In all 
cases statistical significance was determined as p < 0.05.   
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  Chapter 3 
Dissertation Research Approach 
 
3.1 Hypothesis 
The hypothesis of this dissertation is that carbonyl scavenging with phenelzine (PZ) 
will exert an antioxidant neuroprotective effect in the traumatically injured rat brain 
mechanistically related to PZ’s hydrazine moiety reacting with the lipid peroxidation (LP)-
derived reactive aldehydes 4-hydroxynonenal (4-HNE) and acrolein (ACR). 
 
3.2 Aim 1     
Assess the ability of the carbonyl scavenger PZ to protect uninjured, isolated rat 
brain mitochondria from ex vivo exposure to the deleterious, LP-derived reactive aldehydes 
4-HNE and ACR.  
 
3.2.1 Aim 1Rationale 
Following traumatic brain injury (TBI) the generation of excessive free radicals 
initiates lipid peroxidation (LP) cascades. A result of LP is the creation and accumulation 
of LP breakdown products such as 4-HNE and ACR.  4-HNE and ACR are known 
neurotoxins capable of covalently binding to mitochondria and cellular protein targets via 
aldehydic, carbonyl functional groups.[75, 76]  Given the nature of the rapidly reacting and 
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short-lived free radical, targeting and scavenging reactive aldehydes such as 4-HNE and 
ACR may be a more feasible approach for achieving pharmacological antioxidant 
neuroprotective intervention or provide a useful adjunct to traditional lipid peroxyl radical 
(LOO•) scavengers to provide a multi-mechanistic approach for stopping the posttraumatic 
lipid peroxidation process at multiple points. 
As for the consideration of PZ, this compound possesses several advantages.  Primarily, 
PZ possesses a hydrazine functional group (NH-NH2).  The hydrazine functional group 
(i.e. moiety), covalently binds carbonyl-containing compounds like 4-HNE and ACR.[116, 
141, 142] Reports of in vitro cell cultures indicate that hydrazine-containing compounds 
are able to inhibit carbonyl cytotoxicity.[116, 118, 122, 143]  Furthermore, PZ is reported 
to function as a neuroprotective agent by reducing aldehydic toxicity in focal and global 
ischemia-reperfusion stroke models.[122] 
The investigation of mitochondrial respiratory functionality endpoint was chosen based 
on previously published reports that 4-HNE, and more potently, ACR inhibit mitochondrial 
functionality.[67]   
In vivo experiments detailed in Aims 2 and 3 utilized isolated mitochondria which 
were from the same anatomical site of a controlled cortical impact (CCI)-induced TBI, but 
in uninjured “Sham” animals.   
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3.2.2 Experiment 1, Aim 1 
 4-HNE & ACR Dose Response 
Our intent was to determine sub-optimal concentrations of 4-HNE or ACR to 
significantly, but not completely, inhibit mitochondrial function.  Cerebral cortical 
mitochondria were isolated from uninjured, young adult rats and incubated for 10 minutes 
with increasing concentrations of 4-HNE or ACR in a dose-dependent manner.  
Mitochondrial function, and/or disruption thereof, was measured by the mitochondria’s 
ability to respire oxygen using the Seahorse Biosciences XF24e Extracellular Flux 
Analyzer.  Data were expressed in terms of Complex I and Complex II-driven respiration 
rates and compared to untreated mitochondria. 
 
 
 
 
 
 
 
 
 
 
 
71 
  
Table 3.1 Aim 1, Experiment 1; 4-HNE and ACR Dose Response 
 
 
 
 
 
 
                           Corresponds to Figure 4.1 
 
 
 
 
 
 
 
 
 
 
 
 
Aim 1 , Experiment 1 
4-HNE or ACR Dose-Response 
4-HNE  ACR   
Untreated n = 4 Untreated n = 4 
10 µM n = 4 1 µM n = 4 
30 µM n = 4 3 µM n = 4 
100 µM n = 4 10 µM n = 4 
Total n=16 Total n=16 
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Rationale 
In order to determine the ability to PZ to protect mitochondria, it was necessary to 
first investigate which concentrations of 4-HNE or ACR are necessary to elicit ex vivo 
mitochondrial respiratory dysfunction.  The tested concentrations of 4-HNE and ACR were 
broadly based on previously published concentrations of 4-HNE and ACR to significantly 
inhibit isolated mitochondria from rat brain and spinal cord[68] and the observation that 
ACR is ten times more potent than 4-HNE in regards to attenuation of isolated brain 
mitochondrial respiratory function.[72]  It is important to note that no documented cases 
exist demonstrating PZ resurrecting dead mitochondria.  Therefore, it was imperative to 
determine the “sub-optimal dose” of 4-HNE or ACR that significantly reduced 
mitochondrial function, but does not lead to their complete demise.   
Unpublished pilot studies previously generated by our lab justified the 10 minute 
incubation wherein mitochondria were exposed to 4-HNE or ACR.  This was used as the 
standard for all experiments wherein reactive carbonyls are exogenously exposed to 
mitochondria prior to oxymetric studies utilizing the Seahorse Bioscience XF24e 
Extracellular Flux Analyzer.  Mitochondrial oxymetric studies performed by the Seahorse 
Analyzer and traditional Clarke electrode-based Oxytherm provide information that can be 
used to interpret multiple states of respiration.   
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3.2.3 Experiment 2, Aim 1 
 Phenelzine Dose Response.   
Determine the most effective dose of PZ to prevent mitochondrial dysfunction by 
scavenging reactive aldehydes.  Isolated mitochondria were exposed to a 5 minute dose-
dependent pretreatment of PZ, followed by a 10 minute incubation with 4-HNE or ACR.  
Protective efficacy was determined by PZ’s ability to prevent 4-HNE or ACR-induced 
mitochondrial respiratory dysfunction and PZ’s ability to reduce markers of protein 
modification by the aldehydes as measured by western blot.  Mitochondrial respiration was 
expressed in a similar manner as Experiment 1, but protection is compared to mitochondria 
treated by 4-HNE or ACR only.  Phenelzine’s ability to reduce markers of oxidative 
damage (4-HNE or ACR) is also compared to mitochondria treated with 4-HNE or ACR. 
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Table 3.2 Aim 1, Experiment 2; PZ Dose Response.  
 
 
 
 
 
Corresponds to Figure 4.2 (Respiration) and Figure 4.4 (Oxidative 
Damage). 
 
 
 
 
 
 
 
 
 
 
 
 
Aim 1 , Experiment 2 
PZ Dose Response 
4-HNE ACR 
Untreated n = 4 Untreated n = 4 
4-HNE 30 µM n = 4 ACR 3 µM n = 4 
4-HNE 30 µM + PZ 3µM n = 4 ACR 3 µM + PZ 3 µM n = 4 
4-HNE 30 µM + PZ 10 µM n = 4 ACR 3 µM + PZ 10 µM n = 4 
4-HNE 30 µM + PZ 100 µM n = 4 ACR 3 µM + PZ 100 µM n = 4 
Total 20 Total 20 
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Rationale 
The concentrations listed in the table at the time of experimentation were originally 
written as “sub-optimal concentration of 4-HNE or ACR,” which is data gleaned from Aim 
1, Experiment 1.  However, for the sake of continuity, the optimal dose of 4-HNE (30 µM) 
and ACR (3 µM) are listed in the table as discovered from experimentation.   
The dose-response concentrations of PZ used to protect rat mitochondria from 4-
HNE are broadly based on previously published experiments wherein equi-molar 
concentrations of PZ to 4-HNE were found to protect mice mitochondria in vitro.[144] PZ 
dose-response concentrations to protect mitochondrial from ACR insult were the same 
concentrations used as 4-HNE.  However, ACR is approximately ten times more potent 
and the concentration was adjusted as in the previous experiment. 
The rationalization of pre-incubation of PZ to mitochondria before exposure to 
ACR or phenelzine is entirely a proof of principle concept.  The intent of the experiment 
is to determine if PZ can scavenge reactive carbonyls at a known concentration.  Other 
experiments test this idea, under the complex pathophysiology of TBI. 
The endpoints of mitochondrial respiration and markers of oxidative damage are 
used as an index of both mitochondrial function and an indication of the physical presence 
of deleterious 4-HNE- or ACR-protein adducts. 
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3.2.4 Experiment 3, Aim 1 
Phenelzine (PZ) versus Pargyline (PG)   
Investigate the mechanism by which PZ may be able to protect mitochondrial 
dysfunction and prevent oxidative damage.  Isolated mitochondria were exposed to a 5 
minute pretreatment with the hydrazine-containing MAO inhibitor PZ or the structurally 
similar MAO inhibitor PG which lacks the hydrazine moiety, followed by a 10 minute 
incubation of 4-HNE or ACR.  Sub-optimal doses for 4-HNE and ACR defined in 
Experiment 1 were used. Isolated mitochondria from a single rat brain represents n=1.  
Each pool consisted of enough mitochondria to be divided into two groups.  The first group 
was tested with 4-HNE and the second group was tested with ACR.  Optimal dose of PZ 
defined in Experiment 2 was used for PZ and PG.  Protective efficacy was determined by 
PZ’s or PG ability to prevent 4-HNE or ACR-induced mitochondrial respiratory 
dysfunction.  The ability to reduce oxidative damage was also determined for both 
compounds and assessed by western blot. 
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Table 3.3 Aim 1, Experiment 3; PZ vs PG. 
 
Aim 1 , Experiment 3 
PZ v PG 
4-HNE ACR 
Untreated n = 6 Untreated n = 6 
4-HNE 30 µM n = 6 ACR 3 µM n = 6 
PZ 30 µM + 4-HNE 30 µM n = 6 PZ 30 µM + ACR 3 µM n = 6 
PG 30 µM + 4-HNE 30 µM n = 6 PG 30 µM + ACR 3 µM n = 6 
Total 24 Total 24 
Corresponds to Figure 4.3 (Respiration) and Figure 4.5 (Oxidative 
Damage). 
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Rationale 
Phenelzine is an MAO inhibitor that possesses a hydrazine pharmacophore which 
is capable of covalently binding to carbonyl functional groups [116].  It is through this 
means we believe that PZ is able to scavenge deleterious carbonyls.  However, PZ could 
provide mitochondrial protection by simply providing steric hindrance between reactive 
carbonyls and mitochondrial proteins.  Therefore, it is advantageous to determine if another 
structurally similar compound PG, which does not contain the hydrazine moiety, can 
provide mitochondrial protection against 4-HNE or ACR.   
Pargyline and PZ are structurally similar, have similar molecular weights, and both 
are MAO-I (See Figure 3.1).  Therefore, the optimal concentration of PZ determined by 
experimentation was the same molar concentration used to test PG. 
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Figure 3.1. Structural differences between phenelzine (PZ) and pargyline 
(PG).  Both compounds are monoamine oxidase inhibitors.  PZ possesses a 
hydrazine moiety (HN-NH2) functional group whereas PG possesses a 
propyne (H3C≡CH) functional group.   
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3.3. Aim 2 
Determine the ability of the carbonyl scavenger PZ to protect mitochondria after a 
controlled cortical impact induced traumatic brain injury in young, adult rats. 
 
3.3.1 Aim 2 Rationale 
 Exogenous application of TBI-derived deleterious compounds to isolated 
mitochondria is a proof of principle ex vivo assay.  In order to determine if PZ possess the 
ability to protect mitochondria in the wake of the complex pathophysiology of TBI, PZ was 
evaluated in this environment.   
 This Aim seeks to determine if PZ is capable of protecting mitochondrial 
respiratory function, reducing the endogenous accumulation of 4-HNE and ACR and 
maintaining mitochondrial Ca++ buffering capacity after TBI in vivo. 
 
3.3.2 Experiment 1, Aim 2 
In Vivo PZ Protection of Mitochondrial Respiration.   
Determine the ability of PZ to protect mitochondrial respiratory function 72 hours 
after a CCI-TBI.  Rats will receive a severe TBI followed by a 15 minute post-injury dose 
of PZ 10 mg/kg SubQ, followed by subsequent doses of PZ at 5 mg/kg every 12 hours up 
to 72 hours.  Extent of protection is determined by the PZ ability to protect mitochondrial 
respiration.  Mitochondria were isolated from the cortical injury site 72 hours after injury.  
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Data is expressed in terms of State III / State IV respiration i.e. the respiratory control ratio 
(RCR).  
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Table 3.4 Aim 2, Experiment 1 In vivo Mitochondrial Respiration 
Aim 2, Experiment 1 
In vivo mitochondrial respiration 
Sham n = 5-6 
Sham + PZ (10 mg/kg) n = 5-6 
TBI + Vehicle n = 8-9 
TBI + PZ (10 mg/kg) n = 8-9 
Total 26-30 
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Rationale 
In this experiment the dosing of PZ is modified to include “maintenance dosing.”  
Previous publications by our lab used a single 10 mg/kg subcutaneous dose 15 minutes 
after injury[144].  This is a slight reduction of the dosing paradigm which has been 
previously reported for neuroprotection studies performed in gerbils [122].  However, this 
was intentionally reduced to minimize the monoamine oxidase inhibitory (MAOI) effects 
of phenelzine in rats [145].  The inclusion of the repeated maintenance dosing paradigm of 
intended to overlap the time course peak accumulation carbonyls which peak at 72 hours 
post-TBI [72].  The administration of PZ every 12 hours is intended to match the 11.6 hour 
blood serum half-life of PZ in rats, published by the original manufacture Pfizer under the 
drug name Nardil © [146]. Additional support for the 12 hour repeated dosing paradigm is 
derived from a study in which a single dose of PZ (15 mg/kg, subcutaneously) was able to 
increase brain ornithine levels after prior monoamine oxidase inhibition but PZ’s effects 
were only effective for approximately 12 hours after administration [147].   
Previous work indicates that after spinal cord injury the accumulation of 4-HNE 
and ACR peaks at 48-72 hours[45].  Therefore, in order to provide the maximum 
opportunity for PZ to scavenge 4-HNE and ACR, we administer PZ 15 minutes post-TBI 
and every 12 hours until 72 hours to maintain theoretical concentration at 10 mg/kg.  
The choice of ex vivo oxymetric analysis is the Oxytherm, a traditional Clarke-type 
electrode system chosen primarily for consistency with our other recently published in vivo 
experiments published in our lab [144]. 
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3.3.4 Experiment 2, Aim 2 
 In vivo PZ Protection of Mitochondrial Oxidative Damage. 
Determine the ability of PZ to protect mitochondria by decreasing 4-HNE or ACR 
markers of oxidative damage 72 hours after injury.  Rats exposed to a severe CCI-TBI will 
receive the same PZ 10 mg/kg dosing paradigm from Experiment 2.  Western blot 
quantification will be used to analyze the accumulation of lipid peroxidative markers 4-
HNE or ACR, in mitochondrial proteins isolated from the injury. 
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Table 3.5 Aim 2, Experiment 2 
 
 
 
 
   In vivo Mitochondrial Oxidative Damage 
 
 
 
 
 
 
 
 
 
 
 
 
Aim 2, Experiment 2 
In vivo mitochondrial oxidative damage 
Sham n = 5-6 
Sham + PZ (10 mg/kg) n = 5-6 
TBI + Vehicle n = 8-9 
TBI + PZ (10 mg/kg) n = 8-9 
Total 32 
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Rationale 
 This experiment is designed to determine if PZ possesses the same capabilities of 
scavenging carbonyls and protecting mitochondria from the accumulation of oxidative 
damage markers in vivo as demonstrated ex vivo.  
 
3.3.5 Experiment 3, Aim 2 
In Vivo PZ Protection of Mitochondrial Ca2+ Buffering 
Assess the ability of PZ to protect mitochondria against TBI-induced Ca2+ buffering 
dysfunction.  Rats exposed to a severe CCI-TBI will receive PZ 10 mg/kg 15 minutes after 
injury, and 5 mg/kg every 12 hours, up to 24 hours.  At 24 hours, rats will be euthanized, 
mitochondria isolated, and assessed for the ability to buffer calcium. 
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Table 3.6 Aim 2, Experiment 3; Mitochondrial Calcium Buffering  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aim 2, Experiment 3 
Mitochondrial Calcium Buffering 
Sham n = 8-9 
Vehicle n = 8-9 
TBI + PZ (10 mg/kg) n = 8-9 
Total:  24 
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Rationale 
Mitochondria attempt to compensate for the large influx of Ca2+ after TBI by taking 
up (i.e. buffering) the excess cytoplasmic Ca2+.  However, excessive cycling and loading 
of Ca2+ can induce mitochondrial permeability transition (mPT) [102]. The formation of 
the mPT facilitates the loss of the mitochondrial membrane potential (ΔΨ) which 
exacerbates ROS formation, increases lipid peroxidation, release of the Ca2+ and initiates 
apoptotic cellular death pathways [104, 105].     
This experiment is designed to assess the ability of mitochondrial to buffer calcium 
after TBI.  Dysfunctional mitochondria have a reduced ability to buffer this calcium influx 
[108, 110]. Previous reports demonstrate that mitochondria exhibit significantly 
diminished Ca2+ buffering capacity at 3 and 12 hours following CCI-TBI in the mouse.  
Additionally, subsequent to the loss of Ca2+ homeostasis, calcium sensitive cysteine 
proteases begin to degrade spectrin as early as 15 min after injury[148] and have been 
reported to remain active for at least 24 hours[149].  Therefore, in the present experiment 
we chose to examine whether PZ can protect the ability of mitochondria to buffer Ca2+ 24 
hours after CCI-TBI in the rat.  The 24 hour window is consistent with previously published 
reports indicating that time point is within an optimal window of therapeutic treatment 
[108]. 
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3.4.1 Aim 3 
Determine the extent to which PZ is able to provide neuroprotection in rats 
following a CCI TBI. 
 
3.4.2 Aim 3 Rationale 
 PZ has previously demonstrated the ability to spare cortical tissue in rats.  These 
experiments utilized a single SubQ injection of PZ 10 mg/kg 15 minutes after a severe TBI 
and were assessed for cortical sparing two weeks after injury.  PZ treated rats demonstrated 
a significant increase in cortical tissue compared to vehicle (saline)-treated animals [144]. 
This aim is to determine if the ability of PZ in the current dosing paradigm (which 
has an added maintenance dosing aspect: single bolus 10 mg/kg dose followed by a 
maintenance dose of 5mg/kg every 12 hours) is capable of sparing cortical tissue as the 
previously published single dose study. Additionally, this aim seeks to determine if the PZ 
has a clinically relevant therapeutic window. 
 
3.4.4 Experiment 1, Aim 3 
In Vivo Therapeutic Window 
Determine the maximum therapeutic window of PZ to function as a neuroprotective 
agent.  Neuroprotection will be determined by PZm’s ability to prevent cortical cytoskeletal 
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degradation by immunoblotting of spectrin degradation products after a CCI-TBI in young, 
adult rats.  Rats will be given the PZm dosing paradigm (which contains maintenance dosing 
for 72 hours).   
Rats will be given a single subcutaneous dose of PZ (10 mg/kg) at X time after 
injury followed by an additional dose of 5 mg/kg every 12 hours for 72 hours.  At 72 hours 
rats will be euthanized and cortical tissue will be harvested, processed, and analyzed for 
cytoskeletal degradation e.g. spectrin breakdown products (SBDP).  Where, X = the length 
of time PZm treatment will be delayed: 15 minutes, 3 hours, 6 hour, 12 hours, or 18 hours.  
All delayed time points will utilized the same PZm dosing paradigm as histological sparing 
with the same number of doses.  This dosing paradigm is consistent with the dosing 
paradigm intended to theoretically maximize the ability of PZ to scavenge reactive 
carbonyls. 
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Table 3.8 Aim 3, Experiment 1; In Vivo neuroprotection; therapeutic 
window 
 
 
Aim 3, Experiment 1 
In vivo Therapeutic Window 
Treatment 15 min 3 hrs 6 hrs* 12 hrs* 18 hrs* 
Sham n = 8 n = 8 n = 8 n = 8 n = 8 
Vehicle n = 8 n = 8 n = 8 n = 8 n = 8 
PZ (10 mg/kg) n = 8 n = 8 n = 8 n = 8 n = 8 
Total: 24 24 24 24 24 
            *Time points: 6hrs, 12hrs, and 18hrs were discontinued. 
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Rationale 
This experiment was intended to address to the maximum delay of treatment that 
the PZm treatment can be delayed after injury and still have a clinically relevant therapeutic 
window.  The assessment of spectrin degradation was chosen as it is reliable marker of TBI 
damage and reported to have a rapid onset after TBI [150].   
As described in Chapter 1, the connection between mitochondrial dysfunction and 
calpain activation leads to the proteolytic cleavage of spectrin.  And, given the rapid onset 
of degradation, ability of PZ to increase calcium buffering, and increase histological 
sparing, the spectrin degradation is theoretically a viable assay to determine therapeutic 
value. 
Should it become evident that PZm is no longer able to reduce spectrin degradation, 
the last time point to significantly reduce spectrin degradation will designate maximum 
post-TBI time point that initiation of PZ treatment could be delayed (i.e therapeutic 
window). 
 
3.4.3 Experiment 2, Aim 3 
Histological Neuroprotection 
Investigate the ability of PZ to spare cortical tissue following a CCI-TBI in young 
adult rats.  Rats will receive a unilateral severe CCI-TBI, followed by either a single 
10mg/kg PZ treatment 15 minutes after injury (PZs) or multiple doses of PZ (PZm).  Extent 
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of histological neuroprotection will be determined at 72 hours post-injury, by the ability of 
PZs or PZm to increase spared cortical tissue, compared to vehicle-only treated rats. 
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Table 3.7 Aim 3, Experiment 2; In Vivo neuroprotection, Tissue Sparing  
 
 
 
 
 PZm =10 mg/kg, 15 minutes after injury, then 5 mg/kg every 12 hours. 
 PZs = 10 mg/kg, 15 minutes after injury, not maintenance dosing. 
 
 
 
 
 
 
 
 
 
 
 
Aim 3, Experiment 2 
In vivo neuroprotection; tissue sparing 
Vehicle  n = 8 
PZm  n = 8 
PZs n = 8 
Total: 24 
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Rationale 
This experiment will serve as a means to investigate the ability of PZ to spare 
cortical brain tissue. The PZm dosing paradigm is intended to maximize the scavenging of 
carbonyls which peak at 72 hours.  This effort requires an additional “maintenance” aspect 
of the original dosing paradigm PZs which was published with a limited sample size (n = 
4) [144]. Therefore, this experiment will serve two purposes: 1) expand sample size (n) of 
the previously published and 2) differentiate the ability of the two dosing paradigms to 
protect cortical brain tissue.  The 72 hour time point was chosen to determine the effects 
of a completed PZm dosing regimen versus a single PZs treatment regimen.  Furthermore, 
this time point would help to understand how much cortical tissue is preserved at an earlier 
time point. 
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Chapter 4  
Phenelzine protects brain mitochondrial respiratory function from oxidative 
damage by scavenging the lipid peroxidation-derived reactive carbonyls 4-
hydroxynonenal and acrolein 
(Portions submitted for publication) 
 
4.1 Specific Aim 
Assess the ability of the carbonyl scavenger PZ to protect uninjured, isolated rat 
brain mitochondria from ex vivo exposure to the deleterious, LP-derived reactive aldehydes 
4-HNE and ACR.  
 
4.2 Introduction 
A crucial component to keeping the neuron alive after traumatic brain injury is to 
stabilize mitochondrial function.  And, the most definitive way to protect mitochondrial 
dysfunction is to prevent either free radical production or the subsequent LP cascade.  For 
many years, researchers have explored the possibility of pharmacological compounds to 
scavenge free radicals or interrupt LP cascades.  In particular, tirilazad during a phase III 
clinical trial was capable of scavenging lipid peroxyl radicals (LOO•) during the 
“propagation” phase of the cascade [68].  However, a timely pharmacological intervention 
by a LOO• scavengers is limited by the narrow therapeutic window intrinsic to rapidly 
reacting lipid peroxyl radicals.  Additionally, LOO• scavengers only interrupt LP cascades; 
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they are not capable of reversing it.  Fortunately, an alternative means exist to prevent free 
radical-induced LP by targeting the latest stage of the cascade: the generation of the 
aldehydic breakdown-products.  Scavengers that target the deleterious breakdown products 
i.e. reactive carbonyls (4-HNE and ACR) are adeptly known as “carbonyl scavengers.”  
The use of carbonyl scavengers may have the potential to expand the clinical therapeutic 
window and possibly to reverse LP-mediated damage.   
But, not all scavengers are equal.  The most effective carbonyl scavengers are 
capable of covalently binding carbonyls via a hydrazine functional group (-NH-NH2) [116, 
141, 151].  The most ideal scavengers would be those already possessing FDA-approval 
for clinical use. Two such available compounds are hydralazine (HZ) and phenelzine (PZ).  
HZ is used generally to treat hypertension as a potent arterial vasodilator while PZ has been 
used in a variety of conditions, primarily as a monoamine oxidase inhibitor (MAO-I) for 
the treatment of depression.  Regardless, both compounds possess a hydrazine moiety and 
have demonstrated the ability to inhibit carbonyl toxicity within cell culture models [116, 
118, 122, 143].  Additionally, HZ and PZ have both been shown to exhibit neurprotective 
effects in multiple models of neurotrauma.  HZ was demonstrated to function as 
neuroprotectant in the context of spinal cord injury (SCI) while simultaneously reducing 
acrolein accumulation[117].  
On the other hand, PZ has was reported as a neuroprotectant in focal and global 
ischemia-reperfusion models of stroke, and similarly reduced a deleterious “aldehyde load” 
[122].  While both HZ and PZ seem as equally promising candidates for carbonyl 
scavenging in the treatment of TBI, HZ is contra-indicated as its ability to induce 
hypotension which may already exist in patients who have sustained a TBI.   
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Therefore, the intent of this study is to demonstrate that the most clinically relevant 
drug, PZ is able to protect mitochondrial dysfunction as measured by oxythermic 
respiration and oxidative damage markers. Additionally, we investigate the importance of 
the hydrazine functional group by which PZ is believed to be capable of scavenging 
reactive carbonyls. While our lab has previously demonstrated the ability of 4-HNE to 
inhibit mitochondrial respiration and subsequently PZ’s ability to prevent oxidative 
damage [50], the current studies have never been conducted in the high-throughput assay 
utilizing the Seahorse XFe24 analyzer.  In the present study, we conducted experiments to 
determine the dose-response relationship for antagonism of 4-HNE and ACR by comparing 
the mitochondrial protective effects of PZ, which contains the hydrazine group, against the 
structurally similar compound PG, which lacks the hydrazine group.  Moreover, since both 
compounds are MAO inhibitors, the comparison of the two allows for a determination of 
whether MAO inhibition might contribute to the protective effects of PZ. 
 
4.3 Results 
4.3.1 4-HNE and Acrolein Inhibit Brain Mitochondrial Respiration 
Ficoll-isolated cortical mitochondrial bioenergetics were assessed using Seahorse XFe24 
analyzer 10 minutes post-exposure to 4-HNE and ACR.  As depicted in Figure 4.1,  ex-
vivo isolated mitochondria exposed to a 5 minute PZ pretreatment followed by 10 minute 
exposure to increasing concentrations of (A-B) 4-HNE 10 µM, 30 µM, 100 µM or (C-D) 
ACR 1 µM, 3 µM, 10 µM inhibited mitochondrial respiration in a significant, dose-
dependent manner for complex I and complex II-driven OCR.  For mitochondria exposed 
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to 4-HNE, only 30 µM and 100 µM concentrations significantly inhibited complex I and 
II-driven OCR (p<0.05).  4-HNE at 30 µM was deemed a sub-optimal concentration to 
reduce, but not completely inhibit of mitochondrial respiration for both complex I & II.  
However, ACR was able to significantly reduce complex I and II respiration at all tested 
concentrations compared to controls: 1 µM, 3 µM, 10 µM (p<0.05).  ACR at 3 µM was 
deemed sub-optimal.  Suboptimal concentrations of ACR (3 µM) were found to be 
approximately ten fold more potent than 4-HNE (30 µM) to inhibit mitochondrial complex 
I and complex II OCRs.  
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Figure 4.1 4-hydroxynonenal (4-HNE) and Acrolein (ACR) reduce 
Complex I and Complex II driven respiration in a dose dependent fashion 
in cortical mitochondria isolated from young adult, uninjured SD rats.  
Isolated mitochondria were exposed to increasing concentrations of 4-HNE 
for 10 minutes at room temperature and immediately assessed for oxygen 
consumption rates.  4-HNE at 30 µM and 100 µM significantly inhibited 
both Complex I and Complex II driven respiration.  ACR at all tested 
concentrations 1, 3, and 10 µM was able to significantly inhibit 
mitochondrial respiration. One-way ANOVA followed by Dunnett’s 
Multiple Comparison post-hoc test.  * = p < 0.05.  Error bars represent +/- 
SD. N = 4 rats per group. 
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4.3.2 Phenelzine Protects Against 4-HNE or ACR-Induced Mitochondrial dysfunction in a 
Concentration -Dependent Fashion 
The Seahorse XFe24 analyzer was used to determine the ability of PZ to protect 
cortical, isolated mitochondrial OCR exposed for 10 minutes to 4-HNE [30 µM] or ACR 
[3 µM] (Figure 4.2). Concentrations of 4-HNE and ACR were chosen based on previous 
experiments (Figure 4.1).  Mitochondria were incubated with a 5 minute pretreatment of 
increasing concentrations of PZ (3 µM, 10µM, 30 µM) then incubated with a 10 minute 
treatment of 4-HNE or ACR.  Mitochondrial OCR rates are reported for complex I and 
complex II. For mitochondria exposed to 4-HNE, significant protection was observed in 
complex I-driven OCR with 10 µM  and 30 µM concentrations of PZ ( p < 0.05) (Figure 
4.2a).  As for 4-HNE insulted mitochondria, complex II-driven OCR was only significantly 
protected by the maximum tested PZ concentration: 30 µM (p < 0.05) (Figure 4.2b).  In 
similar experiments, PZ, only at the maximum dose tested (30 µM) was able to 
significantly protect ACR-insulted mitochondria for both complex I and II driven OCRs (p 
< 0.05). (Figure 4.2  c, b).  
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Figure 4.2.  Isolated mitochondria were exposed to a 5 min phenelzine (PZ) 
pretreatment, followed by a 10 min incubation of 4-hydroxynonenal (4-
HNE) and Acrolein (ACR) and immediately assed for oxygen consumption 
rates.  PZ pretreatment was able to protect mitochondrial respiration in a 
dose dependent manner.  A) PZ at 10 µM and 30 µM was able to 
significantly protect mitochondrial function against an insult of 4-HNE at 
30 µM for Complex I driven respiration. B) PZ was also able to significantly 
protect Complex II-driven respiration from a 30 µM insult of 4-HNE.  C & 
D) PZ at 30 µM was able to significantly protect Complex I and Complex 
II-driven respiration from 3 µM ACR.  One-way ANOVA followed by 
Dunnett’s Multiple Comparison post-hoc test.  * = p < 0.05.  Error bars 
represent +/- SD. N = 4 rats per group.  
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4.3.3 Phenelzine, but not Pargyline, Protects Against 4-HNE and ACR-Induced 
Mitochondrial Dysfunction 
The comparative abilities of PZ or PG to prevent mitochondrial dysfunction was 
assessed with Seahorse XFe24 analyzer (Figure 4.3).  Concentrations of 4-HNE [30 µM] 
or ACR [3 µM] were chosen based on their demonstrated efficacy to significantly inhibit 
mitochondrial OCR (Figure 4.1).  Similarly, the concentration of PZ [30 µM] was chosen 
based previous experiments demonstrating significant prevention of mitochondrial 
dysfunction (Figure 4.2). With these conditions established, isolated cortical mitochondria 
were treated with either a PZ or PG pretreatment for 5 minutes, followed by ACR or 4-
HNE exposure for 10 minutes.  Mitochondrial OCR was expressed as percent control for 
ADP or succinate-driven respiration rates e.g. complex I and complex II, respectively.  
Mitochondria exposed to 4-HNE [30 µM] or ACR [3 µM] significantly (p < 0.05) inhibited 
complex I (ADP) and complex II (succinate) driven OCR compared to untreated controls 
(Figure 4.3). However, mitochondria exposed to PZ [30 µM] pretreatment significantly 
prevented 4-HNE or ACR-induced mitochondrial OCR for both tested complexes (p < 
0.05).  No significant difference was found between PZ-protected mitochondria and 
untreated controls. In the same experiment, mitochondria were instead pretreated with an 
analogue compound pargyline [30 µM] followed by 4-HNE or ACR insult. Pargyline 
possesses a similar structure to PZ and also serves as a MAO inhibitor, but lacks a 
hydrazine moiety functional group.  Consistent with the hypothesized importance of the 
hydrazine functional group in carbonyl scavenging, PG treated mitochondria demonstrated 
no significant protection and no difference between 4-HNE or ACR only insulted 
mitochondria. 
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Figure 4.3.  Phenelzine (PZ) protects mitochondrial respiration from 4-
hydroxynonenal (4-HNE) and Acrolein (ACR) insult, but pargyline (PG) 
does not.  Isolated mitochondria incubated with 4-HNE (30 µM) or ACR (3 
µM) exhibited significantly impaired mitochondrial function for both 
Complex I and Complex II-driven respiration.  However, a 5 min 
pretreatment of PZ (30 µM) significantly protected mitochondrial 
respiration for both Complex I and Complex II-driven respiration.  
Pargyline, which is also a MAO inhibitor, but lacks a hydrazine moiety was 
not able to effectively protect mitochondrial respiration from 4-HNE or 
ACR insult.  One-way ANOVA followed by Student Newman-Keuls post-
hoc test.  * = p < 0.05.  Error bars represent +/- SD. n = 6 rats per group. 
 
 
 
105 
  
 
4.3.4 Phenelzine Prevents Mitochondrial Oxidative Damage Ex Vivo in a Dose-Dependent 
Fashion 
Western Blot analyses were used to determine if increasing concentrations of PZ 
could reduce oxidative damage to mitochondrial proteins.  50 µg of isolated cortical 
mitochondria were utilized in the same manner as described earlier in this manuscript.  A 
5 minute PZ exposure to isolated mitochondria demonstrated dose-dependent protection 
against exogenously applied 4-HNE [30 µM] or ACR [3 µM] (Figure 4.4). Phenelzine at 
either 10 µM or 30 µM concentrations significantly reduced 4-HNE adducts (i.e. oxidative 
damage markers) when compared to 4-HNE only treated mitochondria (p < 0.05).  
Similarly, PZ at 10 µM and 30 µM significantly reduced ACR adducts (p < 0.05). 
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Figure 4.4.  Phenelzine reduces 4-hydroxynonenal (4-HNE) and Acrolein 
(ACR) in a dose-dependent manner.  Mitochondria were isolated from the 
cortex of uninjured SD rats and exposed to increasing concentrations of PZ 
pretreatment 3, 10, and 30 µM for 5 min, followed by 4-HNE or ACR for 
10 minutes.  Mitochondria were then assessed for oxidative damage 
markers 4-HNE or ACR by Western Blot analysis between 150 kD and 50 
kD.  4-HNE (30 µM) or ACR (3 µM) significantly increased oxidative 
damage.  Phenelzine at 10 and 30 µM was able to significantly ameliorate 
4-HNE or ACR in mitochondria.  One-way ANOVA followed by Dunnett’s 
Multiple Comparison post-hoc test.  Student t-test compared untreated to 4-
HNE or ACR.  #, * = p < 0.05.  Error bars represent +/- SD. N = 6 rats per 
group. 
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4.3.5 Phenelzine, but not Pargyline, Protects against Mitochondrial Oxidative Damage 
Markers 4-HNE and ACR 
Isolated cortical mitochondria exposed to 5 minute pretreatments of PZ (30 µM), 
but not PG, were able to significantly prevent accumulation of oxidative damage markers 
of 4-HNE or ACR by western blot analysis (p < 0.05) (Figure 4.5).  Mitochondria exposed 
to 4-HNE (30 µM) or ACR (3 µM) revealed a significant increase of banding intensity 
compared to untreated controls.  PG + ACR or PG + 4-HNE treatments were not 
significantly differ from 4-HNE or ACR treated mitochondria, respectively.  Additionally, 
PZ-only or PG-only treated mitochondrial (controls) were not significantly different than 
untreated mitochondria.   
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Figure 4.5 Phenelzine (PZ) reduces 4-hydroxynonenal (4-HNE) and 
Acrolein (ACR), but pargyline (PG) does not.  Uninjured rat mitochondria 
were isolated from cortex and were incubated with a 5 min PZ or PG 
pretreatment followed by a 10 min incubation of 4-HNE (30 µM) or ACR 
(3 µM).  Samples were then assessed by Western Blot analysis for measures 
of oxidative damage.  4-HNE (30 µM) or ACR (3 µM) treated mitochondria 
exhibited statistically significant elevations of 4-HNE or ACR compared to 
untreated groups.  However, PZ at 30 µM was able to significantly 
ameliorate 4-HNE or ACR accumulation.  One-way ANOVA followed by 
Dunnett’s Multiple Comparison post-hoc test.  Student t-test compared 
untreated to 4-HNE or ACR.  #, * = p < 0.05.  Error bars represent +/- SD. 
N = 6 rats per group. 
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4.4 Discussion  
Free radical induction of LP is one of the most validated secondary injury 
mechanisms in TBI.  Numerous studies have demonstrated that compounds (antioxidants) 
possessing the ability to interrupt the LP cascade are protective in TBI models. [68]  Most 
notably, tirilazad mesylate (U74006F) was able to inhibit the propagation phase of LP and 
improved post-TBI survival in patients with traumatic subarachnoid hemorrhage in phase 
III clinical trials.[152] Unfortunately, these compounds have an inherently limited 
therapeutic window as their targets rapidly evolve during the course of the LP cascade.  It 
should be noted, however, that much of the  damage caused from LP is attributed to the 
deleterious aldehydic breakdown products.[153]  Two notorious reactive aldehydes, 4-
HNE and ACR, are broadly characterized by their electrophilic functional groups and 
relatively long half-lives.  Such characteristics allow 4-HNE and ACR to become ideal 
targets for pharmacologic scavenging.  
Scavenging reactive aldehydes or “carbonyl scavenging” is a treatment approach 
that essentially serves to provide sacrificial targets for 4-HNE and ACR.  Both 4-HNE and 
ACR can be scavenged in this way.[85]  However, one compound in particular, PZ, 
provides the following distinct advantages as a carbonyl scavenger for the treatment of 
TBI. Primarily, PZ is an FDA-approved and is readily available in a clinical setting. 
Because PZ is not a hypotension-inducing compound, unlike HZ, it would not contra-
indicated for the acute treatment of TBI in which hypotension is not uncommonly seen as 
an injury-induced complication.  Finally, PZ possesses the ability to function as an 
antioxidant against superoxide radical, [116] scavenge unbound carbonyls, and scavenge 
reactive aldehydes already bound to proteins.  Interestingly, 4-HNE and ACR bound to 
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proteins via Michael addition will retain an exposed carbonyl capable of contributing 
further damage, however, PZ in a process dubbed “adduct-trapping” is able to covalently 
bind, sequester the carbonyl, and prevent subsequent damage. [118]  
 While the therapeutic advantages of PZ are apparent, studies only recently have 
begun to elucidate the true implications PZ treatment in neurodegeneration.  Additionally, 
the collapse of mitochondrial functional integrity is tightly associated with neuronal cell 
death.[154]  Therefore, the purpose of the current study was to investigate the ability of PZ 
to function as a carbonyl scavenger and protect mitochondria in an ex vivo model of TBI.   
In order to test PZ’s ability to scavenge reactive aldehydes it was necessary to first 
establish that inhibition of mitochondrial respiration by 4-HNE or ACR could be measured 
in the Seahorse Flux Analyzer and was consistent with previous studies that were 
(oxythermic i.e. Clark Type electrode-based). [50, 72]  Accordingly, we were able to 
demonstrate a concentration-dependent relationship for 4-HNE and ACR to inhibit 
respiration. When mitochondria were exposed to PZ followed by sub-optimal doses of 4-
HNE or ACR mitochondria respiration dysfunction could be prevented.  Additionally, PZ 
pre-treatments were able to attenuate the accumulation of mitochondrial protein oxidative 
damage markers measured via western blot.   
The basis of PZ neuroprotection can exist in several modalities.  For instance the 
PZ ring structure can function as an antioxidant for superoxide radical.  Or, due to the fact 
that PZ inhibits MAO activity, it may provide mitochondrial and therefore neuronal 
protection by the reduction of hydrogen peroxide and other aldehydes [155].  However, in 
the present manuscript we were able to show that PZ was able to protect mitochondrial 
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respiratory function to 4-HNE or ACR insult, whereas the non-hydrazine MAO inhibitor 
PG was not.  Given that these compounds are structurally and functionally related but only 
PZ prevents mitochondrial dysfunction and accumulation of oxidative damage markers in 
mitochondria, two reasonable conclusions can be made: 1) PZ scavenges carbonyls through 
its hydrazine moiety which is consistent with previous predictions [122, 151], and 2) A 
mere mechanical separation of protein target and reactive aldehyde is not sufficient to 
prevent oxidative dysfunction, otherwise PG + ACR or 4-HNE treatment groups would 
have reduced mitochondrial dysfunction and decreased oxidative damage markers.  
Additionally, PG + ACR or 4-HNE groups were not statistically different than 4-HNE or 
ACR alone. 
It should be noted that while there was a 10 -fold concentration difference between 
4-HNE and ACR use to decrease mitochondrial respiration and increase oxidative damage, 
this is consistent with our previous studies.[50, 72] ACR is more potent than 4-HNE, 
however, PZ was able to still prevent mitochondrial dysfunction for both complex I & II –
driven respiration.  Although, the reported data appears that complex II is insulted more 
heavily by 4-HNE and ACR, and therefore PZ treatment has a greater protection for 
complex II these protein complexes are not operating under the same respiration states.  
Complex I-driven respiration is measured during state III respiration wherein oxidation and 
phosphorylation are coupled.  Complex II-driven respiration is reported from state V 
uncoupled respiration.  When inhibition and protection are compared for complex I and 
complex II respiration, in similar uncoupled states, complex one appears to be primarily 
insulted (Data not shown).   
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Furthermore, it appears that Complex II is more susceptible to the same dose of 
insult that is used to inhibit Complex I as seen Figure 4.1.   However, the nature of the 
preparation and assessment of mitochondrial complexes is performed in a linear manner 
and the assessment of Complex II has several minutes of increased exposure time during 
the measurement of respiration.  In other words, 4-HNE and ACR have significantly longer 
time to induce or exacerbate damage as the Seahorse device measures Complex I before 
Complex II. 
In conclusion we are the first to demonstrate in an ex vivo TBI model that PZ can 
function as a carbonyl scavenger to prevent 4-HNE or ACR- induced brain mitochondrial 
respiratory failure and oxidative damage in a dose-dependent manner.  Other experiments 
will investigate the ability of PZ to produce neuroprotective effects in vivo using the rat 
controlled cortical impact, brain injury model.   
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Chapter 5 
Phenelzine protects mitochondrial respiratory and calcium buffering functions 
together with a reduction in mitochondrial oxidative damage after traumatic brain 
injury 
 
5.1 Specific Aim  
Determine the ability of the carbonyl scavenger PZ to protect mitochondria after a 
controlled cortical impact induced traumatic brain injury (TBI) in young, adult rats. 
 
5.2 Introduction 
 The link between mitochondrial dysfunction and TBI is well established and 
discussed in detail in Chapter 1.  Experimental injury models have consistently 
demonstrated that mitochondria sustain acute and prolonged dysfunction [51, 156, 157].  
Injured mitochondria exhibit decreased ability to respire oxygen, impairment of the 
electron transport system (ETS), and a decreased ability to maintain calcium (Ca2+) 
homeostasis. 
 A major source of free radical production following TBI is due to mitochondrial 
reactive oxygen species (ROS) leakage.  Increased ROS production after experimental 
brain and spinal cord injury increases lipid peroxidation (LP) [79, 111, 158-160].  Increases 
in LP results in the accumulation of LP degradation products such as 4-HNE and acrolein 
(ACR) in injured central nervous system tissue proteins [45].  
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Dysfunctional mitochondria are less capable of buffering the influx cytosolic Ca2+ 
after neuronal injury [107, 161].  Ionic calcium (Ca2+) is electrochemically attracted to the 
negative matrix environment surrounded by the inner mitochondrial membrane.  However, 
following TBI excessive glutamate stimulation of N-methyl-D-aspartate (NMDA) 
receptors increases cytosolic Ca2+ and overwhelm the mitochondria [162].  Excessive Ca2+ 
increases ROS production, release of cytochrome C, and induces the formation of the 
mitochondrial permeability transition pore (mPT) [110, 163].  Loss of mitochondrial 
membrane potential is a mediator of these pathological mechanisms and is largely in 
response to the influx of Ca2+ into the mitochondrial matrix.  Membrane potential (ΔΨm) 
is a key component of the chemiosmotic theory of how the electron transport system (ETS) 
functions to create ATP, without ΔΨm mitochondria exhibit reduced mitochondrial 
function [73].  
Previously, our laboratory elaborated the acute time course of mitochondrial 
dysfunction which is significantly elevated 30 minutes after a severe TBI followed by a 
subsequent recovery and then a progressive decline beginning at 24 hours which is at its 
worst 72 hours after injury [73].   Additionally, we have demonstrated in Chapter 4 that 
the exogenous application of LP-derived damage markers such as 4-HNE and even more 
so ACR inhibit mitochondrial respiration ex vivo [72, 124, 144]  
Experimental evidence supports that, following TBI, elevated Ca2+ can induce 
mitochondrial dysfunction [106, 111, 164, 165].  The ability of mitochondria to buffer Ca2+ 
is compromised significantly at 3 and 12 hours post-injury [73].  Mitochondrial Ca2+ 
dysregulation leads to increases of cytosolic Ca2+ which activates calpains whose 
proteolytic activity is elevated acutely as early as 3-4 hours after injury, peaks at 24-72 
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hours and although slowly declining thereafter remains elevated for up to 7 days [33, 166]. 
Oxidative damage markers such as the reactive aldehydes 4-HNE and ACR also have been 
documented beginning within minutes post-injury, and reaching peak levels 48-72 hours 
after injury [64]. 
Our ex vivo work detailed in Chapter 4 indicates that PZ is capable of scavenging 
reactive aldehydes, preventing oxidative damage and improving mitochondrial respiration 
in isolated mitochondria exposed to 4-HNE or ACR.  The primary objective of this chapter 
is to determine if the carbonyl scavenger PZ (10 mg/kg s.c. at 15 minutes after TBI 
followed by maintenance doses of 5 mg/kg s.c every 12 hours for 72 hours) is able to 
protect mitochondria in vivo after a severe controlled cortical impact (CCI)-TBI in young 
adult rats.  Given the relevance described above, the metrics of mitochondrial function 
assessed in this chapter were assessed 1) the ability of mitochondria to respire oxygen, 2) 
accumulation of oxidative damage markers, and 3) the ability of mitochondria to buffer 
Ca2+. 
 
5.3 Results 
5.3.1 Mitochondrial Respiration 
 Following CCI-TBI young adult rats received a subcutaneous injection of either 
normal saline vehicle or PZ (10 mg/kg) 15 min after injury and maintenance doses of 5 
mg/kg every 12 hrs for 72 hrs. Rat were euthanized at 72 hours and did not receive the 72 
hour time point injection. Cortical brain tissue was dissected via cortical punch and 
mitochondria were isolated via ficoll gradient centrifugation (See Chapter 2: Materials 
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and Methods).  Immediately following mitochondrial isolation, mitochondria were 
assessed for their ability to respire oxygen using a Clark-type electrode which is consistent 
with methods our lab has previously published for in vitro [144] and in vivo 
experiments[73, 124] 
 The ability of PZ to protect TBI-induced mitochondrial dysfunction is expressed in 
two forms.  Figure 5.1, depicts mitochondrial function as respiratory control ratio (RCR).  
RCR is a ratio of states III and IV, a purported sensitive metric of mitochondrial function 
[108].  Additionally, PZ’s ability to protect mitochondria is expressed as rate of oxygen 
consumed for each state of respiration as moles of oxygen used per mg of mitochondrial 
protein per minute, Figure 5.2-5.6. 
 
5.3.2 Respiratory Control Ratio  
Mitochondria isolated from PZ treated rats exhibited a significant (p < 0.05) 
increase of RCR after injury compared to vehicle only treated rats and were not 
significantly different than sham only controls. (Figure 5.1) Vehicle treated rats’ 
mitochondria exhibited a significant reduction of RCR after injury when compared to sham 
controls (p < 0.05) and sham + PZ controls (p < 0.05).  Additionally sham + PZ controls 
compared to sham only controls was not significantly different. Sham and Sham + PZ 
groups were significantly different compared to Vehicle groups.  RCR of PZ treatment was 
significantly increased compared to vehicle and not significantly different from either sham 
control variant (Sham or Sham + PZ).  One-way ANOVA followed by Student Newman-
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Keuls post-hoc test.  * = p < 0.05.  Error bars represent +/- SD; n = 8-9 rats per group 
except sham where n = 5 rats per group. 
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Figure 5.1 Effects of phenelzine (PZ) on cortical mitochondrial 
bioenergetics 72 hours after injury following severe controlled cortical 
impact. Mitochondrial respiration was measured with Clark-type electrode 
expressed as respiratory control ratio (RCR).  The RCR is rate of oxygen 
consumption during State III divided by State IV respiration.  Substrates 
during State III and IV are define within the text.  Animals received PZ (10 
mg/kg s.c.) 15 minutes after injury followed by maintenance dosing (5 
mg/kg s.c.) every 12 hours; rats were euthanized at 72 hours.  Sham and 
Sham + PZ groups were significantly different compared to Vehicle groups.  
RCR of PZ treatment was significantly increased compared to vehicle and 
not significantly different from either sham control variant (Sham or Sham 
+ PZ).  One-way ANOVA followed by Student Newman-Keuls post-hoc 
test.  * = p < 0.05.  Error bars represent +/- SD; n = 8-9 rats per group except 
sham where n = 5 rats per group. 
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5.3.3 States of Respiration 
The following details and results represent data obtained from the same experiment 
that generated the RCR values; however, data is expressed as individual mitochondrial 
states of respiration.  Defined states of respiration are slightly modified from their original 
concept [94] to that of more conveniently accepted protocol [93, 167] as indicated in 
Methods. 
 
State II   
As a brief reminder, these assayed mitochondria are the same as those used to 
determine RCR values in section 5.3.1.  Mitochondria in this state are incubated with 
pyruvate and malate but not ADP.  There were no significant difference between controls: 
Sham versus Sham + PZ.  However, there was a significant rate reduction detected between 
PZ group verses that of Sham + PZ (p < 0.05), but not between PZ versus Sham only. 
Additionally, PZ treated rats’ mitochondria demonstrated significantly decreased 
dysfunction compared to vehicle (p <0.05).  There was not a significant reduction of 
respiration detected in vehicle compared to either sham groups (Sham or Sham + PZ). 
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Figure 5.2 Rate of oxygen consumption calculated as nM of oxygen 
consumed per minute per mg of mitochondrial protein during State II 
respiration in the presence of pyruvate and malate but no ADP.  State II is 
the theoretical functional equivalent to State IV respiration and is reported 
here as an internal control for consistency.  Animals received PZ (10 mg/kg) 
15 minutes after injury followed by maintenance dosing (5 mg/kg) every 12 
hours; rats were euthanized at 72 hours. PZ treatment exhibited significantly 
decreased respiration compared to vehicle and Sham + PZ, respectively. 
One-way ANOVA followed by Student Newman-Keuls post-hoc test.  * = 
p < 0.05.  Error bars represent +/- SD; n = 8-9 rats per group except sham 
where n = 6 rats per group.   
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State III 
 State III is the state of respiration wherein Complex I substrates pyruvate and 
malate are present in addition to ADP for activation of Complex V (ATP synthase).  
Together Complex I and ATP synthase drive State III oxidative phosphorylation.  PZ 
exposed mitochondria after TBI exhibited significantly decreased State III respiration rates 
compared to Sham (p <0.05) and Sham + PZ (p < 0.05), respectively.  In fact, PZ treatment 
was not statistically different than vehicle (TBI + saline).  The injury effect was present, 
that is, the vehicle treated group was significantly reduced from both sham variants (Sham 
and Sham + PZ) (p < 0.05). 
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Figure 5.3 Rate of oxygen consumption calculated as nM of oxygen 
consumed per minute per mg of mitochondrial protein during State III 
respiration in the presence of pyruvate and malate and ADP.  Animals 
received PZ (10 mg/kg) 15 minutes after injury followed by maintenance 
dosing (5 mg/kg) every 12 hours; rats were euthanized at 72 hours. Injury 
effect was present: Vehicle group significantly decreased from Sham and 
Sham + PZ).  PZ treatment exhibited significantly decreased respiration 
compared to Sham and Sham + PZ, respectively. One-way ANOVA 
followed by Student Newman-Keuls post-hoc test.  * = p < 0.05.  Error bars 
represent +/- SD; n = 8-9 rats per group except sham where n = 6 rats per 
group.   
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State IV 
During this state of respiration, the previously added ADP has been converted to 
ATP by Complex V driven by the proton gradient supplied by Complex I oxidation of 
substrates (pyruvate + malate).  This is a State IV ADP-limited resting state.  However, in 
State IV the addition of oligomycin to mitochondrial pools completely inhibits Complex V 
activity.  In naïve isolated mitochondria, this state would exhibit diminished respiration as 
the ability to respire oxygen is theoretically still coupled to the ability to generate ATP.  If 
respiration continues then we can deduce that oxidation and phosphorylation is uncoupled.  
In other words, State IV can be used to evaluate mitochondrial leak/ uncoupled respiration. 
PZ exposed mitochondria following TBI, again, exhibited significantly decreased 
rate of oxygen consumption compared to both sham (p < 0.05) and sham + PZ (p < 0.05) 
and vehicle treated TBI groups (p < 0.05) Figure 5.4.  Interestingly, saline following TBI 
(vehicle group) did not exhibit an injury effect as expected; vehicle group was not 
statistically different than either control variant (Sham or Sham + PZ).  Controls were not 
significantly different from each other. 
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Figure 5.4 Rate of oxygen consumption calculated as nM of oxygen 
consumed per minute per mg of mitochondrial protein during State IV 
respiration in the presence of pyruvate, malate, ADP, and oligomycin.  
Animals received PZ (10 mg/kg) 15 minutes after injury followed by 
maintenance dosing (5 mg/kg) every 12 hours; rats were euthanized at 72 
hours.  PZ treatment was significantly decreased compared to Sham, Sham 
+ PZ, and Vehicle groups, respectively. One-way ANOVA followed by 
Student Newman-Keuls post-hoc test.  * = p < 0.05.  Error bars represent 
+/- SD; n = 8-9 rats per group except sham where n = 6 rats per group.   
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State Va 
State V respiration is expressed as State Va and State Vb.  Va indicates State V, 
Complex I-driven respiration after the addition of FCCP, a protonophore.  The 
protonophore allows the mitochondrial membrane to be synthetically uncoupled. 
Respirations reported for this state communicate the maximum respiration rate for which 
Complex I is capable, in the provided conditions without the limiting “tether” of Complex 
V.  In other words, State Va is the maximum respiratory capacity of Complex I in an 
uncoupled state.   
Mitochondria from PZ treated rats exhibited a significant respiratory impairment 
compared to sham (p < 0.05) and sham + PZ (p < 0.05) groups. See Figure 5.5 However, 
unlike State IV respiration, the injury effect was apparent in State Va respiration: vehicle 
groups exhibited significantly reduced rates of respiration compared to both sham (p < 
0.05) and sham + PZ (p < 0.05) groups.  Controls (Sham and Sham + PZ) were not different 
from each other. 
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Figure 5.5 Rate of oxygen consumption calculated as nM of oxygen 
consumed per minute per mg of mitochondrial protein during State Va 
respiration after the addition of pyruvate, malate, ADP, oligomycin, and 
FCCP—an uncoupling protonophore.  Animals received PZ (10 mg/kg) 15 
minutes after injury followed by maintenance dosing (5 mg/kg) every 12 
hours; rats were euthanized at 72 hours.  PZ treatment was significantly 
decreased compared to both Sham groups, respectively.  Vehicle group was 
significantly reduced compared to both Sham groups, respectively. One-
way ANOVA followed by Student Newman-Keuls post-hoc test.  * = p < 
0.05.  Error bars represent +/- SD; n = 8-9 rats per group except sham where 
n = 6 rats per group.   
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State Vb 
 The state of respiration described here is maximal respiratory capacity of Complex 
II (as opposed to State Va which is maximal respiration for Complex I).  For this state of 
respiration rotenone was added to inhibit Complex I activity.  Succinate was added to elicit 
activation of Complex II.  And, since FCCP was previously added, Complex II now 
possesses the conditions to maximally respire oxygen when uncoupled. 
 Consistent again with previous states reporting diminished ability of PZ treated 
groups to facilitate Complex I-driven respiration, PZ + TBI group also exhibits a 
significantly diminished ability to respire oxygen compared to Sham (p < 0.05) and Sham 
+ PZ (p < 0.05) and vehicle (p < 0.05) groups.  Controls were not significantly different 
from each other.  An injury effect was not apparent, i.e. the Vehicle-treated group did not 
exhibit significantly reduced respiration rates when compared to Sham or Sham + PZ 
groups.   
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Figure 5.6 Rate of oxygen consumption calculated as nM of oxygen 
consumed per minute per mg of mitochondrial protein during State Va 
respiration after the addition of pyruvate, malate, ADP, oligomycin, FCCP, 
rotenone and succinate.  Animals received PZ (10 mg/kg) 15 minutes after 
injury followed by maintenance dosing (5 mg/kg) every 12 hours; rats were 
euthanized at 72 hours.  PZ treatment was significantly decreased compared 
to both Sham groups and Vehicle group, respectively.  One-way ANOVA 
followed by Student Newman-Keuls post-hoc test.  * = p < 0.05.  Error bars 
represent +/- SD; n = 8-9 rats per group except sham where n = 6 rats per 
group. 
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5.3.4 Mitochondrial Oxidative Damage 
In a similar but separate experiment with an additional cohort of rats, the ability of 
PZ to reduce markers of oxidative damage was assessed by western blot analysis.  As 
described in Methods, isolated mitochondria were prepared from Sham, Sham + PZ, TBI 
+ Vehicle, and TBI + PZ treatment groups.  Neither variant of sham controls (Sham or 
Sham +PZ) received injury.  PZ-treated rats followed the same dosing paradigm in 5.3.1, 
that is, PZ 15 minutes following injury 10 mg/kg was injected subcutaneously, followed 
by 5 mg/kg maintenance injections every 12 hours for 72 hours.  Mitochondria after 
isolation, were frozen at -80oC until assessed for protein concentration immediately prior 
to immunoblotting procedure. 
Western blots of isolated mitochondria revealed that PZ treatment after injury was 
able to significantly (p < 0.05) reduce the 4-HNE marker of oxidative damage although not 
to the level of Sham only group Figure 5.7.  4-HNE accumulation was significantly (p < 
0.05) elevated compared to both Sham and Sham + PZ control groups.  Control groups 
(sham and sham + PZ) were not significantly different from each other.  
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Figure 5.7 Phenelzine reduces 4-hydroxynonenal (4-HNE) accumulation in 
mitochondria after severe CCI-TBI when treated 15 minutes after injury at 
10 mg/kg, followed by 5 mg/kg every 12 hours.  Rats were euthanized at 72 
hours.  A) Quantification of markers of oxidative damage in cortical 
mitochondria.   B) Mitochondria were assessed for markers of oxidative 
damage by western blot analysis between 150 kd and 50 kd.  4-HNE was 
significantly elevated in Vehicle group compared to both Sham groups, 
respectively.  PZ treatment group exhibited significantly reduced oxidative 
damage compared to Vehicle group, but did not return to Sham levels.  
ANOVA followed by Student Newman-Keuls post-hoc test.  * = p < 0.05.  
Error bars represent +/- SD; n = 8-9 rats per group except sham where n = 
5 rats per group.   
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5.3.5 Mitochondrial Calcium Buffering 
Following severe TBI, subcutaneous injections of either vehicle (saline) or PZ 
treatment were administered 15 min after injury (See Materials and Methods).  
Phenelzine treatment again consisted of 10 mg/kg every 15 minutes after injury and 
subsequent 5 mg/kg dose at 12 hours.  (See Rationale for dosing at 24 hours).  Cortical 
mitochondria were dissected via punch, isolated from the excised cortical tissue via ficoll 
gradient and assayed for the ability to buffer Ca2+.  A typical trace is depicted in Figure 
5.9.  A spectrofluormeter was used to assess extra-mitochondrial Ca2+ levels by measuring 
the intensity of a fluorescent Ca2+-sensitive indicator CaG5N. Mitochondria were 
incubated in sequential additions of pyruvate and malate at minute 1, ADP at minute 2, 
oligomycin at minute 3, and at minute 5 the Ca2+ infusion began. 
One-way analysis of variance (ANOVA) followed by Student Newman-Keuls post-
hoc analysis revealed multiple findings (See Figure 5.8). Firstly, mitochondria from 
vehicle treated rats had significantly reduced ability to buffer Ca2+ when compared to sham 
control groups (p < 0.05); this is consistent with previously published reports that TBI 
reduces mitochondrial buffering capacity [73, 124].   Additionally, rats treated after injury 
with a 24 hours PZ treatment paradigm exhibited a significantly (p < 0.05) increased ability 
to buffer Ca2+ when compared to vehicle treated rats.  However, while PZ-treated rats’ 
mitochondria were better able to buffer Ca2+, the TBI + PZ treatment group’s ability to 
buffer Ca2+ was not statistically different that Sham values. 
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Figure 5.8 Quantification of cortical mitochondrial calcium buffering 
capacity 24 hours after severe CCI-TBI in the rat.  Phenelzine (PZ) 
treatment consisted of single 10 mg/kg injection 15 minutes after injury 
followed by maintenance dosing every 12 hours at 5 mg/kg.  Rats were 
euthanized at 24 hours. Mitochondria from vehicle treated rats 
demonstrated a significantly decreased ability to buffer increasing 
concentrations of Ca2+ (Ca2+) compared to Sham.  PZ treatment 
significantly improved Ca2+ buffing when compared to Vehicle.  PZ 
treatment after TBI was not statistically different than Sham group.  
ANOVA followed by Student Newman-Keuls post-hoc test.  * = p < 0.05.  
Error bars represent +/- SD; n = 8-9 rats per group.  
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Figure 5.9 Typical mitochondrial Ca2+ buffering trace.  A spectrofluormeter 
was used to assess extra-mitochondrial Ca2+ levels by measuring the 
intensity of a fluorescent Ca2+-sensitive indicator CaG5N. Mitochondria 
were incubated in sequential additions of pyruvate and malate at minute 1, 
ADP at minute 2, oligomycin at minute 3, and at minute 5 the Ca2+ infusion 
began.  
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5.4 Discussion 
 Face value interpretation of these experiments demonstrate that a 15 minute post-
injury administration of PZm is able to protect against TBI-induced deficits in 
mitochondrial respiratory function when expressed in terms of RCR, mitochondrial Ca2+ 
buffering, and reduce mitochondrial markers of oxidative damage.  (PZm designates a 
single s.c. injection of 10 mg/kg 15 minutes after TBI and 5 mg/kg every 12 hours thereafter 
for 72 hours; the exception being Ca2+ buffering experiments wherein cortical 
mitochondria were isolated at 24 hours.)  While this is certainly true, further consideration 
of RCR (Figure 5.1) data compared to independent states of respiration (Figures 5.2-5.6) 
are seemingly contradictory. 
In fact, PZ demonstrated significantly (p < 0.05) reduced respiration for every state 
of respiration measured (State II, III, IV, Va and Vb).  How can PZ seem to improve 
mitochondrial respiration (RCR), reduce markers of oxidative damage, increase Ca2+ 
buffering but, simultaneously decrease individual states of respiration? Does the reckoning 
of this undermine or support PZ’s presumed ability to protect mitochondria as 
demonstrated in vitro as detailed in Chapter 4?  The following sections entertain 3 
possibilities.  
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5.4.1 Hypothesis 1: Phenelzine-induced Monoamine Oxidase Inhibition Could Have a 
Greater Proportional Effect on Overall Mitochondrial Oxygen Consumption in Injured 
Mitochondria 
The first consideration regards artifactual bias.  Inherently, one must always 
consider their own ability to perform experiments, but this is not the artifact for which this 
author is considering.  Rather, the isolated mitochondrial preparation itself has inherent 
limitations.  As mentioned in Chapter 1, the mitochondrial respiration assays that we 
employed are only able to detect one component of respiratory function: oxygen 
consumption.  However, the measurement of increased or decreased oxygen consumption 
following the addition of multiple substrates or inhibitors is helpful in dissecting the status 
of  the individual states of respiration [93].   
In the case of the injured mitochondria exposed in vivo to PZ treatment, when 
individual states of respiration are assessed, every individual state is significantly reduced 
compared to the Sham only cohort.  However, when PZ treatment is compared to Sham 
and expressed as RCR, PZ provides protection.  Under closer inspection of the individual 
states of PZ-treated groups, there is a reduction of State IV rate, more so than the decrease 
in State III.  The quotient of these two numbers generates an RCR.  Because RCR is a ratio, 
a relative increase in State III or a relative decrease in State IV will increase the overall 
RCR.  The PZ-treated group as reported by RCR (Figure 5.1) consists of a State III (Figure 
5.3) divided by disproportionately decreased State IV (Figure 5.4).  One possibility that 
might account for the systematic reduction of the individual respiration states in injured, 
but not in non-injured mitochondria, could be due to the effect of PZ-induced monoamine 
oxidase (MAO) inhibition as source of reduced oxygen consumption.  
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Phenelzine is an irreversible, non-specific inhibitor of MAO [151]. The majority of 
monoamine oxidases exist in the outer mitochondrial membrane (OMM) [168].  Therefore, 
it is possible that PZ is preventing the degradation of monoamines by MAO, which 
consume oxygen as a part of the normal processes to breakdown monoamines.  Because 
our assay only can detect total amount of oxygen consumed, we attribute decreased oxygen 
utilization with decreased respiratory function.  However, decreased oxygen utilization 
could be attributed to the inhibition of normal basal catabolic reactions of monoamine 
degradation that normally consume oxygen. 
 In other words, in PZ-treated injured mitochondria, the relative contribution of 
background MAO activity-induced oxygen consumption, compared to the oxygen 
consumption by the injury-compromised electron transport chain, might be greater than 
that occurring in normal mitochondria. Where the ratio of oxygen utilization by MAO 
activity is minor compared to the amount of oxygen consumed by oxidative 
phosphorylation.  This could explain why PZ appears to be exacerbating the TBI-induced 
respiratory dysfunction in the injured, but not in the Sham (non-injured mitochondria).  
Additionally, the reduction of respiration specifically during state IV, would lessen the 
extent of uncoupled respiration and lead to an overall beneficial increase of RCR.  
Mitochondria could be uncoupled but PZ is reducing the effect by decreasing the 
respiration disproportionately in State IV.  
Admittedly, this possibility is undermined by the fact that the concentration of 
monoamines in the mitochondrial preparation, and thus the actual oxygen utilization 
attributable to MAO oxidation of those monoamines, is not presently known.   
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5.4.2 Hypothesis 2: Phenelzine-induced MAO Inhibition Leads to Increased levels of 
Monoamine Neurotransmitters Leading to Autoxidation-induced Free Radical Production 
 The second hypothesis, also related to PZ inhibition of MAO, as to how PZ could 
exhibit negative effects of mitochondrial respiratory states is through a potential increase 
in dopamine neurotoxicity. Immediately following post-injury administration of PZ, 
excitotoxic levels of monoamines (e.g. dopamine) could increase in vivo due to inhibition 
of their principal degrading enzyme (MAO).  As already pointed out, PZ is a MAO 
inhibitor  [151] and prevents the degradation of dopamine which elicits neurotoxicity when 
dopamine autoxidizes in the synaptic cleft [169].  Dopamine autoxidation leads to 
formation of amiochrome-protein adducts and free radicals [170] that inhibit normal 
cellular processes and facilitates lipid peroxidation (LP), respectably.  These effects could 
reasonably happen during the 72 hour treatment time in vivo and serve to “pre-injure” or 
even exacerbate mitochondrial dysfunction before mitochondria are isolated for 
assessment of respiratory function.  This would explain why reduction of respiration is 
only seen in animals with PZ treatment after injury (and not in Sham + PZ animals).  In 
other words, PZ might be exacerbating only the injury effect on the mitochondrial 
respiratory state through dopamine neurotoxicity while mitochondria are still in the rat 
brain, which would account for not seeing this effect in vitro. 
Yet, dopamine neurotoxicity does not account for our laboratory’s previously 
published results showing that a single injection of PZ given 15 minutes after TBI can 
improve mitochondrial RCR when assessed 3 hours after injury [144].  If inhibition of 
MAO increases dopamine levels (sufficient to induce neurotoxicity) which would decrease 
mitochondrial function, our previous experiment would not demonstrate that PZ treatment 
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increases mitochondrial respiration. On the other hand, the fact that mitochondria are 
protected by PZ when assessed at 3 hours post-injury does not preclude the possibility that 
dopamine accumulation and possible dopamine autoxidation might develop more slowly 
and become apparent, particularly in injured mitochondria, by 72 hours.  However, this 
would require increased lipid peroxidation which we do not see.there 
Other researchers have published evidence that undermine this dopamine 
neurotoxicity hypothesis.  In fact, MAO inhibitors (both A and B types) have been shown 
to reduce mitochondrial dysfunction by preventing the degradation of dopamine [168] 
which increase respiration by reducing the degradation products of monoamine catabolism 
such as H2O2 and superoxide radical O
•- that would otherwise hinder oxidative 
phosphorylation [171].  Additionally, the better preserved RCR in 72 hour post-TBI 
mitochondria and a decrease in oxidative damage (i.e. 4-HNE accumulation) at the same 
time point runs counter to the notion that PZ-induced MAO inhibition is increasing 
monoamine oxidation to the point of causing additional oxidative damage. 
 
5.4.3 Hypothesis 3: Possible Negative Effects of Phenelzine-induced GABA Transaminase 
Inhibition Exacerbating Post-TBI GABA Excitotoxicity 
GABA is generally regarded as an inhibitory transmitter which hyperpolarizes 
mature neurons by the influx of chloride ions (Cl-), the result is less electrical signaling and 
reduced Ca2+ influx [172].  However in early development and following neuronal injury 
[173], GABA receptors respond to GABA in an excitatory manner to increase Ca2+ influx 
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[174-176] as a means to modulate growth cones, enhance neuritic outgrowth and mature 
synapses [177-180].  
Chen and colleagues carefully investigated the GABA excitatory actions and 
demonstrated that endogenous levels of GABA in the synaptic cleft after injury is able to 
depolarize Cl- reversal potential that facilitate the efflux of Cl- leading to neuronal 
depolarization instead of the normal Cl- influx that underlies GABA-mediated 
repolarization [181].  Furthermore, application of GABA to traumatized cultured neurons 
has been shown to cause depolarization mediated via increased Ca2+ influx through 
normally Cl- permeable channels[173]. Consequently, voltage-activated Ca2+ channels (L 
and N type) open and Ca2+ floods the cell with concentrations reaching over 600nM [173].  
GABA excitotoxicity has been documented in multiple neuronal injury models and reports 
confer that the reversed role of GABA (e.g. excitatory effects of GABA) occur within a 
window starting approximately 3 hours after injury/insult, exhibit maximum response at 
48 hours, then diminish gradually for the next 2 weeks [173].  Maximum response is defined 
by manuscript’s authors as 63% of the neurons in explanted hippocampal or cortical tissue 
responding to GABA with a Ca2+ influx. 
GABA excitotoxicity can be exacerbated by PZ which can increase GABA levels 
due to an inhibition of GABA metabolism.  Interestingly, PZ is not only an inhibitor of 
MAO but a substrate for it. Phenelzine oxidation by MAO yields 
phenylethylidenehydrazine (PEH) [147].  PEH is a potent inhibitor of GABA-transaminase 
(GABA-T) and GABA-T is the primary means of synaptic GABA clearance [182]. 
Phenelzine has been reported to decrease MAO activity and simultaneously elevate GABA 
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levels.  A single dose of PZ (15 mg/kg) in the rat inhibits 100% of GABA-T activity for 8 
hours, which tapers off to 24 % inhibition 24 hours after injection[183]. 
Given that injured neurons are known to exhibit a reversed, excitatory role for 
GABA and that PZ increases GABA levels, PZ could be exacerbating GABA 
excitotoxicity.  Too much GABA stimulation following trauma would exhibit the same 
drastic Ca++ influx that is associated with glutamate excitotoxicity.  
Our data indicate that PZ is capable of scavenging neurotoxic carbonyls which can 
have beneficial effects like improving mitochondrial respiration (at least in regards to 
RCR) and reducing lipid peroxidative damage (i.e. 4-HNE) to mitochondrial proteins.  
However, PZ multiple dosing over a 72 hour period may aggravate GABA-mediated 
excitotoxic consequences.  The PZ dosing paradigm utilized a single 10 mg/kg s.c. dose 15 
minutes after injury and 5 mg/kg s.c. every 12 hours.  This dosing paradigm was 
intentionally extended to allow maximum exposure of PZ to scavenge reactive aldehydes, 
but this dose may also elevate GABA levels during the period when injured neurons are 
most susceptible to GABA excitotoxicity (e.g. 48 hours).   
Our previously published mitochondrial work indicated that a single dose 
(10mg/kg) of PZ was capable of increasing RCR, 3 hours after injury [144].  The increase 
in respiration suggests that a single dose of PZ may not contribute as drastically to GABA 
excitotoxicity as would multiple doses every 12 hours for 3 days.  Additionally, neurons 
exhibit a limited excitatory response to GABA 3 hours after injury [173] which suggest 
early administration of PZ could also mitigate the GABA excitotoxic response. Which begs 
the question: Would you rather get hit in the face once, or every 12 hours for 3 days? 
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GABA Excitotoxicity on Calcium Buffering 
 Our Ca2+ buffering experiments in Figure 5.8 demonstrate that PZ also protects the 
ability of mitochondria removed from the injured brain to buffer Ca2+.  According to the 
presented GABA excitotoxicity hypothesis, preservation of Ca2+ buffering may be a 
double-edge sword.  On one hand mitochondria are able to better buffer increases of 
cytosolic Ca2+ that would otherwise activate Ca2+-mediated proteases which could destroy 
the cell.  On the other hand, increased Ca2+ within the mitochondrial matrix could disrupt 
the redox potentials which facilitate proton translocation and electron transfer e.g. PZ 
would decrease mitochondrial respiration.  The notion that increased Ca2+ buffering 
decreases mitochondrial respiration is indirectly supported by other labs, which concluded 
that reducing Ca2+ in the mitochondria by pharmacologic uncoupling increases 
mitochondrial respiration and tissue sparing [108].  The uncoupling agents were concluded 
to reduce mitochondrial Ca2+ buffering which lead to restored mitochondrial respiration 
after moderate TBI in the rat.  
In all, PZ is protecting mitochondria dysfunction after TBI in vivo by scavenging 
carbonyls and improving the ability of mitochondria to buffer Ca2+.  Diminished 
mitochondrial respiration in PZ-treated rats suggests that PZ may be exerting a self-limiting 
effect due to GABA-mediated Ca2+ elevations in the mitochondrial matrix which reduce 
the ability of mitochondria to oxidize substrates, translocate protons, and transfer electrons.   
In summary, the neuroprotective properties of PZ appear to be complicated.  We 
have demonstrated that the hydrazine moiety of PZ is able to scavenge deleterious 
carbonyls in normal mitochondria exposed to either 4-HNE or ACR in vitro together with 
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a decrease in aldehydic modification of mitochondrial proteins (Chapter 4), and that these 
effects are also seen in mitochondria assayed from rats subjected to CCI TBI and assessed 
at 72 hours after injury.  Additionally, we have demonstrated that PZ is capable of 
improving mitochondrial Ca2+ buffering capacity after TBI.  However, PZ is a GABA-T 
inhibitor and reduction in functionality of this enzyme could conceivably increase GABA 
levels. Normally a GABA increase might serve to decrease excitotoxicity, but after 
neuronal injury a GABA agonist will exacerbate the injury by facilitating a cytotoxic influx 
of Ca2+.  Even though, PZ treated mitochondria possess higher buffering capacities for this 
increased Ca2+, this can translate physiologically to a reduction of mitochondrial 
respiration. Thus, it appears that PZ treatment may contribute to healthier brain 
mitochondria that exhibit less oxidative damage after TBI and increased ability to buffer 
Ca2+, but they are limited in their maximal respiratory response.    
Given the strong influence of PZ metabolites to modulate intracellular Ca2+, the 
next chapter will investigate PZ’s role in terms of spectrin degradation and histological 
sparing.          
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Chapter 6 
Role of phenelzine in histological sparing of cortical tissue and spectrin degradation 
 
6.1 Specific Aim 3 
Determine the extent to which phenelzine (PZ) is able to provide neuroprotection 
in rats following a controlled cortical impact brain injury. 
 
6.2 Introduction  
 In the previous chapter, the importance of calcium (Ca2+) homeostasis was 
described as a function of mitochondrial condition.  Specifically, the preservation of 
mitochondrial Ca2+ buffering could prevent cytosolic elevations of Ca2+ which would 
preempt the activation of degrading enzymes such as calpains.  Additionally, proper Ca2+ 
homeostasis maintains the chemiosmotic gradient which is vital for the production of 
adenosine triphosphate (ATP)[93].   This chapter primarily focuses on the investigation 
PZ’s therapeutic window and assessment of neuroprotection by characterization of spectrin 
degradation and histological tissue sparing. 
Experimental models of TBI have long established the perturbation of Ca2+ 
homeostasis after injury [184].  One of the most well-established means by which Ca2+ 
homeostasis is lost after TBI is induced via glutamate excitotoxicity.  Wherein, the primary 
insult to the brain serves as a mechanical depolarization stimulus that 1) activates the 
opening of voltage-dependent ion channels (Na+, K+, and Ca2+) and 2) initiates the release 
 
144 
  
of excitatory neurotransmitters such as glutamate which stimulate N-methyl-D-aspartate 
(NMDA) and AMPA receptors on postsynaptic targets. Over-excitation of these receptors 
elicits the influx of Na+ and Ca2+ ions into the neuron [21, 185, 186]. 
Rapid accumulation of Ca2+ can compromise cytoskeletal integrity by activation of 
calcium-sensitive proteases.  Especially important, the rise of cytosolic Ca2+ activates 
cysteine proteases such as calpains.[187]  Calpains target membrane-associated proteins 
and cytoskeletal components that upon cleavage have been reported to increase the 
incidence of cell death.[188]  One specific target of Ca2+-activated proteases is αII-spectrin 
[150], which has become a widely used and reliable means to assess the cytoskeletal 
integrity as a metric of neuroprotection [33, 34, 36, 149, 189] since its original 
characterization [33]. 
αII-spectrin is enzymatically degraded into what are referred to as spectrin 
breakdown products (SBDP).  The particular SBDP exhibit a specificity to the proteolytic 
enzymes which degraded full length spectrin (280 kDa).  For instance, cleavage by calpain 
results in fragments 150 kDa and 145 kDa whereas degradation of spectrin by caspase-3  
results in formation of fragments 150 kDa and 120 kDa all of which can be detected by 
western blot analysis.[190]  The ability to differentiate which proteolytic enzymes provide 
considerable insight into the type of neuroprotection a drug can offer.  For instance, if 
calpain enzymatic activity is increased but not caspase, then with reasonable confidence 
one can argue that mitochondria have not undergone mPT and are relatively stable.  
Otherwise, these mitochondria would have induced pore formation and released 
cytochrome c, the activator of caspase-9.  Caspase-9 is the activator of caspase-3 [191].  
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Caspase-3 cleavage of spectrin is detectable in spectrin degradation immunoblot analysis 
[190].   
Spectrin degradation analysis not only an attempt to qualify neuroprotective 
properties of phenelzine (PZ), but it is also a means to measure therapeutic window.  
Therapeutic window in the context of the following experiments, is described as the 
maximum amount of time that PZ treatment can be delayed and still provide neuronal 
protection. Spectrin degradation in the rat controlled cortical impact (CCI) brain injury 
model is detectable as early as 15 min after injury[148]. Therefore, this endpoint has been  
used to determine the neuroprotective  therapeutic window by evaluating the ability to 
attenuate spectrin degradation  after CCI-TBI with treatment initiation delay times ranging 
to 15 min. to as long as 12 hours [192, 193].  Increasing the delay of PZ treatment would 
help determine the therapeutic window.  
In addition to the assessment of spectrin degradation, the following experiments 
attempt to measure the extent to which PZ can spare tissue after CCI-TBI.  Histological 
stains have previously been reported to correlate strongly in both location and timing of 
calpain-medicated spectrin degradation [33, 148, 194]. 
Thus far, PZ has been described as a monoamine oxidase inhibitor (MAO-I) and a 
carbonyl scavenger capable of binding lipid peroxidation-derived reactive aldehydes such 
as 4-hydroxynonenal (4-HNE) and acrolein (ACR).  To date, PZ does not possess the 
ability to directly bind cytosolic Ca2+.  However, it is plausible that PZ could indirectly 
modulate cytosolic Ca2+ and provide neuroprotection by preserving mitochondrial 
function.  We have documented in the previous Chapter 5 that PZ is able to protect the 
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ability of mitochondria to buffer Ca2+.  It is well established that cytosolic Ca2+ 
concentration is a key regulator in the activation of proteolytic enzymes responsible for 
cytoskeletal degradation.  Therefore, PZ may provide neuronal protection by allowing 
mitochondria to buffer Ca2+ which would reduce the cytosolic Ca2+ and subsequently 
preempt activation of Ca2+ sensitive proteolytic enzymes such as calpains and caspases 
[108, 184, 190]. 
On the other hand, PZ may exacerbate γ-aminobutyric acid (GABA) excitotoxicity.    
GABA typically binds to GABA receptors to suppress action potentials and decrease 
neuronal activity by facilitating the influx of chloride ions (Cl-) which contributes to the 
hyperpolarization of the cell.  Two exceptions to this “suppressant” role of GABA are 
thought to exist to modulate neurite outgrowth during embryonic development and after 
injury [176, 177].  In this role, GABA is an excitatory transmitter that causes a polarization 
reversal to efflux Cl- (rather than the typical influx).  Subsequently, the Cl- influx causes 
voltage-gated Ca2+ channels to activate and facilitate the influx of Ca2+ ions.  The excitatory 
role of GABA after neuronal injury is reported in cortical and hippocampal explants to 
elicit Ca2+ influx in approximately 38% of total neurons 3 hours after injury, maximum 
response of approximately 68% of neurons at 24 hours after injury, and only 9% of neurons 
two weeks after injury [173].  Thus, while PZ can protect mitochondrial Ca2+ buffering, it 
could simultaneously be exacerbating Ca2+ overload  through PZ-metabolite GABA 
transaminase (GABA-T) inhibitory action which would act to increase GABA which in the 
post-injury state is largely excitatory and able to cause an increased Ca2+ influx [147].  
Nevertheless, given the role of PZ to improve mitochondrial Ca2+ buffering, reduce 
oxidative damage and possibly influence critical components of  Ca2+ homeostatic 
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regulation, we aimed to demonstrate the ability of PZ to influence spectrin degradation and 
to preserve cortical tissue sparing.  Should PZ be able to decrease spectrin degradation, we 
intended to develop a therapeutic window to describe the maximum amount of time that 
the initiation of posttraumatic PZ treatment could be withheld after CCI-TBI in the rat and 
still provide neuroprotection.  Additionally, two dosing paradigms were used to investigate 
tissue sparing.  Increasing PZ dosing could theoretically result in an increase of 
neurological protection due to increased carbonyl scavenging, or it could result in a 
possible decrease in tissue sparing likely due to GABA excitotoxicity.  
 
6.3 Results 
6.3.1 Spectrin Degradation 
 Phenelzine treatment was delayed 15 minutes and 3 hours after a severe CCI-TBI 
in the rat.  PZ dosing consisted of a single 10 mg/kg s.c. injection followed by repeated 5 
mg/kg s.c. injections every 12 hours. Male rats were euthanized at 72 hours.  Tissue 
dissected from rat brains by cortical hole punch and was assayed by immunoblotting 
technique for 150 and 145kD spectrin degradation products.  Data were expressed as 
optical density as percent of sham for either 150 or 145 kD bands, normalized to β-tubulin. 
15 minute Delay 
 Phenelzine or vehicle (0.9% Saline) treatments were delayed 15 minutes after CCI-
TBI.  Vehicle (saline) treated animals exhibited significantly higher (p < 0.05) banding 
intensities for 150 and 145 kD bands compared to sham.  The PZ and Vehicle treatment 
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groups exhibited significantly increased banding intensities (p < 0.05) compared to the 
Sham group.  However, PZ treatment group was not significantly different than vehicle 
treated group.  See Figure 6.1. 
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Figure 6.1 A) Western blot of spectrin degradation products.  Phenelzine 
(PZ) treatments were delayed 15 minutes after severe CCI-TBI.  PZ was 
injected at 10 mg/kg 15 minutes after injury and 5 mg/kg every 12 hours 
thereafter.  Rats were euthanized at 72 hours.  B-C)  Spectrin breakdown 
products (SBDP) are quantified by optical density, normalized to β-tubulin 
and expressed as percent control.  B) 150 kD band for vehicle and PZ 
treatment groups were significantly elevated compared to sham, 
respectively.  PZ was not significantly different from Vehicle group.  C)  
145 kD band for Vehicle and PZ treatment groups were significantly 
elevated compared to sham, respectively.  However, PZ was not 
significantly different from sham control.  One-way ANOVA followed by 
Student Newman-Keuls post-hoc test.  * = p < 0.05.  Error bars represent 
+/- SD; n = 8 rats per group. 
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3 hour Delay 
 In a second round of experiments, PZ or Vehicle treatments were delayed 3 hours 
after CCI-TBI.  Similar to the 15 minute delay, Vehicle 
 treated animals exhibited significantly higher (p < 0.05) banding intensities for 150 and 
145 kD bands compared to Sham.  PZ treatment group also exhibited significantly 
increased banding intensities (p < 0.05) compared to Sham group.  However, PZ treatment 
group was not significantly different than the vehicle treated group.  See Figure 6.2. 
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Figure 6.2 A) Western blot of spectrin degradation products after 3 hour 
delayed phenelzine (PZ) treatment.  Phenelzine (PZ) treatments were 
delayed 3 hours CCI-TBI.  PZ was injected at 10 mg/kg 3 hours after injury 
and 5 mg/kg every 12 hours after first injection.  Rats were euthanized at 72 
hours.  B-C) Spectrin breakdown products (SBDP) are quantified by optical 
density, normalized to β-tubulin and expressed as percent control.  B) 150 
kD band for vehicle and PZ treatment groups were significantly elevated 
compared to sham, respectively.  PZ was not significantly different from 
Vehicle group.  C)  145 kD band for Vehicle and PZ treatment groups were 
significantly elevated compared to sham, respectively.  However, PZ was 
not significantly different from sham control.  One-way ANOVA followed 
by Student Newman-Keuls post-hoc test.  * = p < 0.05.  Error bars represent 
+/- SD; n = 8 rats per group. 
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6.3.2 Cortical Tissue Sparing 
Two dosing paradigms were tested PZs and PZm.   
 PZs is a single dose of PZ 10 (mg/kg) injected s.c. 15 minutes after a severe 
TBI.  This single dose had previously been shown by our laboratory to 
increase tissue sparing in the rat when assessed at 14 days post-injury [144]. 
 PZm is a single dose of PZ (10 mg/kg) also injected s.c. 15 minutes after 
severe TBI in the rat followed by an additional maintenance 5 mg/kg dose 
given s.c. every 12 hours.   
In both dosing paradigms, rats were euthanized at 72 hours after the first injection.  
Twelve brain sections were assessed for area of intact cortical tissue and then used to 
determine the volume of cortical sparing as described in Chapter 2: Materials and 
Methods.  Data are expressed as percent of tissue spared compared to contralateral (non-
injured) hemisphere.   
Although perhaps showing an increase in tissue sparing compared to the Vehicle 
group, the PZs group was not statistically different than Vehicle treated group.  However, 
PZm exhibited statistically significant (p < 0.05) increase of tissue sparing compared to the 
Vehicle group.    
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Figure 6.3 Coronal sections of ipsilateral rat brains rat taken at 1.2x 
magnification.  A) Vehicle (0.9% saline) treated rat brain injected 15 
minutes after TBI.  B) Phenelzine (PZs) single dose treated animal, injected 
with a single dose of PZ, 15 minutes after injury at 10 mg/kg.  C)  Rat brain 
of PZ treated with a multiple dosing paradigm (PZm): single subcutaneous 
injection of PZ 15 minutes after injury, followed by maintenance dosing of 
5 mg/kg every 12 hours thereafter.  All groups (Vehicle, PZs, PZm) were 
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euthanized 72 hours after first injection.  Black bar represents 1mm. D) 
Percent of tissue sparing followed by either Vehicle (saline), PZs, or PZm 
treatment.  Rats were euthanized in all treatment paradigms at 72 hours after 
first injection.  PZs did not exhibit a statistically significant amount of 
cortical tissue sparing when compared to Vehicle.  However, PZm 
significantly increased the total volume of spared cortical tissue.  One-way 
ANOVA followed by Dunnett’s post-hoc test.  * = p < 0.05.  Error bars 
represent +/- SD; n = 8 rats per group. 
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6.4 Discussion 
6.4.1 Multiple Phenelzine Dosing Protects Cortical Tissue but Does Not Decrease Spectrin 
Degradation Compared to Sham  
The neuroprotective therapeutic window for PZ in terms of a possible reduction in 
posttraumatic calpain-mediated spectrin degradation was assessed by increasing the delay 
of PZ administration after injury.  The multiple dose PZ paradigm was injected in rats after 
injury with either a 15 minute delay after TBI or, in another cohort, a 3 hours delay.  All 
animals were euthanized and assessed for spectrin degradation 72 hours after the first 
injection.  In both PZ-treated groups (15 minutes and 3 hours delay), neither group 
exhibited a reduction of spectrin degradation when compared to Vehicle-treated injured 
animals. 
However, the same multiple dosing parading that did not demonstrate spectrin 
protection was able to spare cortical tissue, whereas the single dose of PZ did not.  It is 
conceivable that the multiple dosing with PZ over 72 hours would provide more scavenging 
molecules that protect cortical tissue from deleterious carbonyls which would result in the 
observed protection of cortical tissue.  However, this does not account for why spectrin 
degradation was not reduced. Theoretically, little prevention of spectrin degradation would 
imply that cortical tissue will not be spared due to the presumed “degraded” states of 
cytoskeletal components e.g. spectrin.  The following section provides some ideas as to 
this dichotomy between PZ’s ability to increase histologically measured tissue sparing 
while not reducing spectrin degradation. 
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6.4.2 Phenelzine Could Actually Exacerbate Spectrin Degradation  
As previously described in Chapter 5, the PZ metabolite PEH can  inhibit γ-
aminobutyric acid transaminase (GABA-T) leading to immediate increases in the 
“inhibitory” neurotransmitter GABA [195].  However, beginning immediately after injury 
neurons will utilize GABA as an excitatory neurotransmitter that reverses movement of 
chloride ions (Cl-) to now exit the cell causing subsequent activation of voltage gated 
calcium channels and the influx of Ca2+ [173].  In consideration of this, PZ possesses the 
ability to increase GABA levels and therefore to exacerbate neuronal Ca2+influx [196].  
This idea suggest that PZ could worsen neuronal cytoplasmic Ca2+ overload, calpain 
activation and spectrin degradation. However, both PZ treatment delay groups (15 minutes 
and 3 hours) only showed a trend to exacerbate spectrin degradation; neither group was 
significantly worse than Vehicle.  How can PZ have the propensity to exacerbate spectrin 
degradation, but not demonstrate this? 
 
6.4.3 Phenelzine Could Increase Total Intact Spectrin  
It is possible that PZ is worsening spectrin degradation, but it is also possible that 
PZ is simultaneously increasing the expression of spectrin.  The result of which, would be 
a null effect as observed in our spectrin degradation assays.  It is theoretically possible that 
increasing more intact spectrin could yield the potential of even more SBDP.  However, as 
calpain is an enzyme it is bound by the laws of kinematics and therefore have a saturation 
limit which provides the possibility of increase intact spectrin despite activation of calpain. 
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This mechanism is considered is due to the heavy developmental role of GABA excitatory 
response detailed below. 
 As previously mentioned, GABA-medicated Ca2+ influx is a mechanism borrowed 
from early neuronal development [172, 177, 178].  This mechanism is heavily regarded as 
a means to facilitate neurite outgrowth and play a role in synaptogenesis following injury 
[173, 174, 177, 181].  And, PZ is known to exacerbate GABA levels [197, 198].  Therefore, 
it is not unreasonable to speculate that PZ is facilitating the “reconstruction” of the 
cytoskeletal matrix by increasing the degradation of spectrin.  Our assay measures the 
extent of spectrin degradation as a percent of Sham animals, which does not assess the total 
amount of intact spectrin available in the cell.  In other words, there may be more spectrin 
degradation in PZ-treated animals, but we have yet to assess if total intact spectrin is 
increased.  This might explain why cortical tissue sparing can exist “without” a reduction 
of spectrin degradation which would be an observation first of its kind.  Additionally, 
would call into question the validity of SBDP being a well-established surrogate for 
neuroprotection. 
If PZ is increasing calcium buffering of mitochondria post-TBI then it is possible 
to observe decreased calcium buffering at later time points, when the mitochondria become 
overwhelmed.  Other potential biases are explored in the next chapter that may account for 
the diminished ability of PZ to reduce spectrin degradation.   
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6.4.4 Some Calpain Inhibitors Fail to Prevent Spectrin Degradation but Increase 
Behavioral Recovery 
Other reports have demonstrated a “counter-intuitive” relationship related to 
spectrin degradation as well. Calpain-mediated degradation does not always match the 
spatial and temporal characteristics of other axonal pathologies [150].  For instance, post-
TBI neurological recovery was improved in the rat and mouse following treatment with the 
brain-penetrable calpain inhibitors E64 and SJA6017 but no reduction in cerebral spectrin 
degradation was found [34, 199].  On the other hand, another brain-penetrable calpain 
inhibitor MDL-28170 produced a significant reduction in early posttraumatic spectrin 
degradation, but did not increase sparing of cortical tissue [200].  Additionally, when FCCP 
was used to uncouple mitochondria, increased cortical tissue sparing was reported 18 days 
after injury [108].  However, FCCP should have theoretically increased cytosolic Ca2+ to 
the point of activating calpains that degrade spectrin and subsequently preempt the 
possibility of sparing tissue.  Phenelzine may be among these compounds that show a 
dichotomy between increased tissue sparing and/or behavioral recovery improvement 
without any decrease in calpain-mediated spectrin degradation.  
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Chapter 7 
Final Discussion 
 
7.1 Brief Summary of Results 
7.1.1 Summary of Aim 1 Ex Vivo Experiments 
The material presented in Chapter 4, was a means to investigate a “proof of 
concept”.  The aim of the conducted experiments was to “assess the ability of the carbonyl 
scavenger PZ to protect uninjured, isolated rat brain mitochondria from ex vivo exposure 
to the deleterious, LP-derived reactive aldehydes 4-hydroxynonenal (4-HNE) and acrolein 
(ACR).” 
In order to test the concept that PZ can scavenge reactive carbonyls and provide 
protection, several key optimizations needed to first be made pertaining to the exogenous 
application of 4-HNE and ACR to isolated naïve mitochondria.  The metrics of protection 
decided in these experiments were mitochondrial respiration and markers of oxidative 
damage.  We chose these endpoints given the heavy involvement of mitochondrial 
dysfunction associated with TBI secondary injury mechanisms [56, 68, 99, 103, 110, 124, 
160].  The sub-optimal dose (i.e. the dose that significantly decreased mitochondrial 
respiratory function without completely shutting it down) established in these experiments 
was found to be 30µM of 4-HNE and 3µM of ACR which was sufficient to significantly 
(p < 0.05) reduce mitochondrial respiration and to significantly (p < 0.05) increase 4-HNE 
and ACR markers of mitochondrial oxidative damage. 
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The concentrations of 30µM 4-HNE and 3µM ACR were used in the remainder of 
experiments, the purpose of which was to determine the concentration at which a PZ pre-
treatment that could scavenge reactive carbonyls (4-HNE and ACR).  Pre-treatments of PZ 
were a necessary starting point for ex vivo experimentation and it was consistent with our 
previously published methods designed to explore optimal dosing paradigms [72, 144]. 
From these experiments, we determined that the optimal 5 minute pretreatment of 
30µM PZ was able to significantly (p < 0.05) reduce mitochondrial markers of oxidative 
damage and significantly (p < 0.05) increase Complex I and Complex II-driven respiration.  
Substrates and inhibitors of Complex I and Complex II states of respiration are described 
in the Introduction and Material and Methods. 
The 5 minute pretreatment PZ demonstrated the ability to protect mitochondrial 
function.  However, the means by which PZ was able to do so was more appropriately 
examined in experiments that tested PZ against an analogous compound, pargyline (PG).  
PZ is a monoamine oxidase inhibitor (MAO-I) and speculation did exist on the mechanism 
of protection provided by PZ; MAO inhibition has been shown to be protective following 
neuronal injury [51, 168].  However, PG too is an MAO-I but it lacks the hydrazine moiety.  
The hydrazine moiety is the primary nucleophilic functional group responsible for the 
scavenging of neurotoxic aldehydes like 4-HNE and ACR [90, 116].  Accordingly, should 
PG provide the same type and extent of protection as PZ, then one could implicate that 
protection was due to the MAO activity.  However, PG at an equimolar concentration was 
not able to reduce mitochondrial markers of oxidative damage nor was it able to improve 
respiratory function after 4-HNE or ACR insults. 
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Combined, the culmination of these experiments demonstrated that at least in ex 
vivo experimentation PZ could scavenge carbonyls to reduce mitochondrial markers of 
oxidative damage and protect mitochondria against 4-HNE and ACR-medicated 
respiratory insults.  This provided incentive to test PZ’s scavenging abilities in vivo 
following a severe TBI in the rat. 
 
7.1.2 Summary of Aim 2 In Vivo Experiments 
 Given the efficacy of PZ to protect mitochondria ex vivo and reduce markers of 
oxidative damage, the aim of Chapter 5 was to “determine the ability of the carbonyl 
scavenger PZ to protect mitochondria after a controlled cortical impact induced traumatic 
brain injury in young, adult rats.” 
Previously our lab published that PZ (10 mg/kg s.c.) was able to protect 
mitochondrial respiration 3 hours after injury in the rat, and spare significant cortical tissue 
2 weeks after injury [144].  In the current experiments, the dosing regimen of PZ was 
modified to include maintenance dosing of 5 mg/kg every 12 hours for 72 hours. This was 
based on published reports by the original manufacture Pfizer ©, indicating that the blood-
serum half-life of PZ was 12 hours.  Therefore, a maintenance dose of 5 mg/kg was injected 
s.c. every 12 hours to compensate for the approximated amount of PZ excreted.  Despite 
the worst snowfall KY had seen in 15 years, the author of this dissertation ventured into 
the laboratory without fail to deliver injections to the brain-injured rats every 12 hours.  
The rationale to extend the dosing concentration over 72 hours was to match the duration 
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of posttraumatic 4-HNE accumulation [51] as an attempt to maximize the exposure of PZ 
to the reactive carbonyls 4-HNE and ACR. 
In keeping with our ex vivo endpoints to measure mitochondrial function these 
experiments also investigated PZ’s ability to protect respiration, mitigate oxidative damage 
markers, and increase calcium buffering. 
 Interestingly, PZ (10 mg/kg s.c.) injected 15 minutes after a severe controlled 
cortical impact (CCI) TBI, and (5 mg/kg s.c.) every 12 hours thereafter for 72 hours was 
able to significantly improve mitochondrial respiration when expressed as respiratory 
control ratio (RCR).  However, when mitochondrial respiration data was expressed in terms 
of individual states of respiration, PZ significantly (p < 0.05) reduced the measured amount 
of oxygen consumed.  In a similar dosing paradigm, when mitochondria were isolated from 
rats with a similar injury 72 hours after TBI mitochondria exhibited significantly less 4-
HNE.  When mitochondria were assessed with ACR by the same immunoblotting 
technique, the anti-body previously used to detect exogenous applications of ACR became 
ineffective in detecting ACR endogenously after TBI; even though, ACR after neuronal 
injury is present 40x more than 4-HNE [90, 201].   
 Another metric of mitochondrial function assessed was the ability of mitochondria 
to buffer calcium in the same injury and PZ dosing paradigm model.  However, rats were 
euthanized 24 hours after injury to accommodate the therapeutic window determined by 
others [108].  Phenelzine was able to significantly increase the capacity of mitochondrial 
Ca2+ buffering compared to untreated, injured mitochondria.   
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 Although these experiments exhibited curious data in terms of PZ’s ability to 
significantly improve RCR but significantly reduce individual states of respiration, PZ was 
able to significantly reduce mitochondrial markers of 4-HNE oxidative damage and 
significantly increase the ability of mitochondria to buffer calcium.  Therefore, we 
concluded that PZ’s was able to protect mitochondrial function by improving RCR.  In 
order to determine if these findings would translate to neuroprotection we developed 
experiments to investigate spectrin degradation and cortical tissue sparing. 
 
  7.1.3 Summary of Aim 3 Neuroprotection Experiments 
 PZ exhibited mitochondrial protection ex vivo and in vivo.  The ability of PZ to 
provide neuroprotection and the respective therapeutic window of neuroprotection were 
investigated in the following experiments.  In Chapter 6 our aim was to “determine the 
extent to which PZ is able to provide neuroprotection in rats following CCI.”   
 The original intent of the aim was to increasingly extend the treatment delay of PZ 
and assess for spectrin degradation.  Spectrin degradation is a widely accepted marker of 
cytoskeletal integrity in neuronal injury models [33, 184, 189, 190, 202], and we had 
previously demonstrated that a single dose of PZ (10 mg/kg s.c.) following injury increases 
cortical sparing two weeks after injury [144].  At the time, it was an appropriate logical 
deduction to associate spectrin cytoskeletal degradation with histological cortical tissue 
sparing.  Accordingly, we decided that we would use the new extended PZ dosing paradigm 
that spanned over 72 hours to examine the therapeutic window in regards to an anticipated 
protection against spectrin degradation. 
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 We expected that the PZ extended dosing paradigm, referred to as PZm, would 
reduce spectrin degradation after TBI and that the therapeutic efficacy of PZ to afford this 
protection would then taper off as the delay of initial PZ administration increased after TBI.  
Again, we had previously published that PZ is capable of preserving cortical tissue sparing; 
a metric of neuronal protection that, in theory, is associated with the presence of the 
cytoskeletal network which spectrin functions to maintain.   
 Despite this flawless logic, PZm dosing paradigm was not able to significantly 
protect against spectrin degradation when delayed 15 minutes after injury or when delayed 
3 hours after injury.  We speculated about the dosing implications between PZ single dose 
(PZs) and PZ multiple dosing over 72 hours (PZm).  The single dose was able to preserve 
cortical tissue after 2 weeks[144], but multiple doses of PZ had no effect on spectrin 
degradation.  Accordingly, we sought to quantify the cortical tissue sparing of both the 
single PZ dose and a multiple PZ dosing paradigm at a common time point: 72 hours.  72 
hours was chosen based on the time required to complete the multiple dosing paradigm.   
 In these cortical sparing experiments, we demonstrated that the PZ single dose did 
not significantly improve tissue sparing, although a trend may have been apparent.  
However, the PZ multiple dosing paradigm did significantly (p <0.05) increase cortical 
tissue sparing at 72 hours post-TBI.  These data implicate that the dose and frequency of 
PZ administration can play a pivotal role in carbonyl scavenging required to provide 
neuroprotection.  We suspect that the higher dosing paradigm is able to spare cortical tissue 
because the duration of PZ treatment is increased and therefore the capacity to effectively 
scavenge deleterious reactive carbonyls over the entire 72 hours is increased relative to the 
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single PZ dose treatment whose effect would be drastically decreased during the first 24 
hour after its administration.   
However, there are gaps in the understanding of how PZ is able to improve so many 
components of mitochondrial function and provide cortical tissue sparing, but exhibit 
decreased individual states of mitochondrial respiration, while having essentially no 
protection against spectrin degradation.  Mechanisms that could provide a theoretical 
accountability for these conundrums are discussed in the next sections.  
 
7.2 Expansion of General Discussion 
7.2.1 Mitochondrial Respiration 
Three ideas may account for the discrepancy in PZ’s ability to provide increased 
RCR but not increased oxygen consumption for individual states of respiration. The first 
of these which deals with PZ’s effect to reduce the inherent use of oxygen when 
mitochondria are being assessed for respiration.  Phenelzine is an MAO-I and reactions 
that catabolize monoamines utilize oxygen.  Therefore, PZ-treated mitochondria may 
exhibit a higher rate of oxidative phosphorylation, while lacking the ability to consume 
oxygen in ancillary chemical pathways e.g. monoamine degradation.  However, this is a 
less likely postulation given that the amount of neurotransmitters in isolated mitochondrial 
preparations is probably negligible.  And, even if there were an abundance of 
neurotransmitters in the mitochondrial isolations, the sham animals given PZ exhibit no 
decrease in oxygen consumption when compared to Sham only animals. 
 
166 
  
Another idea to consider is that dopamine neurotoxicity could be responsible for 
the exacerbation of the injury effect in PZ-treated animals.  Phenelzine, being an MAO-I, 
could theoretically increase dopamine transmitter levels within neuronal synapses thereby 
increasing levels of  posttraumatic free radical production due to dopamine autoxidation.  
However, this contradicts our experimental observations in that PZ is able to at least reduce 
oxidative damage in mitochondria after TBI.  If dopamine toxicity were responsible for 
decreased states of respiration, then markers of oxidative damage would likely increase, 
not decrease.  Additionally, this idea draws little support in that the RCR would also likely 
decrease. 
The other possibility is that PZ is exacerbating a known phenomenon to occur after 
neuronal injury: γ-aminobutyric acid (GABA) excitation [173].  GABA excitation is likely 
an aberrant developmental mechanism meant to facilitate growth cone modulation by 
allowing the efflux of chloride ions (Cl-) which depolarize voltage-gated channels 
exacerbating the already excitotoxic calcium (Ca2+) influx. [172, 176, 177, 180].  
Phenelzine may indeed worsen this effect further through the inhibitory action of PZ 
metabolites which directly inhibit the primary means of GABA synaptic clearance: GABA-
transaminase (GABA-T).  Treatment with PZ would inhibit GABA-T, GABA levels would 
then rise to stimulate an excitation response e.g. an influx of Ca2+.  The additional influx 
of calcium would facilitate the decreased mitochondrial respiration which has been 
demonstrated in other published works by calcium’s modulation of the membrane potential 
[73, 108].   
Our previously and current data published manuscript seemingly contradicts this 
notion because mitochondria exhibit an increase of respiration (RCR) following a single 
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treatment of PZ.  In the GABA hypothesis, we would expect a decrease in RCR.   However, 
while it is true that PZ can inherently increase GABA levels [147, 197], low doses of PZ 
have been reported to inhibit MAO activity but not affect GABA levels [183].  This may 
explain why a single dose of PZ after TBI would increase respiration.  It would also explain 
why in the current work, multiple doses would decrease individual states of respiration via 
GABA excitotoxicity.     
This theory is also supported by our experiment evidence in Chapter 5 which 
indicates that PZ significantly increases the capacity of mitochondria to buffer higher levels 
of calcium. The additional positive charges on Ca2+ influence many factors contributing to 
oxidative phosphorylation including but not limited to inactivation of matrix enzymes 
necessary for oxidative metabolism, altered local redox potentials for proton translocation, 
or even electron transfer mechanism interference [93].  In other words, PZ is allowing 
mitochondria to buffer calcium for a specified amount of time but the final result is 
decreased respiration. 
 
7.2.2 Cortical Tissue Sparing without Protection from Spectrin Degradation 
 The ability of PZ to influence how the injured neuron handles Ca2+ accumulation 
might also explain why multiple doses of PZ can spare cortical tissue after injury, while a 
single dose may not.  As previously mentioned a low dose of PZ will not affect significantly 
GABA levels.  Under this premise one would expect that a single dose of PZ would be able 
to increase cortical tissue sparing as assessed 72 hours after injury because GABA 
excitotoxicity would not be a factor.  On the contrary we demonstrate that multiple doses 
 
168 
  
of PZ are able to protect tissue sparing but not the single dose.  Firstly, the single PZ dose 
may not entirely qualify as a “low dose” at 10 mg/kg and therefore some neurons would 
still exhibit GABA excitotoxicity.  Secondly, higher doses of PZ that elicit tissue sparing 
may indicate that at 72 hours during the injury evolution, the ability to scavenge deleterious 
carbonyls is a far greater benefit than the deleterious effect of possibly stimulating spectrin 
degradation. 
 This notion though calls for the reappraisal, or at very least, a further investigation 
of the functionality of degraded spectrin. To use an analogy, if one’s home burns down 
then the appropriate means to repair the home would be to strip out all of the charred and 
damaged components of the house and frame.  This may also hold true for synaptic 
plasticity that ensues after neuronal damage.   GABA excitation already exists after 
neuronal injury to modulate neurite outgrowth, specifically by causing an influx of calcium 
that activates specific enzymes required for these remodeling processes.  It is not beyond 
the realm of possibility that some of those intentionally activated enzymes would be 
calpains-- for the purpose of “remodeling” the cytoskeleton i.e. degrading spectrin just as 
one would be required to do in order to rebuild after a house fire. 
 In other words, PZ could exacerbate GABA excitation which increases calcium 
influx that leads to increases of calcium breakdown products.  Counter-intuitively cell 
survival may be prompted by the benefit of reducing mitochondrial respiration in an 
uncoupled state (State IV), as well as the beneficial effect of PZ scavenging deleterious 
reactive aldehydes.  This would require evidence that spectrin breakdown can exist with 
increased cell survival, which has currently not been demonstrated 
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7.3 Experimental Limitations 
7.3.1 Synaptic Mitochondria vs. Non-Synaptic Mitochondria  
We would be remiss not to have considered the implications of experimental 
limitations.  For instance, one of the most noted and speculated limitation is in what type 
of mitochondria are benefiting from PZ exposure.  Our isolation preparation consist of 
synaptic and non-synaptic mitochondria and therefore do not distinguish between 
mitochondria that exist within neurons and that of that other sources such as astrocytes, 
microglia, and vascular elements.  At the very least if the mitochondria being protected 
after injury are indeed from non-neuronal sources—then salvaging this mitochondrial pool 
is still important since the brain’s astrocytic, microglial and vascular mitochondria are still 
important to protect along with the at risk neurons. 
 
7.3.2 Phenelzine Dose Response 
 An extensive dose response was performed ex vivo to establish the optimal dose 
required of PZ to protect against exogenously applied 4-HNE and ACR.  However, both 
dosing paradigms that were used in Chapter 5 were the result of indirect observations 
based upon our work and others’ [122, 144, 145].  The PZ single dose was a modification 
of previously published work, while the inclusion of multiple doses over 72 hours was 
based on the time course for 4-HNE and ACR and the desire to maximize PZ exposure to 
reactive aldehydes. The error in this logic is that this introduces the possibility to activate 
or inactivate cellular mechanisms not previously considered such as the likelihood of PZ 
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to exacerbate GABA excitotoxicity and possibly preempt spectrin degradation 
amelioration.  
 
7.4 Technical Considerations 
7.4.1 Previous Experiment Repeatability  
Within this dissertation project we have investigated the ability of PZ to provide 
neuroprotection using histologic analysis of ipsilateral cortical tissue volume sparing and 
western blot cytoskeletal spectrin degradation assays.  Although the intent of these 
experiments was to ascertain if PZ can spare cortical tissue after CCI-TBI in rats, the spared 
tissue is not necessarily comprised of only spared cortical neurons.  Accordingly, important 
distinctions must be clarified when interpreting data based on a technical understanding of 
these experiments. 
One fervent criticism to be addressed is repeatability of the current histological 
experiments with that of previously published work by our laboratory.  It is absolutely 
necessary to recognize first that the current histology experiment of this dissertation is not 
a repeat experiment of the former published histological experiment: a single dose of PZ 
injected 15 minutes after injury and assessed 72 hours later is not a “recreation” of the 
previously published experiment wherein a single dose of PZ is injected 15 minutes after 
injury and then assessed 2 weeks later.  The opposing critique implies that the current single 
PZ injection did not afford the same histological tissue sparing as we previously published 
and therefore have not provided repeated results.  The nomenclature “opposing critique” is 
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used as because the single dose demonstrated the same percent of protection at 72 hours as 
the same does at 2 weeks although without reaching significance.    
I am not so naïve as to disregard the diminished probability that brain tissue thought 
to be “lost” at a 72 hour time point would “regenerate” and then “exist” two weeks later.  
However, it is a blatant and cavalier assumption to assert that PZ does not at all possess the 
ability to decrease cortical cavitation over time, especially considering the experiment was 
not designed to investigate this possibility.  Furthermore, PZ’s neuroprotective capabilities 
are hardly characterized and do not necessarily follow the same prototypical cortical 
cavitation evolution of a non-drug treated animal after TBI.  Future exploration of PZ’s 
ability to mediate angiogenesis or enhance glial scar tissue formation within the cortical 
tissue previously thought to only exist as a cavity might better address the possibility that 
PZ is able to mediate such a response.   
For argument’s sake, if PZ is not able to provide immediate tissue sparing at 72 
hours but does increase tissue sparing at two weeks, some other underdeveloped biology 
could exist under the influence of PZ.  To assert that tissue lost at 72 hours will never come 
back is an assumption; though it is one based on experience with the CCI model it is not a 
conclusion deduced from experimentation with PZ.  PZ-induced tissue regeneration is a 
not an assumption but rather supposition that must be recognized as a possibility until it is 
definitely dismissed with evidence.  Until that evidence is provided it would be 
inappropriate to anecdotally dismiss.   
Additionally, my own technical capability to process histological sections have 
been regarded as “too delicate... [and] histological preparations would normally lose more 
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dead and dying tissue in the epicenter of the injury.”  In other words, the single dose PZ 
treated animals would have more pronounced cavitation if I was not so careful as to 
preserve the tissue.  To which I retort without hubris, my technique is the way it is for a 
reason.  I aim to investigate the ability of PZ to spare cortical tissue, not only increase or 
maintain the neuronal population.  If I lose tissue in processing, how would I be able to 
make conclusions? 
Interestingly, further consideration of the data from the previous work and the 
current work are more similar than different and may even preempt the necessity for 
hypothetical cavitation recovery argued above. Regardless, my previous argument is not 
superfluous as it is imperative for a scientist to consider all possibilities and deduce from 
those that are most likely and pertinent. 
For instance our previous publication had investigated the ability of PZ to spare 
cortical tissue after a CCI-TBI in the rat [50].  A single injection of PZ was given 15 
minutes after injury and histological quantification of spared cortical tissue volume was 
performed 14 days after injury.  As published, a statistically significant 96.8% (SD +/- 2.3, 
n =4) of ipsilateral cortical tissue in PZ treated animals was spared compared to 
contralateral cortical tissue.  Our current work also investigated the ability of a single dose 
of PZ injected 15 minutes after injury but assessed for cortical tissue sparing 72 hours after 
injury.  As submitted for publication, and presented in Figure 6.3, the mean ipsilateral 
cortical tissue spared was 96.4% (SD +/- 6.3, n =8).  The reported means of cortical tissue 
sparing are both approximately 96%, however, the current experiment was not designed to 
exactly repeat the previous and included another group: the PZ multiple dosing paradigm 
cohort.  Appropriately, when comparing multiple groups an ANOVA was used to 
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determine significance which is similar but different than the previous work reporting 
differences with a standard T-test.  While it may seem appropriate to disregard the multiple 
dosing paradigm group and run another T-test, a Bonferroni correction is necessitated to 
account for multiple comparisons but would increase the chances of making a Type 1 error 
e.g. finding significance when there is none.  Ironically, the Bonferroni correction reduces 
the chances of making a Type 1 error, but increases dramatically the chances of increasing 
a Type II error e.g. lose the power to detect true differences.  The current experiment reports 
a higher variability (SD +/- 6.3, n =8), and Bonferroni correction is used the α increases 
and significance is lost between groups.  
Even though the PZ single dose means that are reported from the current (96.4%) 
and previous work (96.8%) are indeed similar, the means for the vehicle-treated animals 
are not as near.  The previous work reports vehicle-treated animals to have means of 85.9% 
(SD +/- 3.5, n =4) while the current work reports the vehicle treated means at 92.8% (SD 
+/- 2.7, n =8).  See Figure 7.1.  This is another important caveat that highlights that these 
two studies while related are not the same.  One would reasonably expect more cortical 
tissue lesion volume in vehicle-treated animals as dead and dying tissue is cleared between 
72 hours and 14 days. This would suggest that PZ in the previous work has a stronger effect 
as the lesion volume is larger than it is at 72 hours.  This would mean that the effect of the 
drug might targeting neuron loss between 72 hours and 2 weeks more than 0-72 hours. 
However, this would require PZ to somehow target neuron loss between 72 hours and 2 
weeks more than 0-72 hours, which is a concept that has yet to be explored as a viable 
possibility. 
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Figure 7.1 also demonstrates the PZ multiple and single dosing paradigm with the 
ability to increase cortical tissue sparing above 100%.  Given that these measurements are 
made in comparison with the contralateral hemisphere, the PZ treated animals may be 
experiencing some localized swelling of the ipsilateral hemisphere.  This could be from 
increased blood pooling or clotting as well as altering the nascent chemiosmotic 
environment of the injury to attract water molecules. 
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Figure 7.1 (A) Quantification of cortical tissue sparing as reported in 
Chapter 6.  Rats were assessed 72 hours after severe CCI-TBI.  Treatments 
consisted of either PZs or PZm.  PZs group was given a single injection of 
PZ 15 minutes after injury.  PZm group was given an injection of PZ 15 
minutes after injury followed by a maintenance dose every 12 hours for 72 
hours.  ANOVA followed by Dunnet’s post-hoc test.  * = p < 0.05.  
Horizontal bars represent means. Error bars represent +/- SD; n = 8 rats per 
group.  
(B)  Quantification of cortical tissue sparing as previously published 
Student T-test.  * = p < 0.05.  Horizontal bars represent means.  Error bars 
represent +/- SD; n = 4 rats per group.  PZs demonstrates an increased 
variability that the previously published experiment did not.  
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With different surgeons come forth intrinsic differences in variability.  And, gross 
anatomical investigation of our extracted rat brains compared to other labs’ is also 
different.  See Figure 7.2. We value the stochastic nature of the injury response and do not 
excessively wash or clean away the damaged tissue.  This tissue may be of different origin 
e.g. infiltrating microglia or connective tissue supplied in the hematoma.  This occurrence 
of tissue may or may not be classified as neuronal but it is tissue and it does exist where 
there was once a vacant lesion.  We value the possibility of preserving the infrastructure 
for neurite outgrowth; rationalization afforded by experimentation with in vitro neuronal 
outgrowth.  Neurons do like to grow where there exists no substrate.  
One possible limitation is that the Vehicle-treated animals may still be losing tissue 
in the histological processing.  When the gross anatomy of Figure 7.2 is compared to that 
of the histological tissue sparing Figure 6.3 the tissue in vehicle treated animals appears to 
have maybe more cavitation than that evident in coronal sections which suggest that tissue 
could be lost in the vehicle groups.  The solution to rule out this possibility would be to use 
paraffin embedded histological processing to reduce further the chances of tissue being lost 
in free floating processing.  However, our laboratory does utilizes paraformaldehyde in our 
processing which is a polymer of regular formaldehyde that cross links amines at further 
distances for a more natural preservation.  Formaldehyde only preparations can distort 
tissues by virtue of their inherently short length crosslinks and seem to have a more rigid 
quality susceptible to breakage. 
  It is important to note that while we value the measurements of all tissue within 
the cortical lesion, as do other labs [106, 123] this can introduce sampling bias in the 
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investigation of mitochondrial bioenergetics and spectrin degradation assays which will be 
considered in subsequent sections. 
Of more pressing importance is the question of injury severity between different 
studies.  The injuries in each of the studies were performed by different surgeons and as 
such variability would naturally exist between experiments.  The severity of the injury can 
have a major effect on drug efficacy and may account for some experiment differences 
within in experiments.  For instance, the lessened ability of PZ to provide tissue sparing 
with a single dose in the recent experiments maybe be due to PZ having to protect against 
a comparatively profound injury when compared to the original experiments performed in 
2013. 
Additionally, the means by which spared tissue is measure may inappropriately 
include narcotic tissue as the traces are made at 1.25X instead of higher magnification to 
circumvent dying tissue.  Although the methods for measuring spared tissue were the same 
in both experiments, the recent experiments did use a computer device (free hand pen) with 
increased accuracy in tracing the outline of cortical spared tissue as opposed to a track-ball 
mouse.  Taken together, different injury severities and intrinsic bias to count necrotic tissue 
are potentially significant sources of bias.   
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Figure 7.2 Macroscopic morphology of extracted brains and associated 
trauma.  Animal brains where photographed after paraformaldehyde 
perfusion and glucose exposure gradients prior to histological processing 
and sectioning.   Quantification of coronal sections was presented in Figure 
6.3. The images above represent a single prototypical brain from each 
respective group (n =8). 
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7.4.2 Possibility of Mitochondrial Sampling Bias  
The presence of mitochondria in vehicle treated animals is expected to decrease as 
the total amount of tissue is decreased.  In other words, we would expect to see decreasing 
amounts of mitochondrial proteins in our vehicle-treated animals in our in vivo 
experiments.  The logic is that the cavitation that exists 72 hours after injury is sufficient 
to reduce the quantity of mitochondria expected to be isolated in cortical tissue punches 
following experimental TBI. 
 What is observed, however, is similar amounts of mitochondrial protein isolated 
from each group save the PZ multiple dose group which is significantly elevated compared 
to sham.  Figure 7.3  
The elevated mitochondrial samples from the PZ treated groups can be supported 
with the preservation of cortical tissue sparing demonstrated in Chapter 6.  Increased 
concentrations of mitochondria that are isolated from PZ treated rats,  could be in part due 
to an uncharacterized ability of PZ to increase the amount of cells within the lesion e.g. 
microglia that could contribute to the mitochondria pool or increase proliferation of 
ancillary supportive tissue.  A simple procedural intervention for future experiments would 
be to separate the mitochondrial pools and assess that which is only relative to neurons e.g. 
implement synaptic mitochondrial isolation protocols. 
According to Figure 7.3, Vehicle-treated rats do not contribute less mitochondria 
despite having a pronounced lesion volume as evident by histology.  As discussed 
previously, if the vehicle treated animals are losing tissue in the histological preparation 
then one could attribute the lack of mitochondrial deficit to the gross anatomical images 
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that do not appear to have such a pronounced lesion.  Another possibility for finding equal 
concentrations of mitochondria in vehicle treated groups could be due to the increased 
presence of microglia and astrocytes which are facilitating the glia scar suspected in Figure 
7.4, below. 
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Figure 7.3 Quantification of rat cortical mitochondrial protein extracted 
from 8mm punch as measured by Bradford protein assay for mitochondrial 
bioenergetics studies reported in Chapter 5.  ANOVA followed by 
Dunnet’s post-hoc test.  * = p < 0.05.  Horizontal bars represent means. 
Error bars represent +/- SD; n = 8/9 rats per group except Sham and Sham 
+ PZ where n =5/6 rats per group. 
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Figure 7.4 High magnification images of an intentionally chosen Vehicle 
treated rat following a severe TBI at 72 hours post injury.  Sections were 
treated with cresyl violet (Nissl) staining.  Low magnification image at 
1.25x was included for frame of reference.  Black box in 1.2x labeled image 
is the region identified in the 10x magnification image and so forth for the 
40x image.  The 10x magnification highlights with black arrows the abrupt 
cellular condensation of with glia morphology, indicative of the formation 
of the glia scar.  Cortical neurons in the 40x magnification are identified by 
the letter A and red arrow.  Morphology of glia tissue is exemplified in the 
40x image labeled with the letter B and red arrows.  Qualitatively, the 
images suggest that Vehicle treated animals can in some cases have no 
tissue in the approximately 5mm epicenter of the controlled cortical injury.  
However, the regions extracted by the cortical punch (8mm) would also 
sample surviving neurons as well as infiltrating microglia, monocytes, and 
microglia.  The images chosen intentionally have a slightly more 
pronounced cavity lesion volume which seems to correlate with increased 
cellular condensation e.g. formation of glial scar. 
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There is theoretical merit in first preserving tissue, then preserving cortical neurons, 
then determining functionality of those neurons.  This tiered approach may be a slightly 
more feasible means of providing neuroprotection as the former goals may facilitate the 
latter ones.  For example, providing a matrix for astrocytic infiltration and proliferation 
may encourage the astrocytic Nrf2 antioxidant response to lessen ongoing free radical-
mediated damage.  Additional merit can be afforded in allowing glial scar tissue formation 
in an area that would not disrupt the function of surviving neurons. In other words, if glial 
scar formation disrupts normal neuronal circuitry then there may be benefit in facilitating 
scar tissue in the lesion cavity outside the presence of healthy neurons.  While there is 
clinical merit in preserving any tissue, mechanistically the protection of mitochondria to 
afford neuroprotection may require additional experiments to investigate mitochondrial 
function from only neuronal origin and that of other populations. 
 
7.4.3 Decreased Respiration of PZ-treated Mitochondria  
Based upon the increased cortical tissue sparing, there is an expectation that PZ 
would increase mitochondrial respiration or at least preserve State III functionality.  
However, what is observed is a decrease in all states of respiration.  The benefit of this is 
that mitochondria with decreased State IV respiration translates biologically to reduced 
respiration of mitochondria in an uncoupled state.  This is apparent in the reported RCRs 
in Chapter 5 wherein a decreased state IV increases the overall RCR.  The Vehicle-treated 
mitochondria do not have a mean RCR that is below 5, what some consider the threshold 
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for healthy or non-healthy mitochondria.  This may provide an alternative hypothesis as to 
why PZ is able to reduce all states of respiration aside from the GABA hypothesis discussed 
later. 
 If the effect of PZ is not apparent in the Sham treated animals, and the Vehicle-
treated animals do not have dramatically (although significantly) reduced abilities to 
respire oxygen then one can reasonably argue that the sample of mitochondria from the 
Vehicle-treated groups might be exposed to sampling bias.  If the histology of the Vehicle-
treated animals is as pronounced as reported then the punch used to collect cortical tissue 
may only be sampling penumbral tissue that would survive regardless.  In the vehicle 
treated groups, the presence of the lesion cavity implicates that no mitochondria are 
available e.g. there is no tissue in a cavity.  Therefore the tissue in the difference of the 
approximate cavity size  (5mm) and the cortical punch (8mm) samples tissue that has not 
only increase population of microglia with healthy mitochondria but also sample cortical 
neurons that are inherently healthier as they are more distal to the epicenter of injury.  In 
other words, the Vehicle-treated animals have an increased occurrence of dead tissue and 
dead mitochondria that are removed in the isolation preparation.  The effect is that the 
Vehicle-treated groups have an increased respiration at 72 hours.  The treatment of PZ is 
seemingly obligating tissue that would otherwise die to instead remain and accordingly 
contribute more dysfunctional mitochondria to the respiration assay.  Theoretically, merit 
can exist in increasing mitochondrial respiration of non-neuronal cells but, mechanistically 
future experiments should either reduce the severity of the injury i.e. reduce cavity 
formation or assess mitochondrial function at an earlier time point to be able to more 
definitively understand the influence of PZ on dysfunctional mitochondria.  
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7.4.4 Increased Spectrin Degradation and Increased Calcium Buffering Capacity  
Phenelzine preserves ability of mitochondria to more effectively buffer increasing calcium 
concentrations after injury but simultaneously does not prevent the calcium-activated, 
calpain-mediated degradation of spectrin.  The influx of calcium after injury may be 
sufficient enough to activate calpains and subsequently lead to increased cytoskeletal 
degradation.  However, a technical limitation would be similar to that discussed earlier.  
The vehicle treated animals have a more pronounced lesion volume, because the cavity is 
void of dying tissue.  Presumably, the tissue is already dead and cleared, then the amount 
of spectrin degradation in Vehicle-treated animals is reduced.  If PZ is truly increasing 
spared tissue, this tissue could still be damaged, but managing to survive although 
somewhat dysfunctional.  This could result in decreased degraded spectrin in Vehicle-
treated tissue (as it is already cleared) and increased degraded spectrin in PZ-treated 
animals (as more damaged, but still surviving tissue is preserved).  Future experiments will 
be needed to test this hypothesis by reducing the lesion cavitation by decreasing the 
severity of the injury or sampling cortical tissue earlier in the evolution of the cavity, for 
example at 24 hours.   
 
 7.4.5 Preserving Cortical Lesion Volume  
As previously discussed, the effect of PZ does increase cortical tissue sparing 
significantly with a multiple dosing paradigm and to a lesser extent a single dose.  An 
important caveat is that the intent is to preserve any cortical tissue beyond that of only 
cortical neurons.  However, higher magnification of the peri-penumbral regions after PZ 
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treatments subsequent to TBI in the rat do qualitatively demonstrate a larger “transition” 
zone than Vehicle-treated animals.  Qualitatively, Vehicle-treated animals have a more 
abrupt transition from typical “healthy” cortical neurons to that of cell morphologies that 
are indicative of glial scaring.  In both PZ single and multiple treatment groups, the 
transition zones typified by the presence of glial cells and cortical neurons is seemingly 
larger. See Figure 7.4. Further quantification of this penumbral zone would help to directly 
implicate neuroprotection and not simply tissue sparing.   
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Figure 7.5 High 20x magnification images of Vehicle-treated rats (A1-A2), 
PZs (B1-B2), and PZm (C1-C2) processed for tissue sparing analysis in 
accordance with injury and dosing paradigms presented in Chapter 6. A1 , 
B1, and C1 included for reference. Sections were treated with cresyl violet 
(Nissel) staining. 
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A2) Qualitative analysis of A2 depicts sooner transition of cortical neurons 
blue arrows to cells consistent with microglial morphology green arrows.  
B2) Cortical neurons represented by blue arrows appear to transition into 
pyknotic cortical neurons (yellow arrows) over a greater distance starting 
at the roughly drawn black line with black arrows.  A larger zone of 
transition is evident compared to the Vehicle-treated animal.  The transition 
zone, characterized by both pyknotic neurons and glial, tapers off 
dramatically at the edge of the preserved tissue wherein microglial become 
the predominant cell morphology red arrows. 
C2) Cortical neurons blue arrows transition almost entirely through the 
epicenter (tissue directly under the point of impact).  Pyknotic neurons are 
indicated by yellow arrows, while green arrows indicate cells of microglial 
morphology. 
Collectively these images suggest that PZ is indeed sparing cortical tissue, 
and qualitatively appear to be increasing the extent of preserved cortical 
neurons by increasing the transition zone from the point of injury radially. 
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7.5 Ancillary considerations 
7.5.1 Profiling  
 While the generalities of how 4-HNE and ACR are able to induce cytotoxicity for 
both the neuron and the mitochondria have been extensively discussed, the precise means 
of mitochondrial respiratory inhibition have yet to be determined.  Further characterization 
of how 4-HNE and ACR specifically inhibit mitochondrial function or other cellular 
process could translate to a better drug design.  For example, should reactive carbonyls be 
found to bind key enzymes within the mitochondrial matrix that are responsible for 
essential steps in substrate oxidation, future iterations of hydrazine-containing compounds 
could be designed with modified lipophilicity to penetrate with greater ease multiple lipid 
bilayers. 
 Other characterizations would be to further describe the extent of neuroprotection 
by examining protein crosslinking and PZ’s ability to protect against it.  Reactive carbonyls 
have the ability to facilitate protein cross-linking as is such with heat shock protein 90 
(HSP 90) [119], which might have epitopes that current anti-bodies cannot detect due to 
protein complex steric hindrance.    
 
7.5.2 Aberrant Scavenging and Metabolism 
 Additional considerations may be necessary to establish upper bounds of carbonyl 
scavenging after injury.  There could exist a natural point at which the severity of the injury 
generates far too many reactive carbonyls that would require deleterious doses of PZ.  
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Subsequently these high doses of PZ may inappropriately scavenge endogenous useful 
carbonyls such a pyridoxal phosphate.  Pyridoxal is a co-factor that does contain a 
carbonyl, however, the function of which is to potentiate the synthesis of vital 
neurotransmitters like dopamine, serotonin, and to make matters even more complex: 
GABA [141, 203].   
Metabolic clearance may too be another eventual concern.  The metabolism of 
excessively large protein complex that can form due to PZ conjugation may stress the 
metabolic clearance pathways.  Typically, hydrazine-containing compounds that form 
conjugation products undergo degradation and clearance in the liver by glucuronidation, 
N-acetylation, and sulfonation [141].  However, metabolic clearance of super-complexes 
have not been investigate like the degradation of ACR bis-Michael additions.  In this case, 
a single lysine residue would bind two ACR molecules rendering the protein dysfunctional 
but more deleteriously the protein is now capable of binding two more proteins (or PZs) 
through the remaining electrophilic centers on each of the bound ACRs [204].   
These reactions, reported by the same authors, are the second most typical reactions 
formed by ACR when binding to lysine residues.  Not only does this cause a concern for 
metabolic clearance as a complex formed to phenelzine, but also invites the potential to 
create neoantigens that could theoretically simulate drastic immune responses.   
 
7.6 Concluding Remarks 
 Caution is always warranted when inviting a compound with rather complex 
pharmacology in to a biological system.  Special attention should always be made for the 
 
191 
  
entire system and too much focus on pre-defined endpoints may demonstrate some 
miraculous recovery but compromise the integrity of the biological entity.   
For, instance the introduction of PZ may indeed increase neuroprotection by 
increasing mitochondrial function but PZ could also derail a biologically self-limiting 
system. After TBI, reactive aldehydes like 4-HNE and ACR are produced in excess and 
bind to proteins with an affinity for specific protein residues to inhibit overall protein 
functionality.  Separately, but concurrently with, the synthesis of 4-HNE and ACR is the 
activation of deleterious calpains and caspases.  It is not irrational to speculate that the 
“intended” function of reactive aldehydes is to bind and inhibit deleterious calpains and 
caspases to prevent overall neuronal death.  In this context, adding PZ to the system would 
scavenge most of the available reactive aldehydes that could theoretically be responsible 
for inactivating calpain-mediated spectrin degradation.  Without further investigation, PZ 
could be dis-inhibiting natural self-limiting processes.   
The role of phenelzine as a potential neuroprotective agent is certainly still in 
development and several key observations have communicated the complexity of its use 
ex vivo and in vivo.  However, traumatic brain injury is profoundly complicated.  The best 
solution will not be the easiest and low-hanging fruit is a farce.  The complexity of the 
solution needs to match the complexity of the problem.  And, so far PZ is pretty complex.   
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APPENDIX  
 
Appendix A: List of Acronyms and Abbreviations 
 
ΔΨm Mitochondrial Membrane Potential 
Δp Proton Motive Force 
3-NT 3-Nitrotyrosin 
4-HNE 4-Hydroxynonenal 
AA Arachidonic Acid 
ADP Adenosine Diphosphate 
ACR Acrolein 
ATP Adenosine Triphosphate 
ANOVA  Analysis of Variance  
BBB Blood-Brain Barrier 
Ca2+ Calcium Ion(s) 
CaG5n Ca2+-sensitive indicator Calcium Green 5 N  
CCI  Controlled Cortical Impact  
CDC  Center for Disease Control  
CNS  Central Nervous System  
CSF  Cerebrospinal Fluid  
ER  Endoplasmic Reticulum  
ETS  Electron Transport System  
FAD  Flavin Adenine Dinucleotide  
FCCP p-trifluoromethoxy Carbonyl Cyanide Phenyl Hydrazone 
FMNH2 Reduced Flavin Mononucleotide 
GCS  Glasgow Coma Score  
GABA γ-Aminobutyric Acid 
IMM  Inner Mitochondrial Membrane  
IMS  Inner Mitochondrial Space  
iNOS Inducible Nitric Oxide Synthase 
NO Nitirc Oxide 
LP  Lipid Peroxidation  
MAO  Monoamine Oxidase  
MAOI  Monoamine Oxidase Inhibitory  
MOS  Military Occupational Specialty  
mPTP Mitochondrial Permeability Transition Pore 
mtNOS Mitochondrial Nitirc Oxide Synthase 
NADPH  Nicotinamide Adenine Dinucleotide Phosphate-Oxidase  
nNOS Neuronal Nitric Oxide Synthase 
NMDA  N-methyl-D-aspartate  
OCR  Oxygen Consumption Rate  
OMM  Outer Mitochondrial membrane  
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PBS  Phosphate Buffer Solution  
PG Pargyline 
PM  Plasma Membrane  
PUFA(s) Polyunsaturated Fatty Acids 
PZ Phenelzine 
PZm Multiple Doses of Phenelzine 
PZs Single Dose of Phenelzine 
RCR  Respiratory Control Ratio  
RNS  Reactive Nitrogen Species  
ROS  Reactive Oxygen Species  
SBDP  Spectrin Breakdown Products  
SCI  Spinal Cord Injury  
SD  Sprague-Dawley  
SOD Super Oxide Dismutase 
TBI  Traumatic brain injury  
TBS Tris-Buffered Saline 
TCA  Tricarboxylic acid  
VOC  Voltage-operated channels 
UQ Ubiquinone  
UQ•- Semiquinone Anion 
UQH2 Ubiquinol 
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Appendix B: Immunoblotting, No Primary Controls 
 
 
 
Appendix B: Naive rat mitochondrial samples were exposed to a 10 minute 
incubation of 4-HNE (30 µM) or ACR (3 µM).  4-HNE and  ACR were 
incubated consistent with previously described methods and concentrations.  
4-HNE and ACR were also blotted without primary antibodies (right side 
of each western blot) to probe for non-specific binding.  Non-specific 
binding was not present between 150 kD and 50 kD; the defined region of 
interest.  Naïve rat mitochondrial samples assayed for 4-HNE adducts were 
separated on a precast gel (12% Bis-Tris w/v acrylamide; Criterion XT, Bio-
Rad) with XT-MOPS buffer (Bio-Rad). Naïve rat mitochondrial samples 
assayed for ACR adducts were separated on precast gel (4-12% gradient 
Tris-Acetate gels) using MOPS buffer (BioRad).4-HNE rabbit polyclonal 
primary antibody (Alpha Diagnostics) was diluted 1:2,000.  ACR mouse 
monoclonal antibody (Abcam, United States) was diluted at 1:1,000.)  4-
HNE and ACR primary antibodies were detected via 2 hour incubation at 
room temperature with goat rabbit immunoglobulin G (IgG) or anti-mouse 
IgG secondary antibody conjugated to infrared dye (1:5000, IRdye-800CW, 
Rockland) in TBST.   
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